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Regulation of the redox state is essential to maintain cellular homeostasis. In fact, 
dysregulated reactive oxygen species (ROS) production has been associated with 
enhanced tumorigenicity in epithelial cells. However, the pro-tumorigenic effect of 
the accumulation of ROS can turn out to be a double-edged sword, since high 
levels of these species may lower the apoptotic threshold for cytotoxicity. 
Therefore, redox regulation plays an important role in tumor cell survival. 
 
The p38α protein kinase is an important regulator of many cellular responses. It is 
well established that p38α signaling negatively regulates epithelial cell 
transformation, but enhanced p38α kinase activity has been also correlated with 
bad clinical prognosis in some tumor types. This, together with the fact that p38α 
has been implicated in the proliferation of some cancer cell lines, led us to 
hypothesize that this protein kinase could be a good target for cancer therapy. 
 
We performed a screening to try to identify synthetic lethal partners of p38α, but 
we only found one potential candidate. We also investigated the role of p38α in 
the response of tumor cells to chemotherapeutic agents that induce DNA damage. 
Our results provide genetic and pharmacological evidence showing that inhibition 
of p38α cooperates with the chemotherapeutic agent cisplatin to kill tumor cells. 
We show that p38α inhibition results in ROS upregulation, which in turn activates 
the JNK pathway via inactivation of phosphatases, sensitizing human tumor cells 
to cisplatin-induced apoptosis. Using a mouse model for breast cancer, we also 
show that inhibition of p38α cooperates with cisplatin treatment to reduce tumor 
size and malignancy in vivo. Taken together, our results illustrate a new function 
of p38α that helps tumor cells to survive chemotherapeutic drug treatments by 
inducing the expression of antioxidant enzymes, and reveal that the combination 
of p38α inhibitors with cisplatin can be potentially exploited for cancer therapy. 
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Cancer, an ancient and worldwide disease 
Cancer can quite easily be thought of as a modern disease, but it has existed for 
many centuries indeed. It has been clearly identified in studies of Egyptian 
mummies (Granville, 1825) and even depicted in pieces of art along the centuries 
(Vaidya, 2007). However, it is a more common phenomenon nowadays than 
previously, in large extent due to the growth of the world’s population and the 
advances in civilization. The improvement in life expectancy has contributed to 
making cancer such a common disease worldwide, as it is more frequent in elderly 
ages than in younger ones. 
 
During the last quarter of century, research has generated a rich and complex 
body of knowledge, revealing cancer to be a disease involving dynamic changes 
in the genome. There are already several clearly identified causes of cancer (Boyle 
et al., 2003; Peto, 2001) although this is a complex disease that is very variable at 
the cellular and molecular level. The same heterogeneity and variability exist in its 
presentation, development and outcome from one patient to the other, so a lot of 
questions remain to be answered yet. 
 
Tumorigenesis is a multistep process that reflects genetic alterations that drive the 
progressive transformation of normal cells into highly malignant derivatives, which 
have defects in regulatory circuits that govern normal cell proliferation and 
homeostasis. There are more than 100 distinct types of cancer and subtypes of 
tumors can be found within specific organs. This complexity provokes a number of 
questions, like how many distinct regulatory circuits within each type of target cell 
must be disrupted in order for such a cell to become cancerous? Or, which of 
these circuits operate on a cell-autonomous basis, and which are coupled to the 
signals that cells receive from their surrounding microenvironment within a tissue?  
 
1. Molecular traits 
Culture of cancer cells in vitro and dissection of their molecular components has 
yielded much of the knowledge we currently possess about the molecular 
processes underlying cancer development.  Hanahan and colleagues suggested 
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that the vast catalog of cell genotypes is a manifestation of six essential alterations 
in cell physiology that collectively dictate malignant growth: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis and tissue invasion, and 
metastasis (Hanahan and Weinberg, 2000). Acquisition of these biological 
capabilities appears in widely variable sequences, both among tumors of the same 
type and certainly between tumors of different types. But in addition to cancer 
cells, tumors exhibit another dimension of complexity: they contain a repertoire of 
recruited normal cells that contribute to the acquisition of these hallmark traits by 
creating the “tumor microenvironment”. This implies the addition of two more 
hallmarks of cancer involved in the pathogenesis of perhaps all cancers. One 
involves the capability to reprogram cellular metabolism in order to most 
effectively support neoplastic proliferation. The second allows cancer cells to 
evade immunological destruction (Fig.1).  
 
 
 
Figure 1. Schematic representation of the hallmarks of cancer. Hanahan and colleagues 
propose six biological capabilities, together with two other emerging hallmarks and 
enabling characteristics, to explain the cell transformation process and cancer progression. 
(Hanahan and Weinberg, 2011). 	  
2. Mouse models  
The laboratory mouse (Mus musculus) has revolutionized our ability to study gene 
function in vivo and our understanding of the molecular mechanisms of cancer 
pathogenesis. As a model system, mice have several important advantages over 
other mammalian models: they are small in size and relatively inexpensive to 
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maintain, they reproduce rapidly and have large litters, and they can be 
genetically manipulated. Currently, numerous techniques for genetic manipulation 
are available (Cheon and Orsulic, 2011) and this has allowed the generation of a 
number of mouse models to recapitulate human diseases (Frese and Tuveson, 
2007). Here we will just describe one of the mouse models that have been 
generated for breast cancer, the MMTV-PyMT. 
 
MMTV-PyMT model of breast cancer 
Breast cancer is by far the most common cancer diagnosed in women worldwide 
(ranking second in both sexes combined), as it represents nearly a quarter (23%) of 
all cancers diagnosed in women around the world. Besides, it is also the most 
common cause of death from cancer in women worldwide (Cancer Research UK, 
2011). 
 
Genetically engineered mouse models of breast cancer exhibit many features of 
human breast cancer and thus provide valuable models to investigate the biology 
and pathogenesis of this disease. Nonetheless, because of the complexity and 
heterogeneity of breast cancer, no individual model recapitulates all aspects of this 
disease.  
 
Murine polyomavirus (PyV) can cause a wide variety of tumors in different types of 
cells (Dawe et al., 1987; Fluck and Haslam, 1996). The most important 
transforming protein that they produce is the middle T (PyMT) oncoprotein, whose 
transgenic expression can cause tumors in a broad range of tissues (Cecena et al., 
2006; Guy et al., 1992; Rassoulzadegan et al., 1990; Tehranian et al., 1996). 
When PyMT cDNA is expressed under the control of the MMTV mammary gland 
promoter, metastatic carcinomas are induced (Guy et al., 1992). Another 
advantage of the PyMT mouse model is the focal induction of tumors, in contrast 
to the equally metastatic ErbB2/Neu models, in which the whole mammary gland 
coalesces into a large tumor. Thus, it provides a relatively good model for the 
human disease (Lin et al., 2003).  
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Figure 2. Summary of tumor progression and biomarker expression in the MMTV-PyMT 
mouse model of breast cancer. Four tumor stages are observed at different ages of the mice 
and in ducts that are at different stages of development. At the earliest stage (2 to 4 weeks 
after birth), growth of the short, underdeveloped prepubertal ducts takes place from the 
bulbous end buds under the influence of growth factors. In sexually mature mice (from 6 
weeks on, when adenomas are observed), ducts continue to grow from the end buds under 
the control of estrogen and growth factors until they reach the confines of the gland. The 
“Gross” panel displays the overall development of lesions in mammary glands of PyMT 
mice. Tumor lesions are indicated by blue dots. The “H&E” panel displays the 
corresponding histology of primary lesions at different stages of tumor progression. The 
“Cellular morphology” panel schematically illustrates changes in the cytology of the cells as 
well as the integrity of the basement membrane and the presence or absence of 
myoepithelial and focal inflammation. Moreover, the changes in biomarkers during tumor 
progression are summarized in the panel of “Biomarkers”. “T/D”, the ratio of Neu 
expression between lesions and normal ducts in age-matched mammary glands. (Fluck and 
Schaffhausen, 2009) 
 
In MMTV-PyMT mice, the earliest hyperplastic lesions arise at a very early age and 
are located very close to the nipple. The early lesion involves prepubertal, nipple-
proximal buds (end buds) at the ends of growing immature ducts surrounding the 
main collecting duct. Following prepubertal growth, the ducts elongate further 
under hormonal influence, and new lesions arise on the distal end buds. The most 
distal foci arise at a stage of ER-dependent growth. At late stages, the nipple-
proximal tumor fuses with numerous distal foci. Four stages with similarities to 
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human tumors were identified. These stages—hyperplasia, adenoma/mammary 
intraepithelial neoplasia (MIN), carcinoma in situ, and invasive carcinoma—and 
their timing, associated properties, and markers are described in figure 2. 
 
MMTV-PyMT tumors display a large number of deregulated genes, including many 
implicated in breast cancer. These define a number of upregulated pathways: the 
glycolytic pathway; elongation translation factors plus structural RNAs; cell cycle 
regulators; signaling receptors and their effectors, including G proteins; and 
downstream transcription factors (Desai et al., 2002). Hierarchical clustering 
analyses of the MMTV-PyMT tumors along with classified human tumors suggest 
the placement of these tumors in a luminal group. In the human case, the luminal 
group generally expresses ER and ER-dependent genes (Perou et al., 2000) (Fig. 3). 
This is not the case of MMTV-PyMT tumors. However, the luminal subgroup B, 
that expresses only low levels of ER and overexpresses ErbB2, has been defined 
and they show a poor prognosis (Sorlie et al., 2003). This matches better the status 
of the PyMT tumors (Fluck and Schaffhausen, 2009). 
 
Figure 3. Identification of human breast 
cancer subtypes by molecular profiling. 
Breast tumors at the molecular level cluster 
into three main subtypes: luminal-type 
(with subtypes A and B), HER2, and basal-
like. Luminal-type breast cancers express 
the oestrogen receptor (ER) and related 
genes and can be targeted with hormonal 
therapies; the less aggressive (subtype A) 
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cancers may be less sensitive to chemotherapy than the more aggressive ones (type B) 
cancers. HER2 breast cancers, characterized by overexpression of the growth factor receptor 
HER2 with amplification of the HER2 gene, are aggressive with a poor prognosis. HER2 
positive cancers can be targeted with the monoclonal antibody trastuzumab and also may 
be highly chemotherapy sensitive. About half of the HER2 positive cancers express the 
oestrogen receptor. Basal-like cancers do not usually express either of the hormone 
receptors or overexpress the growth factor receptor HER2, a phenotype named “triple 
negative”. Basal-like cancers are highly proliferative and have poor prognosis, although 
many are highly sensitive to chemotherapy. There is no subtype specific targeted therapy. 
(Turner and Jones, 2008; Vargo-Gogola and Rosen, 2007) 
 
The MAPK signaling cascade 
Cells need to be constantly aware of changes in the extracellular milieu to respond 
accordingly, so they have developed a wide variety of mechanisms to receive 
signals, transmit the information and orchestrate the appropriate responses. These 
are often mediated through the activation of transcription factors, which, in turn, 
induce the necessary cellular processes. However, most extracellular agents 
cannot cross the plasma membrane in order to activate their corresponding genes. 
Instead, these agents use intracellular “communication lines,” which are known as 
“signaling pathways”, to transmit their signals to various cytoplasmic and nuclear 
targets.  
 
1. Canonical activation 
In many cases, signaling pathways operate through sequential phosphorylation 
events that are termed protein kinase cascades. This type of signaling mechanism 
is used by the mitogen-activated protein kinase (MAPK) signaling cascades, which 
are a superfamily of evolutionary-conserved serine/threonine protein kinases. Four 
canonical mammalian MAPK cascades have been identified in the last 20 years, 
and those are usually named according to the MAPK components that are the 
central building blocks of each of the cascades. These are the extracellular signal-
regulated kinase 1/2 (ERK1/2) (Boulton et al., 1991), c-Jun N-Terminal kinase 1-3 
(JNK 1-3) (Derijard et al., 1994; Kyriakis et al., 1994), p38 MAPK α, β, γ, ∂ (p38α-
∂) (Freshney et al., 1994; Han et al., 1994; Rouse et al., 1994), and ERK5 (Lee et 
al., 1995; Zhou et al., 1995) pathways (Fig. 4). Each of these cascades consists of a 
core module of three tiers of protein kinases termed MAPK, MAP2K, and MAP3K, 
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but often two additional tiers, the upstream MAP4K and the downstream 
MAPKAPK, which are not always present, can complete five tiers of each cascade 
in certain cell contexts.  
 
 
Figure 4. Schematic representation of the MAPK signaling cascades. (Keshet and Seger, 
2010) 
 
About 70 genes are known today to encode close to 200 distinct components that 
compose the entire MAPK system. This multiplicity of components allows the 
extended specificity and tight regulation, which are hallmarks of these cascades. 
Usually, the ERK1/2 cascade plays a role in proliferation and differentiation, 
meanwhile JNK and p38 MAPK pathways are activated mainly by cellular stresses, 
and therefore they are termed stress-activated protein kinases (SAPKs). The ERK5 
cascade seems to respond equally to certain stresses and mitogenic signals (Keshet 
and Seger, 2010). 
 
The transmission of the signal via each cascade is mediated by sequential 
phosphorylation and activation of the components in the sequential tiers. 
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Therefore, they cooperate in transmitting various extracellular signals and thus 
control a large number of distinct and even opposing cellular processes, such as 
proliferation, differentiation, survival, development, stress response, and apoptosis, 
depending on the cell type and stimulation (Avruch, 2007; Krishna and Narang, 
2008; Raman et al., 2007). In fact, their mis-regulation often leads to diseases like 
cancer, diabetes or inflammation (Dhillon et al., 2007; Jeffrey et al., 2007; Zick, 
2005). 
 
2. The p38 MAPK pathway 
The first member of the p38 MAPK family was identified as a 38 kDa protein (p38) 
that was rapidly phosphorylated on tyrosine in response to LPS 
(lipopolysaccharide) stimulation (Han et al., 1994). This protein was found to be 
the homologue of Saccharomyces cerevisiae Hog1, an important regulator of the 
osmotic response, and is now referred to as p38α (MAPK14). Additional p38 
MAPK family members, which are approximately 60% identical in their amino 
acid sequence, were subsequently cloned and named p38β (MAPK11), p38γ 
(MAPK12) and p38∂ (MAPK13) (Enslen et al., 1998; Goedert et al., 1997; Jiang et 
al., 1996; Jiang et al., 1997; Lechner et al., 1996; Mertens et al., 1996). The four 
p38 MAPKs are encoded by different genes and have different tissue expression 
patterns, with p38α being ubiquitously expressed at significant levels in most cell 
types, whereas the others seem to be expressed in a more tissue-specific manner 
(Cuadrado and Nebreda, 2010). 
 
Inhibitors and therapeutic implications 
Despite their high sequence homology, p38 MAPK isoforms differ in their 
sensitivity to chemical inhibitors (Coulthard et al., 2009). The discovery of 
pathological conditions in which p38 MAPKs are involved (Fig. 5) supports the 
potential therapeutic interest of modulating the activity of these kinases. Pyridinyl-
imidazole drugs, such as SB203580, were the first p38 MAPK inhibitors to be 
identified and they were designed to fit the ATP-binding site (Fig. 6). At low 
concentrations, these compounds inhibit p38α and p38β, but not p38γ and p38∂ 
(Cuenda et al., 1997; Goedert et al., 1997). Several of the compounds have proven 
INTRODUCTION 
 27	  
efficacy in preclinical models and good pharmacological properties and therefore 
have reached clinical trials (Cohen, 2009), like is the case for PH-797804 
(Goldstein et al., 2010). 
 
Figure 5. Physiological roles and pathological implications of p38 MAPKs pathways. p38 
MAPKs play a central role in the regulation of many biological functions, so their 
deregulation can lead to the development of several pathological conditions. (Cuenda and 
Rousseau, 2007). 
 
 
p38 MAPK in cancer 
During the last few years, members of the p38 MAPK family have joined the group 
of signaling pathways involved in the regulation of the cell transformation process. 
It has been shown that p38 MAPK pathway could be involved in some of the 
alterations observed in the physiology of transformed cells: self-sufficiency in 
growth signals, unlimited replication potential, protection against apoptotic cell 
death, de novo angiogenesis, and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000), being most frequently associated with a tumor-suppressor 
function. This role of p38 MAPK can largely be attributed to the inhibitory effects 
of the p38α and p38β isoforms on G1/S and G2/M cell-cycle-checkpoint controls 
(Ambrosino and Nebreda, 2001), to promote growth arrest and induction of 
apoptosis (Bulavin and Fornace, 2004; Kummer et al., 1997; She et al., 2001) or 
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cellular senescence (Bulavin et al., 2002; Haq et al., 2002; Wang et al., 2002). 
Collectively, these data suggest that inactivation of the p38 MAPK pathway will 
enhance cellular transformation by negatively regulating cell proliferation and 
inducing apoptosis.  
 
However, this tumor-suppressor function seems to be mainly operative at the onset 
of cellular transformation (Dolado et al., 2007; Hui et al., 2007; Ventura et al., 
2007), as enhanced p38 MAPK phosphorylation has been correlated with poor 
overall survival in patients with HER-2 negative breast cancer (Esteva et al., 2004) 
or with hepatocellular carcinoma (Wang et al., 2012). A few publications have 
provided evidence for an oncogenic potential of this cascade, as overexpression or 
over activation of p38α has been reported in transformed follicular lymphomas 
(Elenitoba-Johnson et al., 2003) and in thyroid neoplasms (Pomerance et al., 
2006). Nonetheless, the potential pro-tumorigenic roles of p38α signaling are not 
only based on correlations with bad prognosis in cancer, but there is also evidence 
that this pathway may contribute to the survival or proliferation of cancer cell lines 
from different origins, including breast (Chen et al., 2009), colorectal (Chiacchiera 
et al., 2009), prostate (Ricote et al., 2006) or skin (Schindler et al., 2009). 
 
Crosstalk between different signaling pathways is a common theme in cell 
regulation, which is usually highly dependent on cell context. The JNK and p38 
MAPK pathways share several upstream regulators (Fig. 4), and accordingly there 
are multiple stimuli that simultaneously activate both cascades, although interplays 
at the levels of downstream target have also been described in several contexts 
(Wagner and Nebreda, 2009). 
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Figure 6. p38 MAPK activation and inhibition. (a) p38 MAPK is activated in multiple steps. 
ATP is required for phosphorylation of the TGY motif on the activation loop. Once this has 
occurred, there is a conformational change in the kinase, exposing a binding site for a 
substrate. (b) Classical pyridinyl imidazole inhibitors (e.g. SB203580) are similar in shape to 
ATP molecules and compete for ATP-binding site. Once the inhibitor is bound, ATP is 
blocked and phosphorylation of the TGY motif does not occur, leaving p38 MAPK inactive. 
(Coulthard et al., 2009). 
 
3. The JNK cascade 
MAPK8, MAPK9 and MAPK10 genes encode JNK1, JNK2 and JNK3 proteins 
respectively, which are alternatively spliced to create at least 10 isoforms (Dreskin 
et al., 2001; Gupta et al., 1996). In most cells the 46 kDa proteins are mainly JNK1 
isoforms, the 54 kDa proteins are mainly JNK2, the 52 kDa band represents only 
JNK3, and this is often the simplified nomenclature used for JNK bands upon SDS-
PAGE (Keshet and Seger, 2010). JNK1 and JNK2 are believed to be expressed in 
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every cell and tissue type, whereas JNK3 is found primarily in brain and to a lesser 
extent in heart and testis (Bode and Dong, 2007). 
 
The pro-apoptotic role of JNK 
As mentioned above, the JNK pathway is activated by the exposure of cells to 
stress. Nonetheless, its specific role may depend on the cellular context, as it has 
been implicated in both apoptosis and survival signaling (Ip and Davis, 1998). 
Regarding its apoptotic role, it has been demonstrated that JNK is required for 
stress-induced apoptosis mediated by the mitochondrial/caspase-9 pathway in 
response to UV radiation (Fig. 7), as JNK depletion causes failure to release 
cytochrome c and further caspase-3 activation (Tournier et al., 2000). It is also 
known that JNK-mediated apoptosis involves recruitment and regulation of 
members of the Bcl-2 family, which is itself antiapoptotic. Bcl-2 activity is blocked 
by the related BH3-only protein Bim when it is phosphorylated by JNK, thereby 
promoting apoptosis (Kyriakis and Avruch, 2012).  
 
However, most forms of environmental stress do not cause apoptosis under 
conditions that are sufficient for JNK activation. This is partly because the JNK-
dependent apoptotic signaling pathway can be blocked by activation of survival 
pathways, such as NF-κB, Akt and ERK. Thus, JNK pathway functions within the 
overall context of the state of activation of other signaling pathways. The absence 
of an apoptotic response also appears to correlate with the time course of JNK 
activation, being its sustained (but not transient) activation associated with 
apoptosis (Chen and Tan, 2000). 
 
Response of JNK to cisplatin treatment 
Cytotoxic activity of cis-diamminedichloroplatinum (II), or cisplatin (CDDP), was 
recognized more than 35 years ago. It is a small, neutral inorganic complex that 
becomes activated after entering into the cell, replacing its cis-chloro ligands with 
water molecules (el-Khateeb et al., 1999; Kelland, 2000). Such aquated form of 
CDDP is very reactive towards nucleophilic centers of biomolecules like proteins, 
RNA and DNA molecules, membrane phospholipids and microfilaments. Despite 
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the growing evidence on the binding of CDDP to non-DNA targets and their 
importance in CDDP-toxicity, it is generally accepted that the binding of CDDP to 
DNA is largely responsible for its antitumour properties (Fuertes et al., 2003; 
Jamieson and Lippard, 1999). Today it is one of the most effective and commonly 
used chemotherapeutics for the treatment of many solid tumors, including ovarian, 
testicular, bladder, lung and head and neck tumors (Boulikas and Vougiouka, 
2003). 
 
 
Figure 7. Role of the JNK signaling pathway in stress-induced apoptosis. The caspase 
apoptotic machinery is illustrated in a simplified cartoon. Effector caspases, including 
caspase-3, are activated by initiator caspases that are activated by cell surface death 
receptors (caspase-8) and by the mitochondrial pathway (caspase-9). JNK is not required for 
death receptor signaling, but it is required for caspase-9 activation by the mitochondrial 
pathway. Potential targets of JNK include members of the Bcl2 group of apoptotic regulatory 
proteins. (Davis, 2000). 
 
Different tumour cell lines and experimental approaches have been used to study 
the causes and consequences of CDDP-induced MAPK activation. It seems that 
proteins involved in recognition of a platinum atom linked to DNA, are important 
regulators in triggering MAPK signaling pathways. For instance, CDDP and its 
analogue oxaliplatin activate different MAPK, which are further responsible for 
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their cytotoxic effects. CDDP-induced JNK activation seems to be a key pro-
apoptotic mediator of cell death on a panel of four colon adenocarcinoma cell 
lines (Vasilevskaya et al., 2004), whereas upon oxaliplatin exposure this role was 
played by p38 MAPK (Rakitina et al., 2003).  
 
There are several repair systems involved in recognition and repair of CDDP 
adducts like nucleotide excision repair (NER), homologous recombination (HR) 
repair and mismatch repair (MMR) (Brabec and Balcarova, 1993; Jordan and 
Carmo-Fonseca, 2000). Activation of JNK induced by CDDP is substantially 
greater in MMR proficient than in MMR deficient tumor cells (Nehme et al., 1997). 
The activation of MAPK also depends on the nature of the platinum drug. CDDP 
activates JNK slowly and persistently, while transplatin activates this kinase rapidly 
and briefly, or (in some cases) does not activate it at all (Levresse et al., 2002; 
Persons et al., 1999; Sanchez-Perez et al., 1998). The pro-death or pro-survival 
role of MAPK in response to CDDP could depend on the type of activated MAPK, 
but in most of the investigated cell systems JNK activation has a pro-death role 
(Koyama et al., 2006; Krilleke et al., 2003; Li et al., 2005; Mansouri et al., 2003; 
Sanchez-Perez et al., 2002; Sanchez-Perez et al., 1998; Sanchez-Perez and 
Perona, 1999). The time course of MAPK activity appears to be also important, 
because it will decide the fate of CDDP treated cells. Thus, lack of prolonged 
activation of JNK in CDDP-resistant cells determined their survival upon CDDP 
treatment, which was not the case in the sensitive cell line (Li et al., 2005).  
 
The role of c-Jun in CDDP-induced apoptosis was documented in NIH3T3 
fibroblasts derived from mouse embryos lacking c-jun. CDDP induces sustained 
JNK activation that occurs via the MEKK1/SEK1 cascade, causing cell death 
(Sanchez-Perez and Perona, 1999). CDDP resistant mouse fibroblasts lacking c-Jun 
became sensitive after re-expression of c-Jun (Toh et al., 2004). Activation of 
MEKK1 may upregulate pro-apoptotic pathways through c-Jun-dependent FasL 
transcription and simultaneous downregulation of survival pathways that are NF-
κB transcription-dependent (Sanchez-Perez et al., 2002). The timing of JNK activity 
is essential, because it will determine whether cells will survive or undergo 
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apoptosis (Mansouri et al., 2003).  
 
Despite the activation of p38 and ERK by CDDP, the JNK pathway actually 
represents a primary target for the modulation of CDDP lethality in p53 
deficient/mutated cells (Bae et al., 2006).  
 
Signaling pathways are integrated in a very complex network and the final 
response depends on the balance of activity of several of these networks, the cell 
type, as well as proliferation and differentiation status of tumour cells.  The 
important questions are whether MAPK are also indeed in vivo determinants of 
tumour cell response to cisplatin- based therapy, and whether they could be used 
as potential prognostic factors.  
 
4. Pathway inactivation 
Since MAPK cascades are key mediators of most stimulation-induced cellular 
processes, their downregulation is critical to achieve transient activation and to 
regulate signal intensity, which in turn results in specific outcomes. Termination of 
the kinase catalytic activity involve the action of the protein tyrosine phosphatase 
(PTP) superfamily, which are potentially candidate tumor suppressors due to their 
opposing role to the MAPKs (Julien et al., 2011). 
 
The PTP superfamily 
The PTP superfamily comprises 107 members that are broadly grouped into four 
separate families on the basis of their amino acid sequences of their catalytic 
domains (Alonso et al., 2004) (Fig. 8). The first and largest PTP family contains 
type-I cysteine-based PTPs. These phosphatases can be divided further into 
subgroups depending on the similarity of the catalytic domains, comprising either 
tyrosine-specific classical PTPs or the dual-specificity phosphatases (DUSP). The 
second PTP family contains only one phosphatase, low-molecular-mass PTP 
(LMWPTP), that is type-II cysteine-based and tyrosine-specific. It is related to low-
molecular-mass bacterial phosphatases that are evolutionarily conserved (Alonso 
et al., 2004). The third PTP family consists of rhodanese-related type-III cysteine-
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based phosphatases that are both tyrosine- and threonine-specific (Alonso et al., 
2004; Russell and Nurse, 1986). This group consists of three cell cycle regulators: 
Cdc25A, Cdc25B and Cdc25C, which dephosphorylate cyclin-dependent kinases 
(Karlsson-Rosenthal and Millar, 2006). The fourth PTP family consists of aspartic 
acid-based PTPs, which comprises the eyes absent (EyA) tyrosin specific 
phosphatases and haloacid dehalogenase (HAD) family phosphatases (Moorhead 
et al., 2007). The HAD family is a heterogeneous group of phosphatases that can 
be either tyrosine- (Rebay et al., 2005) or serine- (Gohla et al., 2005; Yeo et al., 
2003) specific and have various substrates, including proteins, phospholipids, 
sugars and nucleotides (Lunn et al., 2000; Roberts et al., 2004). Below we will 
describe type-I PTPs. 
 
 
 
 
 
 
 
 
 
Figure 8. Classification 
of PTPs. PTPs can be 
classified into four 
subgroups on the basis 
of their sequence 
similarity and presence 
of functional or binding 
domins. EyA, eyes 
absent; LMWPTP, low 
molecular mass PTP. 
(Patterson et al., 2009). 
 
Classical PTPs 
Classical PTPs can be categorized as receptor PTPs (RPTPs) or non-receptor PTPs. 
(Fig. 9). RPTPs have the potential to regulate signaling through ligand-controlled 
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protein tyrosine dephosphorylation. Many of them display features of cell-
adhesion molecules in their extra-cellular segment and have been implicated in 
processes that involve cell-cell and cell-matrix contact. Cytoplasmic PTPs are 
characterized by regulatory sequences that flank the catalytic domain and control 
activity either directly, by interactions at the active site that modulate activity or by 
controlling substrate specificity. 
 
Dual-specificity PTPs 
This is a very large and heterogeneous subgroup whose unique feature is the 
ability to dephosphorylate both tyrosine and serine/threonine residues within one 
substrate. There are 61 DUSP of very different forms and functions, which can be 
grouped on the basis of the presence of specific domains and sequence similarity. 
One of the best characterized subgroups is the mitogen-activated protein kinase 
phosphatases (MKP), which contains ten protein that can dephosphorylate MAPKs 
at both phospho-threonine and phospho-tyrosine residues simultaneously (Table 
1). 
 
Figure 9. The classical PTPs. Classical PTPs can be categorized as receptor-like (R) or  non-
transmembrane (NT) proteins, although this is not an absolute distinction. (Tonks, 2006). 
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Individual MKPs show substrate specificity preference for one or more of the 
MAPKs, ERK, JNK or p38 (Fig. 10), although the MAPK substrate preference for 
individual MKPs in vitro does not always reflect that in vivo. Many MKPs are 
inducible or early-response genes and demonstrate low expression in resting or 
unstressed cells, with their expression rapidly increasing upon appropriate 
stimulation, e.g. with various cytokines, growth factors or serum. However, the 
kinetics and magnitude of the response of individual MKPs to these stimuli can be 
cell-type and context-specific (Brondello et al., 1997; Ekerot et al., 2008; Keyse, 
2000; Wu et al., 2006). This induction is often dependent on MAPK activation and 
hence is thought to be a negative-feedback mechanism for down-regulating 
mitogenic signaling. In addition, MKPs can be subject to post-translational 
modification. Owing to the presence of the catalytic cysteine residue in the 
catalytic cleft, the enzymatic activity of PTPs including MKPs is sensitive to 
reversible oxidation and inactivation. Reversible oxidation of the conserved 
cysteine within the DUSP catalytic domain abolishes its nucleophilic properties 
and leads to profound changes in the conformation of the catalytic cleft, rendering 
the phosphatase inactive (Kamata et al., 2005). This may be mediated by the 
regulated production of reactive oxygen species such as H2O2 within the cell 
(Chiarugi and Cirri, 2003; Lambeth, 2004; Tonks, 2005) although the regulation of 
this process under normal physiological conditions, as well as in particular disease 
states, requires further clarification.  
 
Table 1. Nomenclature of MKPs 
 
MKPs are listed here according their official HUGO Gene Nomenclature Committee name. 
Alternative names are also listed. The MAPK substrate specificity is listed in order of 
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preference; however, for DUSP2, preference in vitro differs from that in vitro. In vivo, 
DUSP2 inhibits JNK preferentially. Note that MK-STYX is catalytically inactive. The 
subcellular localization of these MKPs is also listed, with the nuclear MKPs most likely to be 
inducible. Adapted from (Dickinson and Keyse, 2006).  
 
Reversible oxidation of PTPs 
The production of reactive oxygen species (ROS), such as hydrogen peroxide, and 
the resulting post-translational modification of proteins by reversible oxidation 
have been implicated in the regulation of tyrosine phosphorylation-dependent 
signaling pathways that are initiated by a wide variety of stimuli, including growth 
factors, hormones, cytokines and cellular stresses (Finkel, 2003; Lambeth, 2004; 
Rhee et al., 2005). Attention was drawn to the PTPs as targets of ROS because the 
signature motif of this family contains an invariant cysteine residue that, due to the 
unique environment of the PTP active site, is characterized by an extremely low 
pKa (den Hertog et al., 2005; Salmeen and Barford, 2005; Tonks, 2005). The low 
pKa at the bottom of the catalytic cleft maintains the conserved cysteine residue in 
a negatively charged thiolate form, allowing nucleophilic attack on the substrate 
phosphate. On the other hand, being negatively charged makes the cysteine 
particularly sensitive to oxidative stress, which inactivates the enzyme activity by 
inducing profound changes in the catalytic site architecture. 
 
Unlike the classical PTPs, the dual-specificity phosphatases contain a second 
cysteine residue within the active site. Following oxidation of the nucleophilic 
cysteine within the signature motif, a disulfide bond is formed with the 
neighboring cysteine protecting the enzymes from the irreversible inactivation that 
would result from higher oxidized species (Salmeen and Barford, 2005). The S–S 
bond can be readily reduced, which ensures the transient nature of the 
modification and returns the enzymes to their active form. 
 
The current model is that physiological stimuli, such as growth factors or 
engagement of antigen receptors, trigger localized production of ROS. This leads 
to oxidation and inactivation of those PTPs that normally function to attenuate the 
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signaling response. Oxidation is transient, with the PTPs being reduced back to 
their active state by the action of cellular reducing agents such as thioredoxin or 
glutathione, leading to signal termination. Although particularly exciting as a new 
tier of control of pTyr-dependent signalling, there are several issues that must be 
resolved before the physiological importance of redox regulation of PTPs can be 
established. For instance, since the active site cysteine is particularly sensitive, it is 
likely that there will be intrinsic differences in sensitivity to oxidation between 
individual PTPs (Groen et al., 2005). It is also likely that those PTPs that are 
colocalized with sites of ROS production will be preferentially oxidized. For 
example, it has been shown that Nox4 regulates the oxidation of PTP1B in 
response to insulin (Goldstein et al., 2005) and colocalizes with PTP1B on 
intracellular membranes (Martyn et al., 2006). Therefore, it will be important to 
define further where in the cell oxidation occurs, the precise source of ROS, such 
as Nox (NADPH oxidases) enzymes (Goldstein et al., 2005) or mitochondria 
(Kamata et al., 2005), and how the localization of the PTPs is regulated. 
 
 
 
Figure 10. Classification and phylogenetic analysis of the MKPs. The three subgroups of 
DUSP proteins together with defining properties are indicated by the coloured ovals. 
(Dickinson and Keyse, 2006). 
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Oxidative stress 
Oxidative stress refers to a situation of an imbalance between pro-oxidant and 
antioxidant factors controlled by multiple components, which might lead to 
cellular damage. Reactive oxygen species (ROS), such as superoxide anion (O2
-), 
hydrogen peroxide (H2O2) and hydroxyl radical (HO·), consist of radical and non-
radical oxygen species formed by the partial reduction of oxygen, which are key 
players in oxidative stress. This results in direct or indirect ROS-mediated damage 
of nucleic acids, proteins or lipids, and has been implicated in carcinogenesis 
(Trachootham et al., 2009), neurodegeneration (Andersen, 2004; Shukla et al., 
2011), atherosclerosis, diabetes (Paravicini and Touyz, 2006), and aging (Haigis 
and Yankner, 2010). 
  
1. Cellular sources of ROS 
In cancer cells high levels of reactive oxygen species can result from increased 
metabolic activity, mitochondrial dysfunction, peroxisome activity, increased 
cellular receptor signaling, oncogene activity, increased activity of oxidases, 
cyclooxygenases, lipoxigenases and thymidine phosphorylase or through cross-talk 
with infiltrating immune cells (Storz, 2005; Szatrowski and Nathan, 1991).  
 
In mitochondria, ROS are produced as an inevitable byproduct of oxidative 
phosphorylation (Fig. 11). The electron transport chain encompasses complexes I–
IV and ATP synthase on the mitochondrial inner membrane. Superoxide is 
generated at complexes I and III and released into the inter-membrane space 
(∼80% of the generated superoxide) or the mitochondrial matrix ( ∼20%) (Han et 
al., 2001). The mitochondrial permeability transition pore (MPTP) in the outer 
membrane of the mitochondrion allows the leakage of superoxide into the 
cytoplasm (Crompton, 1999; Storz, 2006). Superoxide is dismutated to H2O2, 
either in the mitochondrial matrix (by MnSOD) or in the cytosol (by Cu/ ZnSOD). 
H2O2 is a bona fide second messenger that is highly diffusible. Recent data suggest 
that H2O2 may cross cellular membranes through specific members of the 
aquaporin family (Bienert et al., 2007). 
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Growth factors and cytokines stimulate the production of ROS to exert their 
diverse biological effects in cells (Bae et al., 2000; Goustin et al., 1986; 
Sundaresan et al., 1995). For example, an elevation of hydrogen peroxide and 
nitrite oxide levels was detected in tumor cells in response to interferon γ (IFN γ) 
and TNFα (Lo and Cruz, 1995; Tiku et al., 1990). Further, platelet-derived growth 
factor (PDGF), epidermal growth factor (EGF), insulin, transforming growth factor β 
(TGFβ), interleukin-1 (IL-1), tumor necrosis factor α (TNFα), angiotensin and 
lysophosphatidic acid all induce the formation of superoxide (Bae et al., 2000; 
Griendling et al., 1994; Roy et al., 2006; Sundaresan et al., 1995). Activation of 
the small GTPase K-ras downstream of growth factors or its oncogenic mutation 
has been associated with increased generation of superoxide and the incidence of 
various cancers (Aunoble et al., 2000; Minamoto et al., 2000; Minamoto et al., 
2002). Dependent on the cellular system, growth factors and mutant K-ras elevate 
intracellular superoxide levels through NADPH oxidase or mitochondria (Storz, 
2005). NADPH oxidase can also be activated via the RhoGTPase Rac-1 (Chiarugi 
and Fiaschi, 2007). Rac-1-mediated generation of superoxide is induced by cell 
surface receptors including c-Met (Ferraro et al., 2006).  
 
2. Cellular detoxification from ROS 
Under normal physiological conditions, the intracellular levels of ROS are steadily 
maintained to prevent cells from damage. Detoxification from ROS is facilitated by 
non-enzymatic molecules (i.e. glutathione, flavenoids and vitamins A, C and E) or 
through antioxidant enzymes, which specifically scavenge different kinds of ROS 
(Fig. 11). Superoxide dismutases (SODs) are metalloenzymes that catalyze the 
dismutation of superoxide anion to oxygen and hydrogen peroxide. These 
enzymes exist ubiquitously in eukaryotes and prokaryotes. Superoxide dismutases 
utilize metal ions such as copper (Cu2+), zinc (Zn2+), manganese (Mn2+) or iron 
(Fe2+) as cofactors. The different SOD enzymes are located in different 
compartments of the cell and are highly specific in regulating linked biological 
processes (Copin et al., 2000).  
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Figure 11. Major mechanisms of ROS generation and detoxification. Superoxide (O2•–) 
radicals are generated at the inner membrane of the mitochondria as a byproduct of the 
electron transport chain and then release into the mitochondrial matrix or the cytosol via 
the mitochondrial permeability transition pore (MPTP). Superoxide is also generated through 
activation of NADPH oxidases (NOX), for example in response to growth factor receptor 
(GF-R) or cytokine receptor activation. SOD enzymes, such as MnSOD in the mitochondrial 
matrix or Cu/ZnSOD in the cytosol, reduce superoxide to H
2
O
2
. Several cytosolic antioxidant 
systems, including catalase, glutathione peroxidase (GPX) and peroxiredoxins (Prx), detoxify 
cells from hydrogen peroxide by reducing it to water. Both hydrogen peroxide and 
superoxide contribute to cellular signaling but also can form hydroxyl radicals (•OH). 
Hydroxyl radicals are generated from O2•– and H
2
O
2 
in the Fenton reaction and have 
damaging functions for proteins, DNA and lipids. (Liou and Storz, 2010). 
 
Catalase facilitates the transformation of H2O2 to H2O and O2. The major 
localization of catalase in most eukaryotes is in the cytosol and peroxisomes 
(Bendayan and Reddy, 1982; Hashimoto and Hayashi, 1990; Litwin et al., 1987). 
Peroxiredoxins are thioredoxin peroxidases that catalyze the reduction of H2O2, 
organic hydroperoxides and peroxynitrite (Hofmann et al., 2002; Rhee et al., 
1999; Wood et al., 2003). The thioredoxin system consists of thioredoxin and 
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thioredoxin reductase. In its active state, thioredoxin scavenges reactive oxygen 
species and keeps proteins in their reduced state (Arner and Holmgren, 2000). 
Thioredoxin is regenerated by thioredoxin reductases, which utilize NADPH as an 
electron donor (Mustacich and Powis, 2000). 
 
The glutathione system includes glutathione (GSH), glutathione reductase, 
glutathione peroxidases (GPX) and glutathione S-transferases (GST). Glutathione 
protects cells from oxidative stress by reducing disulphide bonds of cytoplasmic 
proteins to cysteines. During this process, glutathione is oxidized to glutathione 
disulphide (GSSG). Glutathione peroxidases (GPX) catalyze the breakdown of 
hydrogen peroxide and organic hydroperoxides (Brigelius-Flohe, 1999; Ursini et 
al., 1995). Glutathione reductase reduces GSSG and refills GSH pools (Carlberg 
and Mannervik, 1975). Under physiological conditions, glutathione almost 
exclusively exists in its reduced form because of a constitutive activity of 
glutathione reductase in cells (Beutler, 1969). Glutathione S-transferases are 
detoxification enzymes that catalyze the conjunction of GSH to a variety of 
exogenous and endogenous electrophilic compounds (Hayes et al., 2005; Sharma 
et al., 2004; Townsend and Tew, 2003).  
 
3. Adaptation to high ROS levels in cancer cells 
Cells can adapt to survive under certain levels of oxidative stress. As cancer cells 
actively produce high levels of ROS and are consistently exposed to such 
endogenous oxidants, one would expect that the intrinsic oxidative stress may 
exert selective pressure to enrich the population of cells that are capable of stress 
adaptation (Kim et al., 2006; Schneider and Kulesz-Martin, 2004). Those cells that 
survive oxidative stress are likely to have acquired adaptive mechanisms to 
counteract the potential toxic effects of elevated ROS and to promote cell-survival 
pathways (Irmak et al., 2003). For example, oncogenic H-Ras-transformed cells, 
which exhibited increased superoxide and hydrogen peroxide levels, were shown 
to express higher levels of antioxidants compared with their non-tumorigenic 
parental cells (Young et al., 2004). Their enhanced antioxidant capability is likely 
to serve as a key mechanism to evade ROS-induced apoptosis, as evidenced by 
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the resistance to hydrogen peroxide-induced cell death that was observed in the 
Ras-transformed cells (Young et al., 2004). These were also found to be more 
sensitive to depletion of glutathione (GSH), leading to ROS accumulation and cell 
death (Trachootham et al., 2006), suggesting a crucial role of antioxidants in cell 
survival.  
 
 
Figure 12. Redox adaptation in cancer development. Severe accumulation of ROS under 
various endogenous and exogenous stress stimuli may induce lethal damage in cells that 
have inadequate stress responses or adaptation. In certain cancer cells, persistent ROS stress 
may induce adaptive stress responses including activation of redox-sensitive transcription 
factors, leading to an increase in the expression of ROS-scavenging enzymes, elevation of 
survival factors, and inhibition of cell death factors, such as caspases. ROS-mediated DNA 
mutations or deletions promote genomic instability and thus provide an additional 
mechanism for stress adaptation. All these events enable cells to survive with the high level 
of ROS and maintain cellular viability. As these transcription factors also have roles in 
regulating the expression of genes that are responsible for proliferation, senescence evasion, 
angiogenesis and metastasis, the redox adaptation processes may promote cancer 
development. Furthermore, the increase in glutathione during adaptation can enhance the 
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export of certain anticancer drugs and their inactivation. This altered drug metabolism 
together with enhanced cell survival may render cancer cells more resistant to 
chemotherapeutic agents. (Trachootham et al., 2009). 
 
 
Thus, it is conceivable that during malignant transformation the oncogenic signals 
both induce ROS generation to stimulate cell proliferation through redox-sensitive 
transcriptional factors, and promote antioxidant adaptive mechanisms to minimize 
oxidative damage. As shown in figure 12, redox adaptation by activating ROS-
scavenging enzymes to counteract increased ROS generation seems to be a major 
mechanism by which cancer cells maintain redox homeostasis. Therefore, 
abrogation of this adaptation mechanism could be an attractive strategy to 
preferentially affect cancer cells and may therefore have therapeutic implications. 
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p38α is known to have a tumor suppressor role based on its ability to negatively 
regulate cell proliferation and to induce cell death. However, most of these studies 
have focused on the investigation of p38α functions during tumor initiation, and 
we still do not fully understand the roles of p38α in tumor progression.  
 
The aim of this work was to determine whether p38α might be necessary for the 
survival of cancer cells to chemotherapy treatments following two approaches: 
- Identify synthetic lethal partners of p38α 
- Determine if the inhibition of p38α synergizes with chemotherapeutic 
treatments to induce tumor cell death. 
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Buffers and solutions 
Laboratory common stock solutions and buffers were prepared as described in 
Current Protocols in Cell Biology (2001), unless purchased, in which case 
references are provided in the “Commercial Reagents and Kits” section. Therefore, 
only unique solutions for this thesis are specified below. 
 
Antioxidants (100 mM stock) 
It is extremely important to adjust pH to 7.5 in both cases. Aliquot solutions and 
store at -20 ºC. Do not freeze again after thawing. 
- GSH: 0.61 g GSH + 20 ml PBS 
- NAC: 0.65 g NAC + 40 ml PBS 
 
Buffer B (to resuspend bacterial pellets) 
50 mM Tris-HCl pH 8.0  10 µg/ml leupeptin 
1 mM EDTA     10 µg/ml pepstatin A 
1 mM DTT     2.5 mM benzamidine 
        1 mM PMSF 
 
Buffer D (for dialysis)      
50 mM Tris-HCl pH 7.5    
0.1 mM EDTA      
2 mM DTT       
50 mM NaCl    
50% glycerol      
   
Buffer H (high salt concentration)  Buffer L (low salt concentration) 
50 mM Tris-HCl pH 8.0     50 mM Tris-HCl pH 8.0  
1 mM EDTA         1 mM EDTA   
1 mM DTT         1 mM DTT 
1% Triton X-100       50 mM NaCl 
500 mM NaCl        1 mM PMSF 
1 mM PMSF 
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HBS buffer (2x)      
10 ml of 1M HEPES     
11.2 ml of 5 M NaCl      
0.3 ml of 1 M Na2HPO4.2H2O    
H2O up to 180 ml (set pH to 7.12 with NaOH) 
H2O up to 200 ml 
 
Kinase buffer 
50 mM Tris-HCl pH 7.5 
10 mM MgCl2 
1 mM DTT 
 
Lysis buffer 
50 mM Tris-HCl pH 7.5  
150 mM NaCl     20 mM NaF 
1% NP-40      0.1 mM Na3VO4 
5 mM EDTA      1 µM microcystin 
5 mM EGTA      Protease Inhibitor Cocktail Set III  
 
Mowiol 
2.4 g Mowiol  
6.0 g Glycerol 
6.0 ml water 
Vortex well and shake for approximately 2 h at RT. Add 12 ml 0.2 M Tris-HCl pH 
8.5. Incubate at 50 ºC for approximately 3 h, with occasional mixing until most of 
the Mowiol is dissolved (it will never dissolve completely). Centrifuge at 5000 xg 
for 15 min to remove the sedimented Mowiol. Add DABCO antifading to 2.5%, 
aliquot and store at -20 ºC (it is stable for at least 1 year). Heat at 40 ºC before use 
(once heated, store at 4 ºC, it can be used for 1 month). 
 
PBS-T 
PBS + 0.1% (v/v) Tween-20 
Either store in 
aliquots at -20 ºC 
or add the 
inhibitors right 
before use 
Filter through 
0.5 µm, 
aliquot and 
store at -20ºC 
ºC 
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Phosphatase buffer 
50 mM Tris-HCl pH7.5   
250 mM NaCl     10 µg/ml pepstatin 
1% (v/v) Triton X-100   1.4 µg/ml aprotinin 
1 mM PMSF      10 µg/ml leupeptin 
 
Tissue lysis buffer 
50 mM Tris-HCl pH 7.5   10 µg/ml pepstatin 
150 mM NaCl     1.4 µg/ml aprotinin 
1% NP-40      10 µg/ml leupeptin 
5 mM EDTA      20 mM NaF 
5 mM EGTA      0.1 mM Na3VO4 
1 mM DTT      1 µM microcystin 
1 mM PMSF 
 
TNB buffer 
100 mM Tris-HCl pH 7.5 
150 mM NaCl  
0.5% Blocking Reagent (see “Commercial Reagents and Kits”) 
(Optional: 0.05% sodium azide to prevent contamination) 
 
 
 
 
Cell lines 
Human cancer cells 
We used cell lines derived from breast (MCF7, MDA-MB-231), cervix (HeLa), 
colon (HCT116, HCT116 p53 KO, HT-29, RKO, SW620) and osteosarcoma 
(U2OS). HEK293-derived 293T cells, provided by M. Serrano (CNIO, Madrid), 
were used to produce shRNA-expressing viruses. 
 
 
Either store in 
aliquots at -20 ºC 
or add the 
inhibitors right 
before use 
Either store in 
aliquots at -20 ºC 
or add the 
inhibitors right 
before use 
Shake for 1 h at 60 ºC to dissolve the Blocking Reagent. 
Aliquot and store at -20 ºC 
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Commercial Reagents and Kits 
Article          Brand            Reference 
40% Acrylamide/Bis (29:1)    Bio-Rad              161-0146 
Ampicillin sodium salt      Sigma       A9518  
Annexin V         BD Biosciences          556547 
Aprotinin          Sigma            A6279 
APS           Sigma            A3678 
ASK1 inhibitor        Otava            7214191049 
BSA           Sigma            A7906 
Benzamidine        Sigma            B6506 
Blocking Reagent       Boehringer Manheim      1096176 
β-mercaptoethanol       Sigma            M7154 
BrightVision poly-HRP anti-IgG   ImmunoLogic         DPVO110HRP 
Cell Death Detection ELISAPLUS kit  Roche            11 920 685 001 
Cisplatin (for cells, 0.5 mg/ml)   Ferrer Farma          657932 
Cisplatin (for mice, 1.0 mg/ml)   Accord                683046-8 
Citrate          Merck       1-06448-5000 
DAPI           Invitrogen          MP-36930 
DAB           Dako       K3468 
DABCO antifading reagent    Sigma            D2522 
DCFDA          Sigma            D6883 
Dharmafect 1        Dharmacon          T-2001 
DMEM          Sigma            D5796 
DMSO (for cell culture)     Sigma            276855 
DMSO (for MTT assays)     Fisher Scientific         W03448 
DNase I          Roche            4716728a 
dNTPs mix (10 mM)      Fermentas          R0192 
Doxorubicin         Sigma            D1515 
DPI           Sigma            D2926 
DTT           GE Healthcare    17-1318-02 
Eosin (1% yellowish solution)    Panreac      251301-1611 
Etoposide         Sigma            E1383 
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FBS           Thermo Scientific        E6541L 
Formalin 10% (buffered)     Sigma            HT501128 
Glutathione         Sigma            G6013 
Glutathione Sepharose 4B beads   GE Healthcare             17-0756-01 
Glycerol          Fluka       49782 
Hematoxylin (Mayer’s)      Panreac      254766-1611 
IPTG           Sigma            I6758 
LB            Invitrogen     12795-084 
Leupeptin         Sigma            L2884 
L-Glutamine 200 mM      LabClinics          M11-004 
Library of inhibitors      Merck Millipore         539746 
LY294002         Merck Millipore         440202 
Methyl cellulose       Sigma       M7140 
Microcystin-LR        Enzo Life Sciences        ALX350012 
Mowiol          Calbiochem          475904 
Mr. Frosty Freezing Container   Thermo Scientific        5100-0001 
MTT           Sigma            M2128 
MycoAlert         Lonza            LT07-318 
NAC           Sigma            A9165 
Neocarzinostatin       Sigma            N9162 
Nitrocellulose 0.2 µm membrane  Protran                10401396  
NP-40          AppliChem          A1694-0250 
Oxidative Stress PCR Array    SABiosciences             PAHS-065Z 
Oxyblot          Millipore           S7150 
PBS 10x          Sigma            D1408 
Penicillin/Streptomycin (100x)   LabClinics          P11-010 
Pepstatin A         Sigma            P4265 
Peroxidase         Dako            S2023 
PFA 16%          EMS            15710 
PH-797804         Selleckchem          S2726 
Phenol:chloroform       Sigma            P2069 
Phosphatase Assay (Ser/Thr)    Promega           V2460 
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Phosphatase Assay (Tyr)     Promega           V2471 
PI            Sigma            P4864 
PMSF           Sigma            P7626 
Polybrene         Sigma            H9268 
Protease Inhibitor Cocktail Set III   Merck Millipore         539134 
Random primers       Invitrogen          48190011 
Rapamycin         Merck Millipore         553210 
Reagent A         Bio-Rad           500-0113 
Reagent B         Bio-Rad           500-0114 
Reagent S         Bio-Rad           500-0115 
Resazurin         Sigma            R7017 
RNA Mini Kit (Pure Link)    Ambion           12183-018A 
RNeasy Mini Kit        Qiagen                74104 
RNase A          Roche            109 169 
Rotenone          Sigma            R8875 
SB203580         Axon MedChem        1363 
siRNA Negative Control     Ambion           4390843 
siRNA DUSP8        Ambion           4390824 
siRNA DUSP10        Ambion           4392420 
siRNA DUSP16        Sta. Cruz Biotech.        sc-61052 
siRNA MAPK14        Ambion           AM51333 
siRNA PTPN12        Dharmacon          L008064-00 
SOC           Invitrogen     15544-034 
Sodium Fluoride       Sigma            S7920 
Sodium Orthovanadate      Sigma            S6508 
SP600125         Calbiochem         420119 
SuperScript II Reverse Transcriptase  Invitrogen         18064-022 
Sybr Green Supermix      Bio-Rad          1708886 
Taq polymerase        Bioline      BIO-21040 
TEMED          Sigma           T9281 
Triton X-100         Sigma           T9284 
Trypsin-EDTA        Sigma           T3924 
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TUNEL          Roche           11684795910 
Tween-20         Sigma           P7949 
U0126          Merck Millipore        662005 
 
Laemmli polyacrylamide gels 
        Stacking 5%  Resolving 10%  Resolving 12% 
40% Acrylamyde/Bis  625 µl      2.5 ml    3 ml 
1M Tris-HCl pH 6.8  940 µl      -      - 
1M Tris-HCl pH 8.8  -        3.75 ml    4.5 ml 
10% SDS      50 µl       100 µl    100 µl 
H2O       3.4 ml      3.6 ml    2.35 ml 
10% APS      25 µl         40 µl     40 µl 
TEMED      6 µl       10 µl     10 µl 
 
Oligonucleotides 
qRT-PCR 
RefSeq        Gene    Sequence (5’-3’) 
NM_004420     DUSP8   FW: GATGACGCAAAATGGAATAAGC 
           RV: CTTCACGAACCTGTAGGCG 
NM_144729     DUSP10   FW: TGAACATCGGCTACGTCATC 
           RV: TGGTGTAAGGATTCTCGGTG 
NM_030640     DUSP16   FW: CAGAATGGGATTGGTTATGTG 
           RV: TAGGCGATAGCGATGGTGG 
NM_002046     GAPDH   FW: GTCGGAGTCAACGGATTTGG 
           RV: TGAGCCCCAGCCTTCTCC 
NM_002083     GPX2    FW: CCTCCCCACCCCTCTAATAG 
           RV: TCTACCTTCTCCCCATCCAG 
NM_002084     GPX3    FW: TGTCAATGGAGAGAAAGAGCAG 
           RV: TCTCAAAGTTCCAGCGGATG 
NM_001509     GPX5    FW: ACATCCTGGCGTACTTGAAG 
           RV: GGGAGAGCAAGTCATTAGGTG 
NM_000190     HMBS   FW: GGAGTATTCGGGGAAACCTC 
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             RV: AAGCAGAGTCTCGGGATCG 
NM_006151     LPO    FW: TGAAAAGACAAGGCACTGGG 
           RV: TGAAGCAAGATGAGGGAAGC 
NM_000963     PTGS2   FW: ACAGGCTTCCATTGACCAG 
           RV: TCACCATAGAGTGCTTCCAAC 
NM_002827     PTPN1   FW: AGAAGGACGAGGACCATGCAC 
           RV: AGTGGAGGAGGGTCAGGCTAT 
NM_002835     PTPN12   FW: GATGGTGCTGTGACCAGGAAC 
           RV: TCATGTCCATTCTGAAGGTGG 
NM_144651     PXDNL   FW: CCAAGTGATTCCCCAGAGAAG 
           RV: GTTGCTTAAGTCAGTGGTTTCC 
NM_032243     TXNDC2   FW: TGATGCCAGTGAATGCGTAG 
           RV: CGTTGCTGGACAGGACTAG 
siRNA (customed) 
RefSeq        Gene    Sequence (5’-3’) 
NM_002827     PTPN1   Sense: UAGGUACAGAGACGUCAGUdTdT 
           Antisense: ACUGACGUCUCUGUACCUAdTdT 
 
Primary antibodies: 
Antigen Brand and reference Dilution (Time / ºC)  Host 
- flow cytometry γ-H2AX Upstate, 05-636   1:200  (2 h / 37)  Mouse 
- IF     P-JNK  BD Biosciences, 612541 1:25 (1 h / 37)   Mouse 
- IHC     Ki67  Novacastra    1:500 (1 h / RT)   Rabbit 
 
- WB 
Antigen    Brand and reference  Dilution  Time / ºC   Host 
Catalase    Abgent, AM2118a   1:1000  4 h / RT   Mouse 
Cleav. caspase 3  Cell Signaling, 9661  1:500   O/N / 4   Rabbit 
γ-H2AX    Upstate, 05-636    1:500   O/N / 4   Mouse 
HSP27    Sta. Cruz, sc1049   1:1000  4 h / RT   Goat 
JNK     Sta. Cruz, sc-571   1:1000  4 h / RT   Rabbit 
p38α     Sta. Cruz, sc-535   1:1000  4 h / RT   Goat 
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p53     Cell Signaling, 2524  1:1000  1 h / RT   Mouse 
p85 PARP   Promega, G734    1:500   O/N / 4   Rabbit 
P-Hsp27 (tissue)  Cell Signaling, 2401  1:500   O/N / 4   Rabbit 
P-Hsp27 (cells)  StressGene, ADI-SPA-523 1:500   O/N / 4   Rabbit 
P-JNK (cells)   BD Biosciences, 612541 1:500   O/N / 4   Mouse 
P-JNK (tissue)  Cell Signaling, 9251  1:500   O/N / 4   Rabbit 
P-MK2    Cell Signaling, 3007  1:500   O/N / 4   Rabbit 
P-p38     Cell Signaling, 9211  1:500   O/N / 4   Rabbit 
Ras     BD Biosciences, 610001 1:1000  4 h / RT   Mouse 
SOD2     Abcam, ab13533   1:1000  4 h / RT   Rabbit 
Tubulin    Sigma, T9026    1:5000  1 h / RT   Mouse 
 
Secondary antibodies 
Antigen        Brand and reference  Time / ºC  Host 
Goat IgG (Alexa Fluor 680)  Invitrogen, A21084   1 h / RT  Donkey 
Mouse IgG (Alexa Fluor 488)  Invitrogen, A11001   1 h / RT  Goat 
Mouse IgG (Alexa Fluor 680)  Invitrogen, A21057   1 h / RT  Goat 
Mouse IgG (Alexa Fluor 800)  Rockland, 610-731-124 1 h / RT  Donkey 
Rabbit IgG (Alexa Fluor 680)  Invitrogen, A21076   1 h / RT  Goat 
Rabbit IgG (Alexa Fluor 800)  Rockland, 611-131-122 1 h / RT  Goat 
(All secondary antibodies were used at 1:5000 dilution) 
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For commercial kits, only those protocols that either vary from the published 
datasheets or are not fully specified, are detailed here.  
All the experiments that involve cell culture were done in sub-confluent conditions 
(unless otherwise specified). 
 
Annexin V staining 
This kit was used to quantitatively determine the percentage of cells within a 
population that are undergoing apoptosis by detecting their exposed 
phosphatidylserines. Counterstaining with PI is used to distinguish between viable 
and non-viable cells, since viable cells with intact membranes exclude PI. 
1. Collect the supernatant of the cells, wash once with cold PBS and collect the 
washing solutions as well). Trypsinize with the minimum possible amount of 
trypsine (since it can alter the cell membrane integrity) 
2. Pellet the cells (200 xg for 5 min at 4 ºC) and wash once more with PBS 
3. Resuspend cells in ~1 ml of 1x Binding Buffer (dilute the 10x stock in water), 
count cells and adjust the concentrations to 106 cells/ml with 1x Binding Buffer 
4. Transfer 100 µl of the solution (105 cells) to a cytometer tube 
5. Add 5 µl of FITC Annexin V 
6. Gently vortex the cells and incubate for 20 min at RT in the dark 
7. Add 5 µl of PI right before going to analyze by flow cytometry 
8. Add 400 µl of 1x Binding Buffer to each tube 
9. Analyze by flow cytometry within 1 h 
 
Bacterial transformation 
1. Add up to 50 ng of DNA to 50 µl of chemo-competent cells and incubate them 
on ice for 30 min 
2. Heat shock in a waterbath at 42 ºC for 45 s 
3. Put back the tubes on ice for 2 min	  
4. Add 250 µl of SOC medium (do not mix!) and incubate for 1 h at 37 ºC with 
light shaking 
5. Plate 80 – 100 µl on pre-warmed plates containing antibiotics and incubate 
O/N at 37 ºC 
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Clonogenic assays 
This is a cell survival assay based on the ability of single cells to grow into 
colonies. It is used to determine cell death after treatment with cytotoxic agents. 
Cancer cells were incubated O/N with 10 µM SB203580 and treated for 1 h with 
cisplatin either 50 µM (HT-29, MCF7) or 10 µM (SW620). Then, 500 cells (HT-29, 
MCF7) or 1000 cells (SW620) were plated per well in 6-well plates. Cells were 
allowed to grow until visible colonies were formed (about two weeks) and were 
processed as follows: 
1. Wash the cells twice with PBS  
2. Fix the cells for 30 min with 4% PFA 
3. Wash cells twice with H2O 
4. Stain cells for 15 min with 0.05% crystal violet 
5. Wash twice with H2O 
6. Drain cells inverted for a couple of minutes  
7. Dishes can be photographed or scanned for colony counting (colonies can be 
counted several months after staining). 
 
DNA oligonucleosomes quantification 
The Cell Death Detection kit ELISAPLUS is used to quantify histone-complexed DNA 
fragments (mono- and oligonucleosomes) that are released into the cytoplasm after 
the induction of apoptosis. Manufacturer’s instructions (Roche) were followed 
exactly (Fig. 13). 
 
Expression and purification of GST-tagged proteins 
I. Expression 
1. Transform BL21 (DE3) Escherichia coli bacterial strain with the expression 
construct DNA for your recombinant protein (see “Bacterial transformation” 
section) 
2. Next morning, keep at 4 ºC the plates containing the bacterial colonies (to 
prevent the growth of “satellite” colonies) 
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Figure 13. Overview of how DNA oligonucleosomes were detected. Cell Death Detection 
ELISAPLUS kit was used following manufacture’s instructions, which are cartooned here. 
 
3. In the afternoon, pick one middle-sized colony and grow it in pre-warmed 25 
ml of LB containing antibiotic (ampicillin 50 µg/ml) 
4. The following day, pour the whole culture in a 500 ml flask of pre-warmed LB 
containing antibiotic (ampicillin 50 µg/ml) 
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5. Grow bacteria until OD595nm ~0.4-0.5 and add 1 mM IPTG  
6. Incubate for 3 h at 37 ºC (or RT for 5 h, or O/N at 18 ºC) 
 
II. Purification (WORK ON ICE) 
1. Spin the bacterial culture by centrifuging at 1400 xg for 20 min at 4 ºC 
2. Resuspend the bacterial pellet in buffer B (see “Materials”) so that the final 
volume is 32 ml 
3. Add lysozyme 1 mg/ml final concentration (32 mg) and keep on ice for 10 - 15 
min 
4. Freeze in liquid N2 and keep at -80 ºC for up to two weeks (optional) 
5. Next day, sonicate the lysates and pour them into ultracentrifuge tubes 
6. Add 4 ml of 10% Triton X-100 and 4 ml of 5 M NaCl (final concentrations: 1% 
Triton and 0.5 M NaCl) 
7. Centrifuge at 17400 xg for 20 min at 4 ºC 
8. Pre-wash Glutathione Sepharose beads: put 700 µl of beads in a conical tube 
and add buffer H up to 14 ml. Centrifuge at 400 xg for 2 min 4 ºC 
9. Incubate the supernatant (from the ultracentrifugation) with the pre-washed 
beads in a conical tube for 1 h at 4 ºC 
10. Wash (4x) in buffer H (400 xg for 3 min at 4 ºC) 
11. Wash (4x) in buffer L (400 xg for 3 min at 4 ºC) 
12. Elute the protein: add to the beads 200 µl buffer L and 500 µl 200 mM 
glutathione (dissolve 1.228 µg of glutathione in 18 ml of 50 mM Tris pH 8.0, 
adjust pH to 7 – 8 and the final volume to 20 ml) 
13. Incubate on ice for 15 min, with gently mixing every 2 – 3 min 
14. Centrifuge at 400 xg for 10 min at 4ºC 
15. Take the supernatant and perform a second round of elution 
16. Once eluted, centrifuge both supernatants at 16000 xg for 5 min at 4 ºC 
17. Check if there is any detectable protein amount in the supernatants (see 
“Protein extraction and quantification” section)  
18. Dialyze O/N in 2 l of buffer D. (Incubate the dialyzing membrane in buffer D 
for few minutes, take out the air with a syringe, inject the protein and then 
remove a little bit more air). 
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Flow cytometry assays 
Cell cycle profiles 
This is a method to stain DNA using ethanol to fix the cells and permeabilize the 
membrane, which allows the dye, propidium iodide (PI), to enter the cells. PI is a 
DNA-binding fluorochrome that gets intercalated into the double helix. 
Ribonuclease A is used to eliminate the staining of the double-stranded RNA. 
1. Wash the cells once with PBS (400 xg for 5 min) 
2. Place 330 µl of cell suspension (without cell clumps!) in a conical tube and add 
600 µl ice-cold 100% ethanol drop-wise to the tube walls. Leave at least for 30 
min at 4 ºC (may be left at this stage for a week). 
3. Centrifuge at 400 xg for 5 min at 4 ºC to remove ethanol 
4. Add 5 ml of cold PBS and wash by centrifuging at 400 xg for 5 min at 4 ºC and 
remove the supernatant 
5. Resuspend in DNA staining solution and incubate (covered with aluminum foil) 
at 30 ºC for 30 min in a waterbath. Volumes per tube: 
   500 µl PBS 
   0.2 mg/ml RNase A  
   20 µg/ml PI  
6. Acquire on an EPICS XL flow cytometer (collect 10000 events) 
 
γ-H2AX staining 
Histone H2AX is recruited to DNA double strand breaks and phosphorylated (γ-
H2AX). This form can be detected by antibodies to quantify DNA damage. 
1. Collect by trypsinization (see “Mammalian cell culture”) sub-confluent cells 
grown in 60 mm ∅ dishes and wash them (2x) with PBS by centrifuging at 200 
xg for 5 min at RT 
2. Resuspend the cell pellets (without clumps!) in 330 µl of PBS and add 660 µl of 
ice-cold 100% ethanol drop-wise to the tube walls. Incubate at 4 ºC at least for 
30 min (cells remain stable at this stage for a week) 
3. Centrifuge at 400 xg for 5 min at 4 ºC to remove ethanol 
4. Wash (1x) with PBS-T by centrifugation at 400 xg for 5 min at 4 ºC 
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5. Wash (1x) with 5 ml of 3% BSA in PBS-T (400 xg for 5 min at 4 ºC) 
6. Incubate γ-H2AX antibody diluted 1:200 in 3% BSA in PBS-Tween 0.05% for 2 
h at RT with gentle shaking 
7. Wash (1x) with 10 ml of PBS-T (400 xg for 5 min at 4 ºC) 
8. Incubate the Alexa Fluor-488 conjugated secondary antibody diluted 1:200 in 
PBS-T for 1 h at RT 
9. Wash (2x) with 10 ml of PBS-T (400 xg for 5 min at 4 ºC) 
10.Resuspend in DNA staining solution and incubate (covered with aluminum foil) 
at 30 ºC for 30 min in a waterbath. Volumes per tube: 
   500 µl PBS 
   0.2 mg/ml RNase A (5 µl from 20 mg/ml stock) 
   20 µg/ml PI (10 µl from 1 mg/ml stock) 
11. Acquire on an FC500 flow cytometer (collect 10000 events) 
 
Gene expression array 
The RT2 Profiler PCR Array System brings together the quantitative performance of 
real-time PCR and the multiple gene profiling capability of microarrays. The 
Human Oxidative Stress and Antioxidant Defense PCR Array profiles the 
expression of 84 genes involved in ROS regulation. Manufacturer’s instructions 
were followed exactly (Fig. 14). Briefly, DNase-treated total RNA from MCF7 cells, 
either control or treated with 10 µM SB203580, was purified with the RNeasy 
minikit (Qiagen). cDNA was generated by reverse transcription from 4 µg of total 
RNA from each sample using the RT2 First Strand Kit, then combined with the RT2 
qPCR Master Mix and added to lyophilized primer pairs in the 96 well plate 
arrays. Thermal cycling was performed in a CFX96™ Real Time System (Bio-Rad) 
and relative gene expression levels were calculated using the ΔΔC(t) method with 
normalization to the average expression of three housekeeping genes (GAPDH, 
HPRT1 and RPL13A).  
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Figure 14. Overview of the PCR Array procedure. Isolated RNA from cell lysates is 
converted to cDNA and the expression of 84 genes involved in ROS regulation is quantified 
by qRT-PCR. 
 
 
Gene knockdown by shRNA 
I. CaCl2-mediated transfection of packaging cells 
1. Prepare 2.5 M CaCl2 and 2x HBS buffer pH 7.12 and keep them at RT 
2. Take 9 µg of DNA for a 100 mm ∅ dish (4.5 µg of shRNA + 4 µg of Δ89 + 0.5 
µg VSVG), 50 µl of 2.5 M CaCl2 and make this mix up to 500 µl by diluting it with 
H2O in a 1.5 ml tube (first add DNA, then H2O and finally CaCl2 drop by drop, 
allowing it to slide down the walls of the tube). Incubate for 5 min at RT and then 
transfer the mix to a 15 ml tube 
3. Add 500 µl of 2x HBS (drop by drop and simultaneous bubbling by air 
injection), vortex for 5 s and incubate the mix for 20 min at RT  
4. Add the mix to the 293T cells in a drop-wise manner  
5. About 6 h later, wash with PBS and add fresh growth medium 
6. Collect the medium containing viral particles 48 h later and add fresh medium 
again to generate new viruses for a second infection 
7. Collect again the medium 24 h later and perform a second round of infection. 
Discard 293T cells  
 
MCF7 
SB 
MCF7 
NT 
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II. Infection with generated viruses 
1. Filter through a 0.45 µm PVDF filter (highly hydrophilic, low retention of viral 
particles) 4 ml of medium collected from 293T cells and mix it with other 4 ml 
of fresh growth medium 
2. Add polybrene to the medium containing viral particles so it reaches a final 
concentration of 8 µg/ml and incubate the mixture for 5 min at RT 
3. Remove media from the plates that will be infected and add the media 
containing the viral particles. If a second round of infection is needed, 24 h 
later repeat steps 1-2  
4. Begin selection with 1 µg/ml puromycin 48 h after the last round of infection 
and keep it for 1 week 
 
Gene knockdown by siRNA 
Cancer cells grown up to 60% confluency in 60 mm ∅ dishes (and a final volume 
of 3 ml) were transfected with 50 nM siRNA following the protocol below: 
1. Mix in tube 1 a 300 µl volume containing 6 µl of 25 µM siRNA + 294 µl of 
serum-free medium 
2. Mix in tube 2 a 300 µl volume containing 6 µl of Dharmafect 1 reagent + 294 µl 
of serum-free medium 
3. Gently mix the contents of each tube by pipetting carefully up and down and 
incubate for 5 min at RT 
4. Add the content of tube 1 to tube 2 for a total volume of 600 µl. Mix by 
pipetting carefully up and down  
5. Incubate for 20 min at RT 
6. Remove culture medium from the cells and wash them once with antibiotic-free 
complete medium 
7. Add 2400 µl of fresh antibiotic-free complete medium to the cells 
8. Add the transfection mix from step 4 to the cells drop wise and incubate cells 
O/N at 37 ºC and 5% CO2 
9. 24 h later replace the transfection medium by complete growth medium 
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GST pull down of JNK-binding proteins 
I. GST-JNK1 binding to beads 
1. Prewash (2x) 50 µl of Glutathione Sepharose beads with 500 µl PBS contining 
protein inhibitors (PBS-PI) at 500 xg for 1 min at 4 ºC 
2. Incubate the beads and GST-JNK1 for 1.5 h at 4 ºC and rotating with 500 µl 
PBS-PI (50 µl beads + 23 µl GST-JNK1 (~100 µg) + 427 µl PBS-PI)	  
3. Recover the protein bound to the beads by centrifuging at 500 xg for 6 min at 4 
ºC. Take the supernatant with a 0.3 mm needle 
4. Wash (1x) with 500 µl PBS-PI at 500 xg for 1 min at 4 ºC 
5. Wash (1x) with 500 µl kinase buffer at 500 xg for 1 min at 4 ºC 
6. Resuspend in 40 µl of kinase buffer 
 
II. Cold phosphorylation of GST-JNK1 
1. Prepare the kinase buffer 
2. Prepare protein mixtures with a ratio 1:10 (kinase:substrate) in a Vf = 50 µl 
40 µl beads·GST-JNK1 (~10 µg) 
  2 µl GST-MKK7 (0.5 µg/µl) 
  3 µl KiB 
  5 µl ATP (3 µl 10 mM + 6 µl KiB) 
3. Incubate for 1 h at 30 ºC with light shaking 
4. Stop the reaction by putting the samples on ice 
 
III. Pull down of GST-P-JNK1 
1. Collect and quantify the human cancer cells (treated or not with 10 µM 
SB203580) in phosphatase buffer 
2. Pre-incubate 2 mg of cell lysates with 10 µg of GST protein for 30 min rotating 
at 4 ºC. Put the samples on ice to stop the reaction. 
Vf ~500 µ l     SW620  SW620 SB 
µl lysate (2 mg)   303.48  284.52 
µl GST (10 µg)   1.25   1.25 
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3. Prewash (2x) 50 µl beads with 500 µl phosphatase buffer at 500 xg for 1 min at 
4 ºC 
4. Incubate rotating the pre-washed beads and the cell lysates with GST protein for 
30 min at 4 ºC  
5. Recover the GST protein bound to the beads by centrifuging at 500 xg for 6 min 
at 4 ºC. Take the supernatant with a 0.3 mm needle  
6. Mix 2 mg of the pre-cleared cell lysates with 10 µg of GST-P-JNK1 (from the 
cold kinase assay) and incubate them for 30 min at 37 ºC with light shaking. 
Put the samples on ice to stop the reaction 
Vf ~300 µ l      SW620  SW620 SB 
µl lysate (2 mg)    –300   ~300 
µl GST-P-JNK1 (10 µg)  50    50 
7. Recover the protein bound to the beads by centrifuging at 500 xg for 4 min at 4 
ºC. Take the supernatant with a 0.3 mm needle 
8. Wash with phosphatase buffer, up to 500 µl, at 500 xg for 3 min at 4 ºC 
9. Resuspend in 40 µl of phosphatase buffer and add 10 µl of LSB5x to run in a gel 
and analyze by mass spectrometry  
 
Histology and immunohistochemistry 
For histological analysis, resected breast tumors were sliced, fixed in 10%-buffered 
formalin and embedded in paraffin wax. Sections of 3 µm were stained with 
hematoxylin and eosin (H-E) and analyzed in blinded fashion by two independent 
observers at the microscope. For each mouse, at least ten high power fields (200x) 
from two tissue slides of two different tumors were analyzed. The malignancy was 
determined based on the microscopic appearance of the tissues (degree of filled 
tubules, rate of cell division, cell size and uniformity) and classified into 4 stages: 
normal tissue, hyperplasia, adenocarcinoma and carcinoma. Hyperplasic tissue 
resembles normal cells, arranged around tubules, well differentiated and with a 
low proliferation rate. Adenoma showed moderately differentiated cells, which still 
retain the glandular-related tissue cytology and architecture, with clear tumor 
margins. Carcinoma showed very abnormal and poorly differentiated cells with no 
significant resemblance to the corresponding parent cells and tissue. 
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Additional immunohistochemical examination of the tumors was done to assess 
cell proliferation by Ki67 staining. Briefly, deparaffinated sections were treated 
with 10 mM citrate pH 6.0 for antigen retrieval, peroxidase was used for blocking 
and after incubation of primary the antibody (Ki67, see “Materials” for timing and 
dilution), BrightVision Poly-HRP-Anti Ms/Rb/Rt IgG and DAB were used for signal 
development. All sections were counterstained with hematoxylin. 
 
Immunoblotting 
1. Separate 50 µg of protein lysates by SDS-PAGE on 10% or 12% Laemmli gels, 
depending on the molecular weight of the protein of interest 
2. After electrophoresis, transfer the proteins in the gel to a nitrocellulose 
membrane using a wet-blotting system (Bio Rad) 
3. Stain with 0.1% Ponceau (in 5% acetic acid) for 2 min to evaluate the efficiency 
of transfer and then wash out the staining with PBS 
4. Block the nitrocellulose membrane incubating for 1 h at RT (or O/N at 4 ºC) 
with 4% non-fatty milk (in PBS) and gently shaking 
5. Rinse the membrane with PBS and incubate the primary antibodies diluted in 
5% BSA in PBS-T (see “Materials” for specific timing and dilutions) 
6. Wash (3x) with PBS-T for 5 min at RT 
7. Incubate for 1 h at RT with the Alexa Fluor-conjugated secondary antibodies 
diluted 1:5000 in 1% non-fatty milk (diluted in PBS-T) 
8. Wash (3x) with PBS-T for 5 min at RT 
9. Scan the membranes in an Odyssey Infrared Imaging System (Li-Cor, 
Biosciences) 
 
Immunofluorescence 
1. Culture adherent cells on coverslides 
2. Place the coverslides on a multi-well plate and fix the cells in 4% PFA for 10 
min 
3. Wash (x3) in TBS for 5 min 
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4. Incubate the cells with 0.5% Triton X-100 in TBS for 10 min to permeabilize 
them 
5. Wash (x3) in TBS for 5 min 
6. Incubate the cells with TNB shaking at RT for 1 h for the blocking 
7. Remove the excess of TNB by touching some dry paper, place the slides face-up 
in a humid chamber and incubate a 60 µl drop of the primary phospho-
antibody diluted 1/25 in TNB for 1 h at 37 ºC  
8. Wash (3x) in TBS for 5 min 
9. Remove the excess of TBS, place the slides face-up in a humid chamber and 
incubate a 60 µl drop of the secondary antibody diluted 1/250 in TNB for 30 
min at 37 ºC  
10. Wash (3x) in TBS for 5 min 
11. For nuclear staining, incubate with DAPI at RT for 2 min 
12. Wash (3x) in TBS for 5 min 
13. Mounting in Mowiol: 
-  30 min before mounting, incubate Mowiol at 55 ºC 
- Immerse the coverslide for few seconds in water to avoid crystal 
precipitation from the buffer salts 
- Remove the excess of water, add 10 µl of Mowiol on a slide and place 
the coverslide face-down carefully onto the Mowiol drop 
- Keep the slides at 4 ºC O/N to allow Mowiol to dry 
 
Mammalian cell culture 
I. Maintenance and cell subculturing 
All the cell lines were maintained in DMEM supplemented with 10% heat-
inactivated FBS, 1% L-glutamine and 1% penicillin/streptomycin at 37 ºC and 5% 
CO2. 
 
Cells were washed once with PBS and incubated with 0.05% trypsin for 3 min at 
37 ºC to detach and subculture them. Then, they were subsequently diluted in 
fresh medium (from 1/4 to 1/12, depending on the proliferation rate), resuspended 
and plated into a new culture dish. 
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II. Cell harvesting 
Subconfluent cell cultures were washed twice with ice-cold PBS and immediately 
frozen on dry ice to keep stored at -80 ºC until further processed. 
For apoptosis quantification, media from the cell cultures were collected on ice, 
together with PBS washings (1x) and the cells resuspended after trypsin 
detachment (see previous section). Cells were pelleted by centrifugation at 200 xg 
for 5 min at 4 ºC. Cell pellets were resuspended in ice-cold PBS and centrifuged 
again at 200 xg for 5 min at 4 ºC for washing. Supernatants were discarded and 
cell pellets were frozen at -80 ºC for further processing.  
 
III. Cell freezing and thawing 
To freeze the cells, subconfluent cell cultures grown on 10 cm ∅ dishes were 
harvested by trypsinization (see section I), resuspended in 2 ml of freezing medium 
(90% FBS + 10% DMSO) and divided into two cryo-tubes. These were stored in a 
Mr. Frosty (see “Materials”) at -80 ºC for up to 48 h and then transferred to liquid 
nitrogen for long-term storage. 
To thaw the cells, cryo-tubes were placed in a waterbath at 37 ºC. In order to 
minimize their exposure to the DMSO present in the freezing medium, cell 
suspensions were quickly transferred to conical tubes containing 5 ml of pre-
warmed growth medium and pelleted by centrifuging at 200 xg for 5 min. 
Supernatants were discarded and cell pellets were resuspended in fresh growing 
medium and plated into new culture dishes. 
 
IV. Cell treatments 
Antioxidants 
100 mM GSH and NAC (see “Materials”) were directly diluted in the media of 
growing cells to reach a final concentration of 5 mM. Cells were preincubated for 
1 h with a mixture of both before the final treatments. 
 
Chemical inhibitors 
Cells were preincubated for the times indicated in the figures with the following 
inhibitors, which were stored in aliquots at -20 ºC:  
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Inhibitor   Target pathway   Stock concentration Final concentration 
ASK1 inhibitor ASK1      10 mM (in DMSO)  10 µM 
DPI    NADPH oxidases  10 mM (in DMSO)  2.5 µM 
LY294002  PI3K      20 mM (in DMSO)  20 µM 
Rapamycin  p70 S6 kinase   100 µM (in ethanol) 50 nM 
Rotenone   m.r.c.* complex I   5 mg/ml (in DMSO) 0.25 µg/ml 
SB203580  p38 α/β MAPK   10 mM (in DMSO)  10 µM 
SP600126  JNK      20 mM (in DMSO)  20 µM 
U0126   MEK1/2     10 mM (in DMSO)  10 µM 
*m.r.c.: mitochondrial respiratory chain 
 
Cisplatin 
This is a small-molecule platinum compound that exerts its anti-tumoral properties 
by creating platinum-DNA adducts, which primarily form intra-strand cross-links 
that activate the apoptotic pathway, resulting in cell death. Treatments were done 
for the indicated times with the concentrations specified below. The stock was 
1.66 mM in physiological saline and it was stored at RT: 
· For apoptosis assays, cells were treated with 100 µM cisplatin. 
· For clonogenic assays, cells were treated with 10 µM (SW620) or 50 µM (MCF7 
and HT-29) cisplatin. 
 
Doxorubicin 
This is an anthracycline antibiotic used in cancer chemotherapy that works by 
intercalating DNA. Cells were treated with 1 µM doxorubicin (from a 10 mM stock 
in PBS stored at 4 ºC). 
 
Etoposide 
This drug is a topoisomerase inhibitor that forms a ternary complex with DNA and 
the topoisomerase II enzyme, preventing re-ligation of the DNA strands and 
therefore inducing their breakage. In the end it induces apoptosis of the cancer cell 
and therefore it is used as a cytotoxic agent. Cells were treated with 100 µM 
etoposide (from a 100 mM stock in DMSO stored at -20 ºC). 
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Hydrogen peroxide 
This is a strong oxidizer used as a positive control for the generation of ROS. Cells 
were treated for the indicated times with 5 mM from an 8.8 M stock stored at 4 ºC. 
 
Neocarzinostatin 
This is a genotoxic drug that induces single and double strand breaks in DNA. It 
can be used as a positive control to induce histone H2AX phosphorylation. Cells 
were treated with 40 nM NCS for 1 h from a 20 mM stock stored at 4 ºC. 
 
Ultraviolet radiation 
This type of light induces thymine dimers as well as DNA double strand breaks. 
Cells were washed with PBS, covered with a thin PBS layer (1 ml every 60 mm ∅ 
dish), irradiated with 400 J/m2 of UV light and incubated at 37 ºC for the indicated 
times. 
 
Mice treatments 
MMTV-PyMT mice (Guy et al., 1992) were provided by William Muller (McGill 
University, Canada). Female mice expressing MMTV-PyMT spontaneously develop 
breast tumors with 100% penetrance. When breast tumors reached a size of 200 
mm3 [V=(π*l)*w2], mice were given a single injection of 6 mg/Kg cisplatin or 
vehicle (physiological saline) in the tail vein. The p38 MAPK inhibitor PH797804 
(Hope et al., 2009) was prepared at 1 mg/ml in 0.5% methyl cellulose (in PBS) and 
0.025% Tween-20 and administered to the mice by oral gavage (10 mg/Kg) every 
24 h. Groups of at least four mice (each of them developing from two to four 
tumors) were used per condition in every experiment. 
 
mRNA processing and PCR analysis 
I. RNA isolation and purification 
Total RNA was extracted from cells using the RNA Mini Kit from Ambion and was 
digested with DNase I as follows: 
1. Add 1 µl of DNase I to the RNA and incubate for 1 h at 37 ºC (50 µl RNA + 40 
µl RNase-free water + 10 µl buffer 10x + 1 µl DNase I) 
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2. Add, in the hood, 100 µl of phenol:chloroform and mix by vortexing 
3. Centrifuge at 16000 xg for 5 min at 4 ºC 
4. Take the upper phase (colorless, ~70 µl) and add 1/10 of sodium acetate 3 M (7 
µl) and 1 µl of glycogen 
5. Add 2.5 volumes of ice-cold 100% ethanol (195 µl) 
6. Keep for 1 h at -80 ºC 
7. Centrifuge at 16000 xg for 10 min at 4 ºC and remove the supernatant 
8. Wash with 1 ml of 70% ethanol (vortex) 
9. Centrifuge at 16000 xg for 5 min at 4 ºC 
10. Discard the supernatants and leave the tubes opened for 10 min so ethanol 
can evaporate 
11. Resuspend in 30 µl RNase-free water 
12. Determine the RNA concentration by measuring the absorbance at 260 nm 
and its quality by monitoring the ratio of absorbance 260/280 
 
II. Reverse transcription PCR 
cDNA was obtained from 1 µg of the purified RNA following exactly the 
SuperScript II Reverse Transcriptase protocol from Invitrogen in a final volume of 
20 µl. 
 
III. Semi-quantitative PCR 
The mix for one reaction of 50 µl was prepared as follows: 
 32 µl H2O     2.5 µl 10 µM primer 3’ 
 5 µl buffer 10x    1 µl 10 mM dNTPs 
 1.5 µl 50 mM MgCl2  5 µl cDNA (diluted 1/5) 
 2.5 µl 10 µM primer 5’  0.5 µl 500U Taq polymerase 
 
The program (denaturation at 94 ºC for 5 min, 20 - 30 cycles of denaturation at 94 
ºC for 30 s, annealing at 55 ºC for 30 s, elongation at 72 ºC for 60 s and a final step 
of elongation at 72 ºC for 10 min) was run. GAPDH gene expression was used as a 
reference and the PCR products were analyzed by 2.5% agarose gel 
electrophoresis. 
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IV. qRT-PCR 
The mix for one reaction of 10 µl was prepared as follows: 
0.25 µl 10 µM primer 5’ 
0.25 µl 10 µM primer 3’ 
0.5 µl H2O 
5 µl Sybr Green Supermix 
 
4 µl of cDNA (diluted 1/12) were loaded in triplicates in a 96-well plate and 6 µl 
of the mix reaction were added. The plate was sealed and centrifuged for 1 min at 
200 xg and run as follows: 50 ºC for 2 min, 95 ºC for 10 min, 40 cycles of 
denaturation at 95 ºC for 15 s, annealing at 56 ºC for 15 s, elongation at 72 ºC for 
60 s, and three final steps of 95 ºC for 15 s, 60 ºC for 2 min and 95 ºC for 15 s. 
GAPDH and HMBS were used as reference genes and the ΔΔC(t) method was 
used to quantify gene expression.  
 
MTT assay 
This assay is based on the cleavage of the yellow tetrazolium salt MTT to purple 
formazan crystals by metabolic active cells. These crystals are solubilized and the 
resulting colored solution is quantified using a 96 well plate spectrophotometer- 
reader. The intensity of absorbance is directly proportional to the number of 
metabolic active cells. Therefore, it can be used either to monitor the proliferation 
of cells or to measure the number of viable cells after a cytotoxic insult. For 
proliferation assays, 2000 cells/well were plated and different time points were 
measured up to 6 days. For viability assays, 10000 cells/well were plated and the 
percentage of viable cells was determined at the end of the experiment. In both 
cases, the metabolic active cells were measured as follows: 
1. Add 10 µl of MTT reagent to cells growing in triplicates in 96-well plates with 
100 µl of medium and incubate for 1 h at 37 ºC 
2. Remove the medium, add 200 µl of DMSO and incubate shaking at RT for 15 
min so the crystals are completely solubilized 
3. Read the absorbance between 550 and 600 nm setting a reference wavelength 
above 650 nm 
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Oxyblot analysis 
As a consequence of the oxidative modifications, carbonyl groups are introduced 
into protein side chains by a site-specific mechanism. This kit provides reagents for 
immunodetection of these carbonyl groups (after a derivatization reaction with 
DNPH), which is a hallmark of the oxidation status of proteins. 
1. Transfer 10 µg of protein sample contained in a volume of 5 µl into each two 
1.5 ml tubes (one of the aliquots will be subjected to the derivatization reaction 
and the other will serve as a negative control). 
2. Denature each 5 µl aliquot of protein by adding 5 µl of 12% SDS for a final 
concentration of 6% SDS 
3. Derivatize the sample by adding 10 µl of 1x DNPH solution to one of the tubes. 
To the aliquot designated as the negative control, add 10 µl of 1x 
Derivatization-Control solution instead of the DNPH solution 
4. Incubate both tubes at RT for 15 min 
5. Add 7.5 µl of Neutralization Solution to both tubes and add 1 µl of ß-
mercaptoethanol to the sample mix. 
Both the treated sample and the negative control are now ready to load into a 
polyacrylamide gel and be transferred to a membrane for further 
immunodetection, following manufacturer’s instructions. 
 
Phosphatase assays: 
- JNK targeted-phosphatases activity 
I. Hot phosphorylation of GST-JNK1 
1. Prepare the kinase buffer 
2. Prepare protein mixes with a ratio 1:10 (kinase:substrate) in a Vf = 144 µl 
26.8 µl GST-JNK1 (4.5 µg/µl) 
24.0 µl GST-MKK7 (0.5 µg/µl) 
  9.2 µl KiB 
84.0 µl ATP (2.4 µl 10 mM + 2 µl 32P-γ-ATP (10 µCi/µl, Perkin Elmer) + 
79.6 µl KiB) 
3. Incubate for 1 h at 30 ºC with light shaking 
4. Stop the reaction by freezing the samples 
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II. GST-32P-JNK1 pull down 
1. Prewash (2x) 100 µl Glutathione Sepharose beads with 1 ml PBS containing 
protease inhibitors (PBS-PI) at 500 xg for 2 min at 4 ºC 
2. Incubate the prewashed beads and the protein with PBS-PI for 2 h at 4 ºC and 
rotating (up to 500 µl) 100 µl beads + 144 µl GST-JNK1 (i.e. 120 µg) + 256 µl 
3. Recover the protein bound to the beads by centrifuging at 200 xg for 6 min at 4 
ºC. Take the supernatant with a 0.3 mm needle 
4. Wash (2x) with PBS-PI: up to 1 ml, at 200 xg for 3 min at 4 ºC 
5. Wash (1x) with phosphatase buffer, up to 1ml, at 200 xg for 3 min at 4 ºC 
6. Resuspend in 240 µl of phosphatase buffer (~0.05 µg/µl of GST-JNK1) 
 
III. Phosphatase assay 
1. Collect and quantify the human cancer cells (treated or not with 10 µM 
SB203580) in phosphatase buffer. For the negative control, add phosphatase 
inhibitors to the phosphatase buffer (20 mM NaF, 10.4 mM NaVO, 1 µM 
microcystine) 
2. Mix 100 µg of cell lysates with ~0.5 µg of GST-32P-JNK1 (from the previous pull 
down) and incubate them at 37 ºC for the desired time points (5 - 30 min) with 
light shaking. Stop the reaction by adding LSB5x 
Vf ~65 µ l      SW620  SW620 SB 
µl lysate (100 µg)    25.8   31.1 
µl P-GST-JNK1 (0.5 µg)  10    10 
µl PhB       16.2   10.9 
µl LSB5x      13    13 
 
- Ser/Thr or Tyr specific phosphatase activity 
To measure these phosphatase activities, we used two different phosphatase assays 
from Promega. These systems determine the amount of free phosphate generated 
in a reaction by measuring the absorbance of a molybdate:malachite 
green:phosphate complex. They include chemically synthesized Ser/Thr- or Tyr-
phosphorylated peptides that are dephosphorylated by cell lysates. Generic Tyr 
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and Ser/Thr phosphatase activity was measured following manufacturer’s 
instructions (Fig. 15). Briefly, reactions were performed in 50 µl of volume 
containing 5 µg of phospho-peptide and 750 µg of cell lysate in 50 mM Tris pH 
7.5, 250 mM NaCl and 0.1 mM DTT buffer. After incubation at 30ºC for the 
indicated times, the reaction was stopped by addition of 50 µl molybdate dye and 
absorbance was measured at 630 nm. 
 
 
 
 
 
 
 
 
 
Figure 15. Overview of 
the phosphatase assays 
from Promega. The 
protocol was used to 
measure phosphatase 
activity from cell lysates. 
 
 
 
Protein extraction and quantification 
I. Protein extraction from cell lines 
1. Frozen dishes containing sub-confluent grown cells are thawed on ice, scrapped 
in ~100 µl of lysis buffer and transferred to a 1.5 ml tube. (If cells are already 
pelleted, directly add the lysis buffer onto the pellets).  
2. Vortex the cell lysates and keep on ice for 15 min (vortex every 5 min). To 
detect γ-H2AX, it is necessary to sonicate the cell lysates 
3. Centrifuge at 16000 xg for 15 min at 4 ºC 
4. Quantify the supernatants 
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II. Protein extraction from mouse tissues 
1. Immerse breast tumors resected from mice in a suitable volume (~500 – 1500 
µl) of ice-cold tissue lysis buffer  
2. Mechanically disrupt the tumors in a Precellys apparatus (Bertin Technologies) 
3. Vortex the tissue lysates and keep on ice for 15 min (vortex every 5 min) 
4. Centrifuge at 16000 xg for 15 min at 4 ºC 
5. Quantify the supernatants 
 
III. Determination of protein concentration 
The BioRad DC Protein Assay Reagents (based on the method of Lowry) were used 
as follows to measure protein concentrations: 
1. Place 2 µl of every lysate into a 96-well plate, in duplicates 
2. Mix in a 1.5 ml tube 10 µl of Reagent S and 500 µl of Reagent A 
3. Add 25 µl of the previous mixture to every 2 µl of lysate 
4. Add 200 µl of reagent B 
5. Read absorbance at 750 nm and compare to a BSA calibration curve 
 
Resazurin assays 
Resazurin is a blue non-fluorescent dye until it is reduced to the highly red 
fluorescent product resofurin. It is used as an oxidation-reduction indicator in cell 
viability assays. At the end of the treatments, media from cells was replaced by 
fresh media containing 10 mg/l Resazurin (from a 1 g/l stock in PBS) and incubated 
for 4 h at 37 ºC. Fluorescence was measured using 530 nm excitation and 590 nm 
emission wavelengths. 
 
ROS detection 
DCFDA is a cell permeable nonfluorescent probe until its oxidation occurs within 
the cell. Esterase cleavage of the lipophilic blocking groups yields a charged form 
of the dye that is much better retained by cells than the parent compound. 
Oxidation of this probe was detected by monitoring the increase in fluorescence 
with a flow cytometer using excitation filters appropriate for fluorescein (FITC). 
To visualize intracellular ROS levels, subconfluent cells were incubated for 30 min 
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at 37ºC with 10 µM DCFDA. Then cells were trypsinized with the minimum 
possible amount of trypsin and resuspended in 1 ml PBS with 1.4 µg/ml aprotinin. 
Cells were counter-stained using propidium iodide and analyzed by flow 
cytometry using the FlowJo software. 
 
Statistical analysis 
For ROS measurements, p-values were calculated using an unpaired two-tailed 
Student’s t-test, under the null hypothesis that the mean is equal to zero. For 
mouse tumor sizes, we compared each treatment (p38 inh. and CDPP) with the 
double therapy (p38 inh. + CDPP) using a two-way ANOVA and applied the 
Bonferroni correction. p<0.05 was considered statistically significant. 
 
TUNEL 
This kit identifies DNA strand breaks generated during the apoptotic process by 
terminal deoxynucleotidyl transferase (TdT), which catalyzes polymerization of 
labeled nucleotides to free 3’-OH termini with modified nucleotides in an 
enzymatic reaction. Manufacturer’s instructions (Roche) were followed exactly. 
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To determine whether p38α could be considered as a therapeutic target in cancer, 
we followed two different approaches: (i) to look for synthetic lethal partners of 
p38 MAPK and (ii) to study whether its inhibition could synergize with 
chemotherapeutic agents to induce cancer cell death. 
 
(i) Synthetic lethal partners of p38 MAPK in cancer cell viability 
Two genes are considered to be synthetically lethal if mutation of either alone is 
compatible with cell viability but mutation of both leads to cell death (Kaelin, 
2005). The concept of synthetic lethality applied to cancer therapy was proposed 
as a promising alternative to the unspecific and aggressive chemotherapeutic 
treatments in some types of cancer. There are already remarkable results using this 
approach, such as the use of poly(ADP-ribose) polymerase (PARP) inhibitors to 
treat BRCA-mutated breast tumors (Fong et al., 2009).  	  
1. p38 MAPK is not a synthetic lethal partner of ERK1/2, mTOR or PI3K pathways 
With the aim of finding synthetic lethal partners of p38 MAPK, we started by 
combining its inhibition with that of other relevant pathways for cancer cell 
survival, such as ERK1/2 and mTOR. We measured apoptosis by detecting the 
released DNA oligonucleosomes in U2OS cancer cells and found that there was 
an additive effect in the induction of programmed cell death when combining the 
inhibition of p38 MAPK and ERK1/2 pathways, but the effect was modest 
compared with a positive control provided by the kit (Fig. 16A). We then thought 
we might be able to see a bigger effect after cytotoxic challenging of the cells, so 
we treated them with cisplatin and doxorubicin, which are two chemotherapeutic 
agents used in the clinic for cancer treatment. A synergistic effect was not 
observed in any of the cases, but the differences in apoptosis among the various 
treatments became more apparent, maintaining the previously observed additive 
effect of inhibiting both p38 MAPK and ERK1/2 pathways (Fig. 16B). 
 
Besides apoptosis, we decided to check the viability of the cancer cells using 
resazurin, a compound that becomes fluorescent when the cells metabolize it, 
indicating the number of alive cells. We also checked the effect of inhibiting the 
RESULTS 
 86	  
PI3K pathway in both U2OS and HeLa cancer cells. As expected, cell viability was 
not significantly reduced in basal conditions after inhibition of the kinase pathways 
(Fig. 17A), and after treatment with cisplatin or doxorubicin these differences were 
increased, although never reached a synergizing effect (Fig. 17B).  
 
 
Figure 16. Inhibition of p38 MAPK together with the ERK1/2 pathway has additive effects 
inducing apoptosis in U2OS cancer cells. Apoptosis was measured with the Cell Death 
Detection ELISA kit from Roche. (A) U2OS cells were incubated with SB203580 (SB), 
rapamycin (RAPA) and U0126 (U0), alone or in combination with SB203580, overnight. 
“Positive” is an internal positive control of the kit. (B) U2OS cells were incubated with 
SB203580, rapamycin, U0126, alone or in combination with SB203580, overnight followed 
by cisplatin (CDDP) or doxorubicin (DOXO) treatment for 8 h.  
 
It was really striking that inhibition of only the p38 MAPK pathway sufficed to 
reduce viability of the cancer cells after the cytotoxic treatments, so we decided to 
further characterize this observation, which will be addressed in the second part of 
the “Results” section. 
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Figure 17. The combined inhibition of p38 MAPK and ERK1/2 or PI3K pathways do not 
synergize to reduce cancer cell viability. (A) U2OS and HeLa cancer cells were incubated 
with SB203580 (SB), LY294002 (LY) and U0126 (U0), alone or in combination with 
SB203580, overnight. (B) U2OS and HeLa cancer cells were incubated with SB203580, 
LY294002, U0126 (alone or in combination with SB203580) overnight followed by 
cisplatin (CDDP) or doxorubicin (DOXO) treatment for 8 h. Cell viability was measured 
with the resazurin assay. 
 
2. Potential synthetic lethal interactions between eEF2 kinase and p38 MAPK in 
response to cisplatin treatment 
Since the previously tested kinase pathways were not synthetic lethal partners of 
p38 MAPK, we performed a screening to analyze 84 chemical inhibitors that target 
36 different cell signaling pathways (Suppl. Fig. 1 and Suppl. Table 1). Based on 
experiments from figures 16-17, we anticipated that we would see bigger changes 
in cell survival under cytotoxic conditions, so we decided to compare control cells 
A 
B 
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with cells incubated with SB203580, both treated with cisplatin. We also decided 
to take into account the possible role of p53, so we used for the screening both the 
HCT116 colon cancer cell line and its derivative that lacks p53 expression (p53 
KO). First, we confirmed that both cell lines responded to the chemotherapeutic 
agents cisplatin, doxorubicin and etoposide, and also observed that inhibition of 
p38 MAPK further reduced cell viability (Fig. 18).  
 
 
Figure 18. p38 MAPK inhibition reduces the viability of HCT116 WT and p53 KO cancer 
cells upon cytotoxic insults. HCT116 and HCT116 p53 KO cells were pre-incubated with 
SB203580 (SB) for 2 h followed by treatment with cisplatin (CDDP), doxorubicin (DOXO) 
or etoposide (ETO) for 15 h. Cell viability was measured with the resazurin assay. 
 
Therefore, we performed the screening in both p53 WT and KO HCT116 cell lines 
measuring cell viability with resazurin after cisplatin treatment, in the presence or 
absence of SB203580, as explained above. We did the screening twice, plating 
either 10000 or 20000 cells per well, and after calculating the fold changes of cell 
viability relative to the cells where p38 MAPK was inhibited (primary data are 
provided in Suppl. Figures 2-3), we observed that the combined inhibition of the 
eEF2 kinase pathway together with that of p38 MAPK, reduced around two fold 
the cell viability in p53 WT cells (Fig. 19). Based on these data, although further 
characterization of this observation needs to be done, the eEF2 kinase can be 
considered as a putative synthetic lethal partner of p38 MAPK. 
 
 
HCT116! HCT116 p53-/-!
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Figure 19. Inhibition of eEF2-kinase signaling cooperates with the inhibition of p38 MAPK 
to reduce cancer cell viability. Fold survival relative to untreated cells is represented. 
10000 (A) or 20000 (B) HCT116 p53 WT (WT) and p53 KO (KO) cells per well were plated 
in the presence or absence of SB203580 (SB).  
 
Ours results indicate that the eEF2 kinase pathway might function as a synthetic 
lethal partner of p38 MAPK only in p53 WT cells, since there was not a significant 
change in cell viability in HCT116 p53 KO cells. Nonetheless, we still need to 
properly characterize the role of eEF2 kinase as a putative synthetic lethal partner 
of p38 MAPK in response to cisplatin treatment. It is necessary to use genetic tools 
to specifically deplete both kinases and make sure the inhibitors are not affecting 
other related pathways. Furthermore, it would be interesting to know whether all 
p38α is the main isoform involved or whether others have a role as well. 
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Figure 20. Inhibition of p38 MAPK sensitizes cancer cells to apoptosis upon cytotoxic 
insults. (A)	   HT-29, SW620 and MCF7 cells were incubated with SB203580 (SB) for 2 h 
followed by treatment with cisplatin (CDDP) for 24 h, and then they were stained with PI 
and Annexin V. The percentages of apoptotic cells are indicated. (B)	   HT-29 cells were 
incubated with SB203580 O/N followed by cisplatin for 8 h, as indicated. Apoptosis was 
measured with the Cell Death Detection kit ELISA PLUS. (C)	   HT-29 cells were treated as in 
(A) and the apoptotic sub-G0/G1 population was quantified by flow cytometry.  
 
(ii) Sensitization to chemotherapy by p38α  inhibition 
1. Inhibition of p38 MAPK signaling sensitizes cancer cells to apoptosis 
While looking for synthetic lethal partners of p38 MAPK, we realized that 
inhibition of this pathway reduced human cancer cell viability when combined 
with a chemotherapeutic agent (Figs. 16-18). To determine the role of p38 MAPK 
signaling in the survival of cancer cells exposed to chemotherapeutic agents, we 
treated human breast and colon cancer cells with cisplatin together with 
SB203580. Then we monitored apoptosis by different techniques. Annexin V 
staining revealed that the combination of cisplatin with SB203580 significantly 
potentiated the induction of apoptosis in both colon and breast cancer cells when 
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compared with the treatment of cisplatin alone (Fig. 20A). We confirmed this 
finding in HT-29 colon cancer cells by measuring the release of DNA 
oligonucleosomes (Fig. 20B) or by quantifying the percentage of cells that were in 
the subG0/G1 phase of the cell cycle (Fig. 20C).  
 
 
 
Figure 21. p38 MAPK might be necessary for the basal proliferation of some cancer cells. 
A panel of human colon (A), breast (B) or cervix (C) cancer cell lines was grown in the 
presence of absence of the p38 MAPK inhibitor SB203580 and monitored for four days. Cell 
viability was assed by the MTT assay. 
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C 
RESULTS 
 92	  
2. Regulation of apoptosis by p38 MAPK does not correlate with its role in cancer 
cell proliferation 
p38 MAPK might have a role in the proliferation of some human cancer cells, such 
as HT-29, RKO, MCF7 and HeLa cells (Fig. 21). We have shown that some of 
these cancer cells (HT-29, SW620, MCF7, HeLa) are sensitized to apoptosis after 
p38 MAPK inhibition. Interestingly, sensitization to apoptosis seems to be 
independent of the implication of p38 MAPK in cell proliferation as shown in 
figure 21 or of the p53 status in the cels (Table 2).  
 
Table 2. Molecular features of selected human cancer cell lines 
Cell line Organ Disease p53 status ER 
HeLa Cervix Adenocarcinoma Low expression N/A 
HT-29 Colon Adenocarcinoma Mutated N/A 
MCF7 Breast Adenocarcinoma WT Expressed 
MDA-MB-231 Breast Adenocarcinoma Mutated Not expressed 
RKO Colon Carcinoma WT N/A 
SW620 Colon Adenocarcinoma Mutated N/A 
 
 
Moreover, incubation with SB203580 for up to four days did not induce DNA 
damage, as measured by γ-H2AX staining in both colon and breast by 
immunoblotting (Fig. 22). 
 
 
 
Figure 22. Inhibition of p38 MAPK does not cause DNA damage. Cancer cells were 
incubated with SB203580 (SB) for 2 or 4 days (“2d” and “4d”, respectively) and treatment 
with neocarcinostatin was used as a positive control (“pos.”). The indicated antibodies were 
detected in total cell lysates by immunoblotting. 
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3. Inhibition of p38 MAPK upregulates the JNK pathway, which sensitizes to 
apoptosis 
Several studies indicate that p38 MAPK signaling can negatively regulate the JNK 
pathway in different cell contexts, mainly in non-transformed cells (Perdiguero et 
al., 2007b; Wagner and Nebreda, 2009). Since JNK signaling plays an important 
role in apoptosis induction (Davis, 2000), we investigated whether the JNK 
pathway was implicated in the enhanced apoptosis observed in cisplatin-treated 
cancer cells upon p38 MAPK inhibition. We found that inhibition of p38 MAPK 
signaling with SB203580, as shown by the reduced phosphorylation of its 
downstream target Hsp27, resulted in enhanced phosphorylation of the JNK 
substrate c-Jun in three different human cancer cell lines from breast or colon 
origin (Fig. 23A). It has been reported that the JNK pathway is an important 
mediator of cisplatin effects (Brozovic and Osmak, 2007). Accordingly, the JNK 
chemical inhibitor SP600125 impaired the enhanced apoptosis observed in 
cisplatin-treated cancer cells when p38 MAPK was inhibited, as determined by the 
reduced levels of processed p85PARP, which is one of the fragments released 
when PARP is cleaved by caspases during programmed cell death. (Fig. 23B). 
These results indicate a functional interplay between both signaling cascades in 
cancer cells, with the JNK pathway mediating the enhanced apoptosis induced by 
cisplatin upon p38 MAPK inhibition. 
 
To exclude possible off-target effects of the chemical inhibitors, we used RNAi to 
downregulate the expression of p38α. We confirmed that siRNA-mediated 
depletion of p38α mimicked the effect of the SB203580 inhibitor and enhanced 
JNK phosphorylation (Fig. 24A). Moreover, siRNA or shRNA-mediated 
downregulation of p38α increased the levels of cisplatin-induced apoptosis in both 
breast and colon cancer cells (Figs. 24B-C). Processed p85PARP was increased 
when MCF7 cells were incubated with siRNA of p38α compared with the 
scrambled siRNA (control) and this correlated with higher phosphorylation of JNK 
(Fig. 24B). Moreover, the subG0/G1 population of SW620 was increased when 
p38α was depleated by shRNA compared to the non-targeting shRNA used in 
control cells (Fig. 24C). Recapitulation of the effects observed with SB203580 by 
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genetic downregulation of p38α indicates that this p38 MAPK family member is a 
major contributor to the observed functional interplay. 
 
 
 
Figure 23. p38 MAPK inhibition in cancer cells upregulates the JNK pathway and sensitizes 
to apoptosis. Total cell lysates were analyzed by immunoblotting with the indicated 
antibodies. (A) HT-29, SW620 and MCF7 cells were treated with increasing concentrations 
(1-10 µM) of SB203580 (SB) for 6 h. (B) MCF7 cells were incubated O/N with 10 µM 
SB203580, alone or in combination with 20 µM SP600125 (SP) for 1 h, followed by 8 h 
treatment with cisplatin (CDDP). 
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Figure 24. p38α  downregulation activates JNK and increases apoptosis in cancer cells 
treated with cisplatin. Total cell lysates were analyzed by immunoblotting with the 
indicated antibodies. (A) MCF7 cells were incubated with p38α siRNA (sip38α, 50 nM for 
48 h) or treated with increasing concentrations of SB203580 (1-10 µM). A scrambled siRNA 
(siCtrl.) was used as a negative control. (B) MCF7 cells were incubated with p38α siRNA or 
siControl as in (A) and then treated for 8 h with cisplatin. (C) SW620 cells were infected 
with lentiviruses expressing shRNAs against p38α (shp38α) or a non-targeting control 
(shControl). After one week of puromycin selection, pools of cells were treated for 24 h with 
cisplatin and the apoptotic subG0/G1 population was quantified by flow cytometry and 
indicated by a solid line. (D) HT-29 cells were infected with shRNAs against JNK1 and 
JNK2 (shJNK1/2) or a non-targeting control (shControl). After one week of puromycin 
selection, pools of cells were incubated overnight in the presence or absence of SB203580 
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and then treated for 8 h with cisplatin. (E) HT-29 cells were infected with lentiviruses 
expressing shRNAs against JNK1 (shJNK1) and JNK2 (shJNK2) or a non-targeting control 
(shControl), as indicated. After one week of puromycin selection, pools of cells were treated 
as in (D).  
 
Next, we used shRNAs to downregulate JNK1 and JNK2, which confirmed a key 
role for this signaling pathway as a mediator of the apoptosis induced by cisplatin 
in cancer cells. Interestingly, the downregulation of JNK1 and JNK2 also decreased 
the enhanced apoptosis induced by cisplatin when p38 MAPK signaling was 
inhibited in HT-29 colon cancer cells (Fig. 24D). In contrast, the independent 
downregulation of only JNK1 or JNK2 did not significantly affect cisplatin-induced 
apoptosis in cancer cells (Fig. 24E). These results indicate that JNK1 and JNK2 are 
both involved in the sensitization to cisplatin-induced cell death upon p38α 
inhibition.  
 
4. Increased ROS levels mediate JNK activation and apoptosis sensitization 
It has been reported that JNK signaling can be activated by ROS (Shen and Liu, 
2006) and high endogenous ROS levels have been correlated with activation of 
the JNK pathway in human cancer cells (Dolado et al., 2007). There is also 
evidence that p38 MAPK signaling can sometimes impair ROS accumulation 
(Gutierrez-Uzquiza et al., 2012) and p38α downregulation has been associated 
with an oxidative stress gene expression signature (Mateescu et al., 2011). We 
therefore hypothesized that inhibition of p38 MAPK signaling might result in 
increased ROS levels, which in turn would activate the JNK pathway. We found 
that inhibition of p38 MAPK signaling with SB203580 produced a modest but 
consistent increase in the endogenous ROS levels of different human cancer cell 
lines (Fig. 25A). Similar results were observed upon shRNA-mediated 
downregulation of p38α (Fig. 25B), suggesting that this is a key family member to 
drive the observed effects. 
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Figure 25. p38 MAPK inhibition increases ROS levels. (A) The indicated cancer cells were 
incubated overnight either with DMSO or SB203580 (SB) and ROS levels were measured 
with the DCFDA probe by flow cytometry. Fold increase of ROS compared to the control 
cells is indicated in the bars diagram. (B) SW620 cells were infected with lentiviruses 
expressing shRNAs against p38α (shp38α) or a non-targeting control (shControl). Pools of 
cells were selected with puromycin for one week and basal ROS levels were measured with 
DCFDA by flow cytometry. Total cell lysates were analysed with the indicated antibodies. 
(C) MCF7 cells were incubated overnight with SB203580 and pre-treated for 1 h with a 
mixture of GSH and NAC antioxidants (AOX), or treated with 5 mM H
2
O
2
 for 1 h, as 
indicated. Cell lysates were analyzed by immunoblotting using Oxyblot and the total 
protein oxidation signal per lane was quantified using tubulin as a reference (Oxy/Tub). 
 
C 	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To confirm the significance of the observed changes in ROS, we measured the 
effect of p38 MAPK inhibition on the overall oxidation state of cellular proteins 
using a chemical derivatization protocol. These experiments showed that the 
enhanced ROS levels induced by incubation with SB203580 resulted in higher 
levels of protein oxidation in the cancer cells (Fig. 25C).  
 
We then investigated if the enhanced ROS production was linked to cisplatin-
induced apoptosis. Certainly, we found that the sensitization to apoptosis 
produced by p38 MAPK inhibition and JNK upregulation, was rescued by 
incubation with antioxidants to scavenge ROS (Fig. 26A). Importantly, this reduced 
levels of p85PARP correlated with lower phosphorylation of JNK, confirming that 
JNK is a main inducer of apoptosis after cisplatin treatment and suggesting that its 
activation might be related to ROS production. This is also consistent with the 
observed increased viability of human cancer cells after cytotoxic treatments if 
they were previously incubated with antioxidants (Fig. 26B). The ROS scavengers 
were able to rescue cell viability almost to the levels of untreated cells. Of note, 
clonogenic assays confirmed that the reduced apoptosis observed with 
antioxidants correlated with higher overall survival of the cancer cell population 
(Fig. 26C). Taken together, our results indicate that ROS induced upon p38 MAPK 
inhibition are responsible for the upregulation of the JNK pathway, which in turn 
induces apoptosis. 
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Figure 26. Increased ROS are involved in the sensitization to apoptosis through JNK. (A) 
MCF7 cells were pre-treated for 1 h with antioxidants (AOX), followed by incubation 
overnight with SB203580 (SB) and then treated with cisplatin (CDDP) for 8 h. Total cell 
lysates were analyzed by immunoblotting with the indicated antibodies. (B) The indicated 
human cancer cells were pre-treated for 1 h with AOX followed by 15 h incubation with 
cisplatin. Resazurin or MTT reagents were used to determine the remaining viable cells. (C) 
Clonogenic assays after O/N incubation with SB203580 followed by 1 h treatment with 50 
µM cisplatin for MCF7 and HT-29 cells, or 10 µM cisplatin for SW620 cells. The bars 
diagrams represent number of colonies.  
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Since ROS upregulation potentiated cisplatin-induced apoptosis, we wondered 
whether cancer cells that have high basal levels of ROS would be also sensitized 
to apoptosis upon p38 MAPK inhibition. To address this question, we selected the 
breast cancer cell line MDA-MB-231, which has higher levels of basal ROS than 
MCF7 cells (Fig. 27A). We found that MDA-MB-231 cells also showed JNK hyper-
activation in response to p38 MAPK inhibition, and this effect was impaired by 
treatment with antioxidants (Fig. 27B). Consistently, basal levels of JNK activation 
was higher in MDA-MB-231 cells than in MCF7 cells, directly correlating with 
their endogenous ROS levels. Moreover, inhibition of p38 MAPK signaling 
induced a time-dependent accumulation of ROS in MDA-MB-231 cells (Fig. 27C). 
In agreement with these observations, p38 MAPK inhibition further activated JNK 
signaling enhancing apoptosis in cisplatin-treated MDA-MB-231 cells, and 
incubation with antioxidants reduced JNK activation and the consequent apoptotic 
response (Fig. 27D), and therefore increased cell viability (Fig. 27E). These results 
indicate that the mechanism linking the inhibition of p38 MAPK with ROS 
accumulation, JNK activation and apoptosis induction is probably relevant to 
different types of cancer cells, regardless of their basal ROS content. 
 
 
A B 
C E D 
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Figure 27. p38 MAPK inhibition sensitizes cancer cells that bear high ROS to apoptosis. 
Total cell lysates were analyzed by immunoblotting with the indicated antibodies. (A) 
Endogenous ROS levels of MCF7 and MDA-MB-231 cancer cells were measured with the 
DCFDA probe by flow cytometry. Fold increase of ROS levels compared to MCF7 cells is 
represented. (B) Cells were incubated O/N in the presence or absence of SB203580 (SB), 
and pre-treated for 1 h with a mixture of GSH and NAC antioxidants (AOX). (C) MDA-MB-
231 cells were incubated for the indicated times with DMSO, SB203580 or 5 mM H
2
O
2
 for 
10 min. ROS levels were measured with DCFDA by flow cytometry. (D) MDA-MB-231 cells 
were pre-treated for 1 h with AOX, followed by 16 h incubation with SB203580 and then 
treated for 8 h with cisplatin (CDDP). (E) MDA-MB-231 cells were pre-treated for 1 h with 
AOX followed by 15 h incubation with cisplatin. Resazurin was used to determine the 
percentage of viable cells. 
 
5. Inhibition of p38 MAPK downregulates antioxidant enzymes 
To characterize the mechanism by which inhibition of p38 MAPK increases the 
levels of ROS, we investigated how SB203580 affects the expression of genes 
associated with the regulation of oxidative stress. We analyzed a gene expression 
array of 84 genes looking for changes after p38 MAPK inhibition in MCF7 cells 
(see “Methods”). The analysis (Suppl. Fig. 4) revealed eight genes encoding 
proteins with antioxidant activity whose expression was downregulated more than 
1.5 fold in response to p38 MAPK inhibition. Re-examination of the expression of 
these candidate genes with custom primers showed that three genes were 
significantly downregulated upon p38 MAPK inhibition both in breast and in colon 
cancer cells (Table 3). One of the genes was PTGS2, which encodes the anti-
inflammatory protein cyclooxygenase 2 (COX-2). This was described as an anti-
oxidant gene in the array but we were not aware of clear evidence linking COX-2 
to antioxidant activity. We used shRNAs to downregulate COX-2 in SW620 colon 
cancer cells but found no evidence that this protein had a major anti-oxidant role; 
if anything there was a slight decrease in ROS levels upon COX-2 downregulation. 
As a control, shRNA-mediated downregulation of p38α in the same cells showed 
the expected increase in ROS production (Fig. 28A). Therefore, the regulation of 
COX-2 expression by p38 MAPK does not seem to impinge on the ROS levels of 
cancer cells and we decided not to further characterize this candidate. 
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Table 3. Antioxidant enzyme-encoding genes regulated by p38 MAPK in cancer cells 
RefSeq Name Array MCF7 HT-29 
NM_002083 GPX2  -1.91 -1.38 1.83 
NM_002084 GPX3  -1.49 -1.07 -1.31 
NM_001509 GPX5 -1.96 -2.16 -1.50 
NM_000637 GSR -1.70 -1.17 1.09 
NM_006151 LPO -1.88 1.50 -5.56 
NM_000963 PTGS2 -5.87 -4.09 -1.53 
NM_144651 PXDNL -1.86 -9.52 -1.45 
NM_032243 TXNDC2 -3.15 -1.91 -2.35 
The expression of eight candidate genes identified in the array was validated by qRT-PCR in 
breast MCF7 and colon HT-29 cancer cells. Numbers indicate fold changes in the 
expression of genes upon incubation of the cells with SB203580 to inhibit p38 MAPK 
signaling. Genes downregulated at least 1.5 fold in both cell lines are in bold. 
 
The other two genes regulated by p38 MAPK were GPX5 and TXNDC2, which 
encode a glutathione peroxidase and a thioredoxin, respectively, two well-known 
enzymes with antioxidant activity. Interestingly, we found that siRNA mediated 
downregulation of GPX5 or TXNDC2 sufficed to enhance the basal JNK activity 
levels in MCF7 cells (Fig. 28B). This indicates that GPX5 and TXNDC2 are both 
good candidates to mediate the upregulation of ROS observed upon p38 MAPK 
inhibition in cancer cells. Thus, we hypothesized that reduced expression of these 
antioxidant enzymes after inhibition of p38 MAPK would induce ROS 
upregulation and activation of the JNK pathway. 
 
Since mitochondria are one of the main sources of ROS in the cell, we also 
investigated the possibility that p38 MAPK could regulate the mitochondrial 
production of ROS. In the same line, we also wondered about the possible 
contribution of NADPH oxidase (Nox) enzymes to ROS generation after p38 
MAPK inhibition. We observed that the Nox inhibitor DPI did not affect the 
production of ROS after p38 MAPK inhibition but rotenone, an inhibitor of the 
mitochondrial respiratory chain, was able to block it (Fig. 28C). This indicates that 
regulation of mitochondrial activity might also contribute to the production of ROS 
upon p38 MAPK inhibition. 
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Figure 28. Downregulation of antioxidant enzymes induces JNK activation. (A) SW620 
cells were infected with lentiviruses expressing shRNAs against PTGS2 (shCOX-2) and p38α 
(shp38α) or a non-targeting control (shControl). Pools of cells were selected with puromycin 
for one week and levels of ROS were measured with DCFDA by flow cytometry. (B) MCF7 
breast cancer cells were transfected with siRNAs against GPX5 (siGPX5), TXNDC2 (siTXN) 
or scramble (siControl). The expression levels of the indicated mRNAs were determined by 
semi-quantitative RT-PCR (left panel). Total cell lysates were analyzed by immunoblotting 
with the indicated antibodies (right panel). (C) MCF7 cells were pretreated for 1 h with 2.5 
µM DPI or 0.25 µg/ml rotenone (ROT), incubated for 6 h with DMSO or SB203580, and 
ROS levels were measured with DCFDA by flow cytometry. (D) Different breast (MCF7, 
MDA-MB-231) and colon (SW620) cancer cells were treated O/N with SB203580 (SB). 
Total cell lysates were analyzed by immunoblotting with the indicated antibodies. 
 
A recent report (Gutierrez-Uzquiza et al., 2012) has proposed that p38α regulates 
ROS production in MEFs through the antioxidant enzymes catalase and SOD. 
However, inhibition of p38α did not affect the protein levels of these enzymes in 
the cancer cells we analyzed (Fig. 28D), suggesting that regulation of ROS 
production by p38α may involve different mechanisms in non-transformed and 
tumor cells. 
 
6. Inactivation of JNK phosphatases by increased ROS levels 
Previous reports have shown that ROS can lead to the inhibition of phosphatases, 
since their catalytic cysteine is susceptible to inactivation by oxidation (Kamata et 
al., 2005; Teng et al., 2007). Thus, we investigated whether the activation of JNK 
signaling observed upon p38 MAPK inhibition was due to the ROS-mediated 
inactivation of JNK phosphatases. With that aim, we expressed and purified 
recombinant GST-JNK1 and GST-MKK7 proteins and performed an in vitro kinase 
assay (see “Methods”). Then, we purified the in vitro-phosphorylated JNK1 protein 
and incubated it with lysates of cancer cells, which had been treated or not with 
SB203580 (Fig. 29A). We observed that the lysates of SB203580-treated cells were 
less efficient at dephosphorylating JNK1, suggesting that JNK phosphatases were 
less active in cells where p38 MAPK was inhibited, probably due to their higher 
levels of ROS. As a control, we confirmed that treatment with phosphatase 
inhibitors impaired JNK1 dephosphorylation by the cell lysates (Fig. 29B).  
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Figure 29. Increased ROS levels inactivate JNK phosphatases. (A) Schematic representation 
of the phosphatase assay. (B) Recombinant GST-JNK1 protein was incubated with MKK7 
and 32P-γ-ATP, affinity purified and then incubated for the indicated times (0-30 min) with 
total cell lysates obtained from SW620 cells treated or not with SB203580. As a control, 
phosphatase inhibitors were added to the SW620 cell lysates (30+inh). The amount of 
phosphorylated JNK1 was visualized by autoradiography and was quantified relative to the 
amount initially present at time 0. 
 
We took advantage of the fact that we could purify the in vitro-phosphorylated 
recombinant JNK1, to check what phosphatases could be bound to it. For this 
experiment, we first incubated the GST-JNK1 protein to the beads and then we 
proceed with the phosphorylation by MKK7. The phosphorylated GST-JNK1 bound 
to the beads was incubated with lysates from SW620 cancer cells either treated or 
not with SB203580. The beads were then recovered, washed and analyzed by 
SDS-PAGE. We selected for mass spectrometry (MS) analysis three areas of the gel 
where different patterns of proteins could be observed between lysates of cells, 
treated or not with S203580 (Fig. 30). The proteins identified in bands 1, 2 and 3 
are listed in Supplementary Tables 2, 3 and 4, respectively.  
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Figure 30. SDS-PAGE from GST-JNK1 
incubated with cancer cell lysates. 
Laemmli gel stained with coomassie. I: 
GST+lysate, II: MKK7+lysate, III: JNK1 + 
control lysate, IV: JNK1 + SB lysate, V: 
JNK1. Bands 1, 2 and 3 were sent for mass 
spectrometry (MS) analyses. 	  	  
Most of the pulled down proteins that were identified either in the control lysates 
or in the SB203580-treated ones, were cytoskeletal keratins. Since we did not pull 
down any phosphatase, we decided to follow another approach to identify what 
type of phosphatases was affected by the ROS produced upon p38 MAPK 
inhibition. First, we measured either the Tyr or Ser/Thr phosphatase activity of 
human cancer cells that were incubated or not with SB203580. We observed that 
in lysates of cells where p38 MAPK was inhibited, the rate of dephosphorylation of 
Tyr phosphopeptides was significantly reduced in comparison with control lysates 
(not treated with SB203580). In contrast, dephosphorylation of Ser/Thr 
phosphopeptides was less affected by p38 MAPK inhibition. As a control, 
treatment with H2O2 significantly reduced both types of phosphatase activities (Fig. 
31A). To follow up on these results, we focused on Tyr phosphatases that are 
susceptible to ROS inactivation and that have been reported to negatively regulate 
JNK activity, such as PTP1B, PTP-PEST, DUSP8, DUSP10 and DUSP16 (Keyse, 
2008; Wu et al., 2008). Furthermore, these phosphatases have been shown to be 
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dysregulated in breast and colon cancer cells (Labbe et al., 2012). We used 
siRNAs to downregulate each of these five phosphatases and found that DUSP8 
downregulation sufficed to enhance the basal phosphorylation of JNK in MCF7 
cells (Fig. 31B). The result with DUSP16 was not reproducible. This identifies 
DUSP8 as a phosphatase that controls the basal activity of JNK, and whose 
inactivation due to increased ROS levels could explain the observed activation of 
JNK induced by p38 MAPK inhibition in MCF7 cells. However, DUSP8 did not 
seem to play a major role in the regulation of basal JNK phosphorylation in other 
cancer cells (Fig. 31C), suggesting that different ROS-regulatable phosphatases 
might control the basal levels of JNK phosphorylation in different types of tumor 
cells. 
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Figure 31. Increased ROS levels inactivate JNK phosphatases. (A) SW620 cells were 
incubated with SB203580 (SB) O/N or with 5 mM H
2
O
2
 for 1 h and the Ser/Thr or Tyr 
phosphatase activities were measured in total cell lysates with the kits from Promega. (B) 
MCF7 cells were transfected with siRNAs against PTPN1, PTPN12, DUSP16, DUSP8 or 
DUSP10, or with a scramble control, and 48 h later total cell lysates were analyzed by 
immunoblotting with the indicated antibodies. Downregulation of the target genes was 
confirmed by qRT-PCR, as shown in the histogram. (C) The indicated cancer cell lines were 
transfected with siRNAs against PTPN1, PTPN12, DUSP16, DUSP8 and DUSP10, or with a 
scramble control, and 48 h later total cell lysates were analyzed by immunoblotting with 
the indicated antibodies. As a positive control, some cells were incubated O/N with 
SB203580 before immunoblotting. 
 
We also considered the possibility that inhibition of p38 MAPK could impinge on 
upstream activators of the JNK pathway, but we were not able to detect the 
phosphorylation levels of endogenous MKK4 and MKK7 in these cancer cells. 
Thus, we used an inhibitor of ASK1, a MAP3K that can mediate oxidative stress-
induced phosphorylation of JNK activators. We used UV radiation to fully 
stimulate JNK activation through ASK1, together with increasing concentrations of 
the ASK1 inhibitor (0-10 µM), and we confirmed that ASK1 inhibition blocked the 
activation of JNK induced by UV (Fig. 32A). However, neither JNK activation nor 
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the enhanced apoptosis induced by cisplatin upon p38α inhibition were affected 
by ASK1 inhibition (Fig. 32B). Taken together, our results indicate that phosphatase 
inhibition plays a key role in the ROS-induced upregulation of JNK activity 
triggered by p38 MAPK inhibition. 
 
 
Figure 32. ASK1 inhibition does not affect cisplatin-induced apoptosis upon p38 MAPK 
inhibition. In both panels, total cell lysates were analyzed by immunoblotting with the 
indicated antibodies. (A) MCF7 cells were treated with the indicated concentrations of 
ASK1 inhibitor O/N and then irradiated with 50 J/m2 UV followed by 30 min incubation. 
(B) MCF7 cells were incubated O/N with SB203580 and/or 10 µM ASK1 inhibitor followed 
by cisplatin treatment for 8 h.  
 
 
7. Inhibition of p38 MAPK cooperates with cisplatin to reduce breast 
tumorigenesis in mice 
To obtain in vivo evidence for the implication of p38 MAPK signaling in the 
response of cancer cells to cisplatin, we used the MMTV-PyMT mouse model of 
breast cancer. These mice develop spontaneous tumors in the mammary glands 
that become palpable when females are around 2.5 months old. Tumors were 
allowed to grow until they reached 200 mm3 and then four different treatments 
were applied. 
 
A B 
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Figure 33. Cisplatin cooperates with p38 MAPK inhibition to reduce breast tumors in 
mice. (A) MMTV-PyMT female mice with breast tumors of 200 mm3 in volume were treated 
with a single-dose of cisplatin followed by daily administration of the p38 MAPK inhibitor 
PH-797804 (10 mg/Kg) for 18 days. Tumor size was measured at the indicated times and 
normalized relative to the original size of each tumor when the treatment began. The graph 
compiles the results of two independent experiments, in which a minimum of four mice was 
used per condition. *** = p<0.0001, ** = p<0.001, * = p<0.05, ns = p>0.05. (B) H-E and 
Ki67 staining of breast tumors analyzed at day 7. Images are 20x. (C) TUNEL staining of 
breast tumors analyzed at day 7. (D) Total cell lysates obtained from two representative 
mice of each condition were analyzed by immunoblotting with the indicated antibodies. (E) 
Protein oxidation in tumor samples was analyzed by immunoblotting using Oxyblot, and 
the total protein oxidation signal per lane was quantified with tubulin as a reference. Results 
were confirmed using three mice per condition. 
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In the first experiment, female mice were treated either with a single dose of 
cisplatin (Evers et al., 2010), with daily administration of the p38 MAPK inhibitor 
PH-797804 (Xing et al., 2009), with the combination of both, or only with vehicle 
of the inhibitor and physiological saline (control animals). We monitored tumor 
evolution for 18 days (except for the control animals, which had to be sacrificed 
before due to the size of their tumors). As shown in figure 33A, tumors from 
control mice (“Vehicle”) increased their size over time; tumors from mice treated 
with PH-797804 slightly decreased during the first 10 days, but then they started to 
grow again; tumors from mice treated with cisplatin decreased almost to a 50% of 
their initial size; and tumors from the double treatment were reduced about 90%. 
Thus, in agreement with our observations in human cancer cells, we found that the 
combination of cisplatin treatment with p38 MAPK inhibition showed a clear 
additive effect and reduced the size of breast tumors in mice more than treatment 
with cisplatin alone.  
 
Immunohistochemical (IHC) analysis based on Ki67 staining confirmed reduced 
levels of tumor cell proliferation in the single treatments, and to a greater extent in 
the double treatment at day 7 (Fig. 33B). At this point of the experiment, all three 
treatments induced a decrease in tumor size but they were all within the same 
range, so we decided to compare tumors at the molecular level. Apoptotic events, 
as determined by TUNEL staining (Fig. 33C) or by cleaved caspase-3 detection by 
immunoblotting (Fig. 33D), were higher in the tumors from mice subjected to the 
double treatment. The fact that at an early time point (day 7), when tumors have 
more or less the same size, we already saw higher apoptosis and lower 
proliferation in the case of the combined therapy, could explain its additive effect, 
consistent with what we observed in the human cancer cell lines. 
 
We also investigated whether p38 MAPK inhibition in mice would induce 
activation of JNK in the breast tumors as well. Indeed, we confirmed that JNK was 
activated in tumors of mice treated with the p38 MAPK inhibitor, and this was 
further enhanced in tumors of mice subjected to the double treatment (Fig. 33D). 
To correlate the results in vivo with those obtained in cancer cell lines, we 
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analyzed the general oxidation state in the breast tumor proteins by Oxyblot, 
which revealed higher levels of oxidation in mice treated with the p38 MAPK 
inhibitor and cisplatin (Fig. 33E). These results indicate that the inhibition of p38 
MAPK combined with cisplatin treatment cooperate to induce tumor cell 
apoptosis, which correlates with increased ROS and JNK pathway activation in the 
breast tumor cells.  
 
 
Figure 34. p38 MAPK inhibition reduces tumor malignancy in a mouse model of breast 
cancer. (A) H-E and Ki67 staining of breast tumors analyzed at day 18. Images are 20x. (B) 
H-E stained sections of breast tumors were analyzed in blinded fashion at day 18. Samples 
were classified as carcinoma, adenoma, hyperplasia and normal tissue based on the 
microscopic analysis of the tissue.  
 
Importantly, IHC analysis of the tumors at the end of the experiment showed that 
the double treatment kept on reducing the proliferative capacity of the tumor cells 
(Fig. 34A). Moreover, evaluation of the tumor grade showed that tumors were in a 
less advanced stage (Fig. 34B).  Considering that the size of the tumors is also 
strongly reduced by the combined treatment, a better prognosis could be expected 
in the event of a possible relapse after therapy termination. 
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To test this hypothesis, we repeated the experiment under the same conditions 
described above, but we stopped treatment with the p38 MAPK inhibitor after 15 
days and then monitored the evolution of each group of tumors up to 24 days (Fig. 
35).  We found that the rate of growth of the tumors coming from mice that were 
treated with the double therapy was slower than with the individual therapy, 
indicating that new tumors would probably appear later after the combined 
treatment. 
 
 
Figure 35. After therapy termination, relapse in the double treatment is slower. MMTV-
PyMT female mice with breast tumors of 200 mm3 in volume were treated with a single-
dose of cisplatin followed by daily administration of PH797804 (10 mg/Kg) up to 15 days, 
when the therapy was stopped. Tumor size was measured at the indicated times and 
normalized relative to the original size of each tumor when the treatment began. 
 
 
8. Different types of transformed cells are sensitized to apoptosis after p38 MAPK 
inhibition 
Other types of human epithelial cancer cells might also rely on this mechanism of 
response to cytotoxic treatments, as we have observed enhanced JNK activation 
upon p38 MAPK inhibition, both with chemical compounds (Fig. 36A-B) and by 
genetic downregulation (Fig. 36C-D) of p38α. We confirmed that combination of 
cytotoxic treatments, either cisplatin or doxorubicin, with the inhibition of p38 
MAPK sensitized to apoptosis. (Fig.37A). Besides, ROS was implicated as well in 
the sensitization of RKO cancer cells to death after cisplatin incubation and UV 
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radiation (Fig. 37B), as we demonstrated for other breast and colon cancer cell 
lines.  
 
 
 
Figure 36. Impairment of p38 MAPK activates the JNK pathway in epithelial cancer cells. 
Total cell lysates were analyzed by immunoblotting with the indicated antibodies. (A) 
U2OS cancer cells were incubated with SB203580 for 24h. (B) HCT116 and HCT116 p53-/- 
colon cancer cells were treated with increasing concentrations of SB203580 (0.5 – 10 µM) 
for 24 h. (C) HCT116 cells were infected with shRNA against p38α (shp38α) or a non-
targeting control (shCtrl.). After one week of puromycin selection, pools of cells were 
collected for their analysis. (D) RKO colon cancer cells were incubated with p38α siRNA 
(sip38α, 50 nM for 48 h) or treated with SB203580.  
 
 
Interestingly, when analizing by immunofluorescence U2OS cells, we observed 
that SB203580 mainly induced JNK activation in the cytoplasm, in contrast with 
the nuclear localization of active JNK observed after UV radiation (Fig. 38).  
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Figure 37. p38 MAPK inhibition sensitizes some  epithelial cancer cells to cell death. (A) 
U2OS and RKO cells were pre-incubated with SB203580 for 2 h followed by treatment with 
cisplatin (CDDP) or doxorubicin (DOXO) for 15 h. Apoptosis was measured with the Cell 
Death Detection ELISA kit. (B) RKO cells were pre-incubated for 1 h with a mixture of 
antioxidants (AOX) followed by treatment with cisplatin or UV radiation for 15 h. Cell 
viability was measured by MTT. 
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Figure 38. p38 MAPK inhibition induces JNK activation mainly in the cytoplasm. U2OS 
cells were incubated with SB203580 for 6 h or 400 J/m2 UV for 1 h. Phosphorylated JNK 
was detected by immunofluorescence.  
 
 
We also investigated the effect of depleting p38α in H-Ras transformed MEFs. We 
found that H-Ras p38α WT MEFs beared much lower basal ROS levels than H-Ras 
p38α KO, even after treatment with H2O2 (Fig. 39). Also, JNK signaling was more 
efficiently activated in challenged H-Ras p38α KO MEFs than in WT ones (Fig. 
40A), in agreement with previous observations where high ROS levels induced 
JNK activation. We then postulated that transformed MEFs deficient in p38α 
should be more sensitized to apoptosis after cisplatin treatment. Therefore, we 
incubated them with this drug and measured the apoptotic subG0/G1 population 
by flow cytometry (Fig. 40B).  We found that, not only H-Ras transformed p38α 
KO MEFs were more susceptible to cisplatin-induced apoptosis than WT, but also 
that pre-incubation with antioxidants strongly reduced the apoptotic population.  
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Figure 39. H-Ras transformed p38α  WT MEFs bear lower levels of ROS than p38α  KO 
ones. Basal levels of ROS were measured with the DCFDA probe. Transformed p38α WT 
MEFs were also incubated for 1 h with H
2
O
2
 prior to ROS measurement. Total cell lysates 
were analyzed by immunoblotting with the indicated antibodies.  
 
 
Taken together, these results indicate that the p38 MAPK pathway negatively 
regulates cisplatin-induced apoptosis in transformed fibroblasts as in epithelial 
cancer cells. It should be noted that p38α negatively regulates the onset of Ras-
induced MEF transformation (Dolado et al., 2007), but it is apparently required for 
survival in cisplatin-treated transformed MEFs, suggesting differential roles of p38α 
signaling depending on the stage of cell transformation.  
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Figure 40. Transformed p38α  KO MEFs activate JNK signaling more efficiently than WT 
and they are more sensitized to cisplatin-induced apoptosis. (A) After 8 h incubation with 
cisplatin (CDDP) or UV radiation, total cell lysates were analyzed by immunoblotting with 
the indicated antibodies. (B) The apoptotic subG0/G1 population (indicated by a solid line) 
was analyzed by flow cytometry, either in basal conditions (NT), after 1 h incubation with 
antioxidants (AOX), 24 h treatment with 100 µM cisplatin (CDDP), or with the indicated 
combinations (CDDP+AOX). 
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Reactive oxygen species (ROS) might function as a double-edged sword. A 
moderate increase of ROS may promote cell proliferation and survival. However, 
when the increase of ROS reaches a certain level (the toxic threshold), it may 
overwhelm the antioxidant capacity of the cell and trigger cell death (Fig. 41).  
 
 
 
Figure 41. Normal versus cancer redox biology. Cancer cells typically bear higher 
endogenous ROS levels than normal cells due to their increased metabolism and oncogenic 
signaling. This reduces their tolerance to exogenous ROS stress reaching more easily the 
cell-death threshold (horizontal dotted line). (Trachootham et al., 2009). 
 
Under physiological conditions, normal cells maintain redox homeostasis with low 
levels of basal ROS by controlling the balance between ROS generation (pro-
oxidants) and elimination (antioxidant capacity). Normal cells can tolerate a 
certain level of exogenous ROS stress owing to their antioxidant capacity, which 
can be mobilized to prevent the ROS level from reaching the cell-death threshold. 
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In cancer cells, the increase in ROS generation from metabolic abnormalities and 
oncogenic signaling may trigger a redox adaptation response, leading to an 
upregulation of antioxidant capacity and a shift of redox dynamics with high ROS 
generation and elimination to maintain the ROS levels below the toxic threshold. 
As such, cancer cells would be more dependent on the antioxidant system and 
more vulnerable to further oxidative stress induced by exogenous ROS-generating 
agents or compounds that inhibit the antioxidant system. A further increase of 
oxidative stress in cancer cells is likely to cause elevation of ROS above the 
threshold level, leading to cell death.  
 
This idea puts into perspective the biological relevance of our work. We show that 
the inhibition of p38α signaling in cancer cells suffices to increase ROS levels (by 
downregulating antioxidant enzymes), which in turn inactivate JNK phosphatases. 
The JNK pathway is an important mediator of apoptosis induction in response to 
different chemotherapeutic agents, in particular cisplatin (Bae et al., 2006; 
Sanchez-Perez et al., 2000). Therefore, p38α-mediated ROS increase in cancer 
cells inactivates JNK phosphatases, which stimulates JNK-induced apoptosis in 
response to cisplatin. Although we have robust data supporting these findings, 
there are still some points that are worth discussing. 
 
p38α  negatively regulates JNK in cancer cells through ROS downregulation 
1. Interplays between JNK and p38 MAPK  
The JNK and p38 MAPK pathways can cooperate in the response to certain stimuli 
as they share several upstream activators (Cuevas et al., 2007). For instance, they 
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synergize in murine fibroblasts to induce AP1 transcriptional activity in response to 
UV and anisomycin insults, as p38α can sometimes mediate the expression of 
both Jun and its partner Fos (Hazzalin et al., 1996).  
 
Nevertheless, the most frequent scenario is that they display opposite effects. There 
are a number of reports illustrating this interplay both in basal or under stress 
conditions (Wagner and Nebreda, 2009), which mainly focus on non-transformed 
cells, like cardiomyocytes (Nemoto et al., 1998), mouse embryonic fibroblasts 
(Wada et al., 2008) or myoblasts (Perdiguero et al., 2007a). In all the cases, p38α 
exerts an inhibitory role on the JNK pathway. The mechanisms described involve 
both upstream and downstream levels of regulation, as p38α negatively regulates 
the JNK activator MLK3 (Muniyappa and Das, 2008) and changes in expression of 
the JNK-activating adaptor proteins Grsp2 and HPK1 (Hui et al., 2007). 
 
Much less literature describing the antagonistic roles of both MAPKs in cancer is 
available, and in none of them describes an interplay mediated by ROS. Here, we 
show a novel mechanism of regulation of the JNK pathway activity by p38α 
through ROS downregulation. 
 
It is not so clear whether JNK has could have an inhibitory role on the p38 MAPK 
cascade, with the exception of a report showing that Jun-deficient hepatocytes 
have increased p38α phosphorylation (Stepniak et al., 2006). Nevertheless, it is 
not known until what extent this is a general mechanism. We did not address this 
possibility but it would be interesting to know whether there can be a bidirectional 
DISCUSSION 
 124	  
regulation. Nonetheless, as p38α maintains the levels of ROS low, we would not 
expect a sensitization of the cancer cells to apoptosis if inhibition of JNK would 
upregulate p38α, and this is not biologically interesting.  
 
2. Regulation of ROS by p38 MAPK 
p38α is a stress-activated protein kinase, so it is not surprising that it has been 
reported to be activated by ROS. What is interesting is the fact that p38α itself can 
regulate ROS levels in cancer cells. We have addressed how the inhibition of 
p38α increases ROS levels in cancer cells. Experiments using rotenone suggests 
that electron transport through the mitochondrial respiratory chain may contribute 
to ROS generation after p38α inhibition. Furthermore, we also identified two 
antioxidant genes in an array, GPX5 and TXNDC2, which are positively regulated 
by p38α signaling in cancer cells. Thus, p38α may negatively regulate ROS 
accumulation at different levels. Of note, p38α signaling has been reported to 
negatively regulate ROS accumulation in MEFs through the upregulation of the 
antioxidant enzymes catalase and superoxide dismutase (Gutierrez-Uzquiza et al., 
2012), but we found no evidence for the regulation of these two enzymes by p38α 
in human cancer cells. This indicates that p38α signaling can probably regulate 
ROS accumulation by different mechanisms in transformed cells. In fact, the 
different sensitivity of transformed and non-transformed cells to ROS has been 
proposed to be therapeutically useful (Mateescu et al., 2011; Raj et al., 2011; 
Shaw et al., 2011). 
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3. Activation of JNK by ROS 
ASK1 has been proposed as a key regulator of apoptosis in response to oxidative 
stress through the activation of MKK4 and MKK7 (Takeda et al., 2008). 
Nevertheless, these JNK upstream activators are unlikely to be implicated in the 
JNK activation process that we describe here. Instead, our results indicate that the 
inhibition of JNK phosphatases by the accumulation of intracellular ROS (a 
mechanism that has been suggested in other cellular contexts (Karisch et al., 2011; 
Ostman et al., 2011)) may account for the hyperactivation of the JNK pathway 
upon p38α impairment.  
 
We have found no evidence that p38α inhibition affects the expression of the 
inducible nuclear phosphatase MKP1 (Keyse, 2008), which based on 
overexpression experiments was proposed to regulate cisplatin-induced JNK 
activation (Sanchez-Perez et al., 2000). However, by analyzing cytoplasmic 
phosphatases that have been reported to target JNK phosphorylation (Dickinson 
and Keyse, 2006), we show that DUSP8 controls the basal levels of JNK 
phosphorylation in MCF7 breast cancer cells. DUSP8 has been shown to interact 
with JNK in non-stimulated cells (Sanchez-Perez et al., 2000). Curiously, we 
provide evidence that DUSP8 is unlikely to play a major role regulating the basal 
levels of JNK phosphorylation in other human cancer cells. Taken together, our 
results indicate that different cysteine-based phosphatases might be involved in the 
regulation of basal JNK activity depending on the cancer cell type. 
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Sustained JNK activation sensitizes cancer cells to apoptosis 
We have previously reported that p38α activation in non-transformed cells 
induces apoptosis in response to the expression of some oncogenes, whereas the 
JNK pathway does not seem to be involved in this process (Dolado et al., 2007). 
Contrary to the above scenario at the onset of cell transformation, we now show 
that enhanced JNK activity sensitizes cancer cells to apoptosis induced by 
chemotherapeutic drugs. This response seems to be conserved in different types of 
tumor cells, suggesting that it could be potentially exploited for cancer therapy in 
combination with oxidative stress-inducing agents (Engel and Evens, 2006). Our 
results imply that whereas p38α plays a key role inducing apoptosis in response to 
ROS accumulation during tumor initiation (Dolado et al., 2007), this function 
seems to have been taken over by JNK in advanced tumor stages, where JNK 
hyperactivation sensitizes to apoptosis induced by chemotherapeutic agents. Thus, 
inhibition of p38α may sensitize tumor cells to these treatments by increasing the 
basal levels of ROS through downregulation of antioxidant enzymes and 
generating higher levels of activated JNK that will potentiate the induction of 
apoptosis in response to genotoxic insults.   
 
We provide evidence for the biological relevance of this mechanism in the 
response of cancer cells to chemotherapeutic treatments, extending previous 
reports on the implication of ROS in JNK-mediated apoptosis (Hou et al., 2008; 
Kamata et al., 2005). 
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p38α  inhibition sensitizes to chemotherapy  
1. In vitro evidence  
Previous reports have suggested that inhibition of the p38 MAPK signaling 
pathway may help chemotherapeutic agents to kill cancer cells. This is the case for 
myeloma cell lines treated with bortezomib (Navas et al., 2006), lymphoma cell 
lines treated with etoposide (Kurosu et al., 2005), or glioma cell lines treated with 
temozolomide (Demuth et al., 2007). Moreover, the downregulation of MK2, a 
downstream effector of p38α, sensitizes p53-deficient mouse embryionic 
fibroblasts (MEFs) transformed with oncogenic Ras to doxorubicin or cisplatin 
treatment (Reinhardt et al., 2007). In these cases, the enhanced cytotoxic effect 
observed upon p38 MAPK inhibition has been associated with defective G2 cell 
cycle arrest. Recent work has also proposed that p38α signaling may play an 
important role regulating the expression of pro-survival proteins in the G2-arrested 
cells (Phong et al., 2010). Independently of a putative role of p38α in the 
regulation of cell cycle checkpoints in human cancer cells, we show that 
p38α inhibition results in ROS upregulation and JNK activation sensitizing to 
cisplatin-induced tumor cell death. It seems unlikely that cell cycle arrest would 
be required for ROS upregulation in response to p38α inhibition, although we 
cannot rule out that G2 arrest might contribute to the reduced tumor cell 
proliferation observed upon treatment with the p38 MAPK inhibitor.  
 
Our results also indicate that the additive effect of p38α inhibition and cisplatin 
treatment is probably independent of p53, as we have observed this pro-apoptotic 
effect in cancer cells with different p53 status. Of note, p38α inhibitors could also 
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potentially ameliorate cisplatin-resistance, which has been proposed to rely on 
p38 MAPK activity (Galan-Moya et al., 2011). Altogether, our results illustrate a 
new mechanism by which p38a contributes to tumor cell survival, and suggest that 
the combination of p38a inhibitors with chemotherapeutic agents should be 
considered for cancer therapy. 
 
2. In vivo evidence 
Using the MMTV-PyMT mouse model for breast cancer and a p38α inhibitor that 
is in Phase II clinical trials for antiinflamatory processes (Goldstein et al., 2010; 
Hope et al., 2009), we confirmed that inhibition of p38α cooperates with cisplatin 
to kill tumor cells in vivo. Importantly, upon treatment with cisplatin and a p38 
MAPK inhibitor, not only breast tumors are smaller, but they also look 
histologically less malignant and tumor cell proliferation is significantly reduced.  
Altogether, these results may explain the slower growth of relapsed tumors grow 
slower when they have been treated with the combined therapy. 
 
Comparative gene expression analyses of the MMTV-PyMT tumors along with 
different types of human breast tumors suggest the placement of PyMT tumors in a 
luminal group (Fluck and Schaffhausen, 2009), which are less sensitive to 
chemotherapy (Turner and Jones, 2008). This provides a potential therapeutic 
advantage for our suggested combined therapy with a p38 MAPK inhibitor, as we 
have shown that it sensitizes tumors to cisplatin treatment.  
Nonetheless, it appears that even though cisplatin is widely used for the treatment 
of solid tumors like those from colon or ovary, in the case of breast cancer is only 
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applicable to the basal (or triple negative) subtype. Instead, doxorubicin 
derivatives are more widely used as chemotherapeutic agents to treat luminal 
breast cancers. It would be interesting to check whether the additive effect that we 
have reported with cisplatin also takes place with doxorubicin treatment in vivo. In 
principle, we would anticipate that this should be the case, since we already 
showed in vitro sensitization of some human cancer cell lines to doxorubicin 
treatment after p38 MAPK inhibition. 
 
Proposed model 
Based on the data presented, we propose a model were p38α contributes to 
cancer cell survival by keeping ROS levels low through, at least, two different 
mechanisms: (i) inducing the expression of antioxidant enzymes and (ii) regulating 
mitochondrial function. Therefore, upon treatment with cisplatin, cancer cells 
undergo apoptosis (Fig. 42A), which is increased when p38α is inhibited (Fig. 
42B). In this situation, ROS are increased and inhibit phosphatases that target JNK, 
further activating this pathway and therefore sensitizing to apoptosis. 
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Figure 42. Proposed model. (A) p38α prevents the accumulation of ROS by inducing the 
expression of antioxidant enzymes and by regulating the mitochondrial function. JNK 
induces apoptosis after cisplatin treatment. (B) When p38α is not active, intracellular ROS 
levels increase, inactivating JNK-targeted phosphatases and inducing the hyperactivation of 
JNK in response to cisplatin treatment, which further sensitizes cancer cells to apoptosis.  
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1. eEF2 kinase might be a synthetic lethal partner of p38 MAPK in p53 wild-type 
cancer cells treated with cisplatin. 
 
2. p38 MAPK is not essential for the proliferation of all cancer cells. 
 
3. Impairment of p38α upregulates the JNK pathway in basal conditions and 
sensitizes cancer cells to apoptosis, independently of their p53 status. 
 
4. Inhibition of p38 MAPK increases ROS levels, which lead to the inactivation of 
JNK phosphatases in cancer cells. 
 
5. Inhibition of p38 MAPK cooperates with cisplatin to reduce the size and 
malignancy of tumors in a mouse model of breast cancer. 
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Library of inhibitors 
The InhibitorSelect™ 96-Well Protein Kinase Inhibitor Library III consists of 84 
protein kinase inhibitors, the majority of which are cell-permeable and ATP-
competitive. They are supplied in a 96 well-plate format (Suppl. Fig. 1) at a 
concentration of 10 mM in DMSO (except for 3 of them, which are 5 mM). Their 
target pathways are specified in Suppl. Table 1. 
 
Suppl. Table 1. Pathways targeted by InhibitorSelect™ Protein Kinase Inhibitor Library III 
Target kinases    
AK DNA-PK MLCK PKG 
Akt eEF2 Myt1 Plk 
Aurora GSK-3 p90RSK Ras/Rac 
c-Abl IKK PAK Rho 
CaMK IP3K PI3K RIPK1 
Cdks Lck PIKfyve Src 
CK1,2 MEK PIM Ste11 
c-kit MAPK PKA Tpl2 
Chk1 MAPKAPK2 PKC Wee1 
 
 
Suppl. Figure 1. Protein kinase inhibitor library array. 96 well-plate display of the 84 
inhibitors. 
1 2 3 4 5 6 7 8 9 10 11 12
116890 124029 181305 191500 203294 203303 203881 203882 208922 217699 217707 BLANK
A
Adenosine 
Kinase 
Inhibitor
Akt Inhibitor 
XII, Isozyme-
Selective, Akti-
2
Arcyriaflavin 
A, Synthetic
1-
Azakenpaullo
ne
Bisindolylmale
imide III, 
Hydrochloride
Bisindolylmale
imide V
CR8, (R)-
Isomer
CR8, (S)-
Isomer
CaMKII 
Inhibitor, CK59
Cdk1 Inhibitor 
IV, RO-3306
c7/Cdk9 
Inhibitor 0
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
218697 218713 218714 219445 219448 219457 220485 234501 238806 238811 238900 BLANK
B
Casein Kinase 
II Inhibitor I
Keratinocyte 
Differentiation 
Inducer
Casein Kinase 
II Inhibitor IV
Cdk2 Inhibitor 
II
Cdk2/5 
Inhibitor
Cdk Inhibitor, 
p35 Chk2 Inhibitor
Compound 
401
Cdk2/9 
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II
4-Cyano-3-
methylisoquin
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Control, 
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e
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IKK-2 Inhibitor 
V
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VI
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VII
IKK-2 Inhibitor 
VIII
IKK-3 Inhibitor 
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II
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II 0
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D 
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Suppl. Figure 2. Screening data (10000 cells/well). Numbers in blue correspond to cells 
treated with DMSO and cisplatin; in red to cells treated with 1 mM doxorubicin; and in 
green to non-treated cells. Absolute values of cell survival (measured by resazurin) are 
indicated for HCT116 p53 WT cells (A), p53 WT cells treated with SB203580 (SB) (B), p53 
KO cells (D), KO cells treated with SB (E); and the ratios vs. SB treatment were calculated 
for WT (C) and KO cells (F). Significant differences are highlighted in yelow. 
WT 1 2 3 4 5 6 7 8 9 10 11 12
A 8686 8974 8517 9543 9018 8952 8909 8781 9889 9815 10147
B 10818 3399 11853 12723 10331 8116 10204 9464 5212 9760 10517
C 155 9636 5351 10717 10988 3687 9398 3893 9639 11279 10281 9919
D 7737 11072 11415 10142 10900 10922 6913 8399 9751 10616 10728 10101
E 9727 6709 9764 10345 10655 9813 10917 4581 11314 8597 9854 10183
F 10292 9143 5323 9051 7537 10246 5751 9738 11430 1415 10900 28744
G 10644 7792 5193 7590 9458 8899 7370 6665 5610 9588 10054 27877
H 9163 9976 7860 9575 9470 9452 9639 8027 5558 6517 8295 26971
WT+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 7843 9767 8616 10167 8501 8767 8016 7832 9530 9245 9115
B 10907 3153 10713 11143 10138 8058 9773 9380 6016 9503 10470
C 63 8420 5445 9895 9706 5521 7952 3500 8275 10232 9954 9481
D 8586 9888 10297 7908 9340 8958 7888 7640 9865 10025 10587 9476
E 6868 7436 9701 9267 9052 9631 8146 5778 9975 9177 9482 9107
F 8372 8497 5950 8705 7035 8837 4769 9340 11009 2702 10189 25651
G 7559 8850 5335 8319 8970 8335 7324 6636 3990 9108 7664 24782
H 6894 8858 6614 6098 8716 8071 7972 6077 4994 5886 6239 23387
WT/WT+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 1.11 0.92 0.99 0.94 1.06 1.02 1.11 1.12 1.04 1.06 1.11
B 0.99 1.08 1.11 1.14 1.02 1.01 1.04 1.01 0.87 1.03 1.00
C 2.46 1.14 0.98 1.08 1.13 0.67 1.18 1.11 1.16 1.10 1.03 1.08
D 0.90 1.12 1.11 1.28 1.17 1.22 0.88 1.10 0.99 1.06 1.01
E 0.90 1.01 1.12 1.18 1.02 1.34 0.79 1.13 0.94 1.04
F 1.08 0.89 1.04 1.07 1.16 1.21 1.04 1.04 0.52 1.07 1.13
G 0.88 0.97 0.91 1.05 1.07 1.01 1.00 1.41 1.05 1.31
H 1.34 1.13 1.19 1.57 1.09 1.17 1.21 1.32 1.11 1.11 1.33
KO 1 2 3 4 5 6 7 8 9 10 11 12
A 5677.5 8126.5 6710.5 6567.5 7088.5 5100.5 5360.5 5328.5 6056.5 4848.5 5737.5
B 8348.5 1729.5 7930.5 7269.5 7596.5 5244.5 5511.5 6901.5 3625.5 7148.5 8836.5
C 43.5 4942.5 6638.5 7945.5 7219.5 1432.5 4221.5 856.5 3139.5 7321.5 7947.5 6561.5
D 5990.5 6195.5 7607.5 5117.5 7556.5 6254.5 5231.5 9228.5 6319.5 8800.5 7839.5 6810.5
E 6497.5 4895.5 8410.5 8442.5 7040.5 7172.5 7204.5 3983.5 7525.5 4262.5 6316.5 6538.5
F 8305.5 6497.5 5725.5 6689.5 3592.5 6043.5 1703.5 6231.5 8081.5 1917.5 8100.5 21035.5
G 8609.5 5631.5 4707.5 2098.5 6914.5 3623.5 6259.5 5673.5 3103.5 7839.5 6983.5 20275.5
H 6982.5 7007.5 4536.5 6452.5 7664.5 7300.5 7340.5 7490.5 3298.5 3769.5 5789.5 18811.5
KO+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 5074.5 8349.5 6023.5 6457.5 6368.5 6162.5 5017.5 4995.5 5964.5 5303.5 4712.5
B 8466.5 2044.5 8555.5 7114.5 7443.5 5506.5 6232.5 6758.5 3574.5 5771.5 8411.5
C 43.5 5209.5 4986.5 7685.5 6304.5 2265.5 3611.5 828.5 4745.5 6927.5 6594.5 7477.5
D 5896.5 6006.5 8565.5 5040.5 8260.5 6454.5 6941.5 7623.5 7001.5 7116.5 7396.5 9418.5
E 9306.5 5926.5 8681.5 7689.5 6025.5 6536.5 5981.5 4702.5 6776.5 5919.5 6880.5 6303.5
F 9163.5 5240.5 5114.5 5739.5 4919.5 6097.5 2994.5 5330.5 7712.5 4324.5 7783.5 19162.5
G 6463.5 5367.5 3755.5 3330.5 5888.5 4294.5 5344.5 4679.5 1872.5 6454.5 5665.5 16124.5
H 5524.5 5702.5 4600.5 4841.5 6411.5 6061.5 6995.5 7072.5 3113.5 3561.5 4552.5 15302.5
KO/KO+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 1.12 0.97 1.11 1.02 1.11 0.83 1.07 1.07 1.02 0.91 1.22
B 0.99 0.85 0.93 1.02 1.02 0.95 0.88 1.02 1.01 1.24 1.05
C 1.00 0.95 1.33 1.03 1.15 0.63 1.17 1.03 0.66 1.06 1.21 1.08
D 1.02 1.03 0.89 1.02 0.91 0.97 0.75 1.21 0.90 1.24 1.06
E 0.83 0.97 1.10 1.17 1.10 1.20 0.85 1.11 0.72 0.92
F 1.24 1.12 1.17 0.73 0.99 0.57 1.17 1.05 0.44 1.04 1.13
G 1.05 1.25 0.63 1.17 0.84 1.17 1.21 1.66 1.21 1.23
H 1.34 1.23 0.99 1.33 1.20 1.20 1.05 1.06 1.06 1.06 1.27
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Suppl. Figure 3. Screening data (20000 cells/well). Numbers in blue correspond to cells 
treated with DMSO and cisplatin; in cyan to cells treated only with DMSO; in red to cells 
treated with 1 mM doxorubicin; and in green to non-treated cells. Absolute values of cell 
survival (measured by resazurin) are indicated for HCT116 p53 WT cells (A), p53 WT cells 
treated with SB203580 (SB) (B), p53 KO cells (D), KO cells treated with SB (E); and the 
WT 1 2 3 4 5 6 7 8 9 10 11 12
A 25525 29624 24668 30879 23908 25451 23587 23629 26908 24983 27620
B 32231 22632 34546 30844 33430 27377 25427 29743 18196 31007 32685
C 13037 28974 27897 31731 31600 17291 25002 24183 31113 31799 30831 51303
D 27963 31600 33094 27512 29299 28444 27033 32532 24992 33841 32695 52017
E 31751 25004 34484 32582 32711 32295 34389 18436 31062 24116 27547 49988
F 30318 26547 23009 28412 29680 30019 23210 33413 32953 16312 30594 25741
G 50314 27413 24411 28798 29702 29184 26731 27216 21845 30565 28235 24515
H 50223 30397 29014 22562 25402 24087 22403 27804 17089 20844 24542 22448
WT+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 26327 28875 23725 28092 22265 24250 22866 22898 25199 25393 23676
B 30635 22223 31121 29494 29416 25653 24147 27419 18157 27553 29437
C 6768 25876 27713 29973 31230 21479 25103 21861 30257 29099 28641 48917
D 27598 26393 30675 24818 29823 29432 28094 29742 25673 30586 28174 49275
E 29477 23721 32871 31455 27894 30188 29724 22239 29645 24023 25210 48766
F 49343 47121 22809 27179 28786 27673 21103 30819 33757 20159 28888 22944
G 50168 47556 35607 46605 49583 48928 44901 41298 21990 49132 47910 20194
H 47476 25004 26935 25292 27017 25954 26747 26800 18367 19342 29877 18882
WT/WT+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 0.97 1.03 1.04 1.10 1.07 1.05 1.03 1.03 1.07 0.98 1.17
B 1.05 1.02 1.11 1.05 1.14 1.07 1.05 1.08 1.00 1.13 1.11
C 1.93 1.12 1.01 1.06 1.01 0.81 1.00 1.11 1.03 1.09 1.08
D 1.01 1.20 1.08 1.11 0.98 0.97 0.96 1.09 0.97 1.11 1.16 1.04
E 1.05 1.05 1.04 1.17 1.07 1.16 0.83 1.05 1.00 1.09
F 1.05 0.56 1.01 1.05 1.03 1.08 1.10 1.08 0.98 0.81 1.06
G 0.58 0.69 0.62 0.60 0.60 0.60 0.66 0.99 0.62 0.59 1.17
H 1.03 1.22 1.08 0.89 0.94 0.93 0.84 1.04 0.93 1.08 0.82
KO 1 2 3 4 5 6 7 8 9 10 11 12
A 22737 23747 21660 26562 22731 20493 16726 17536 21802 23019 25625
B 27969 15938 30229 29469 27938 24638 25395 26178 13924 26482 26992
C 4262 26611 27120 29754 27883 10406 22878 8847 22989 26934 28454 46422
D 24687 31535 29759 23013 29101 27406 23748 29284 23041 31285 28169 46883
E 29066 23356 32323 31791 30354 29797 29114 17914 28988 25058 24507 47055
F 29406 24244 21444 24780 22597 25749 17903 26251 29712 19829 28546 19116
G 49446 24349 17987 18983 26384 23240 22560 23640 18253 27827 24833 18256
H 44013 21343 19033 20182 25663 21004 23581 24708 12540 15078 21609 17992
KO+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 24935.5 23130.5 20017.5 23715.5 20330.5 20472.5 16165.5 16779.5 20922.5 21083.5 19487.5
B 27065.5 16444.5 27170.5 25868.5 25392.5 22518.5 24595.5 25276.5 13876.5 23815.5 26267.5
C 3624.5 24744.5 24882.5 26965.5 27401.5 15786.5 21215.5 10933.5 22503.5 24846.5 26284.5 46113.5
D 23587.5 28000.5 28557.5 21640.5 26489.5 26588.5 23871.5 27105.5 23795.5 28002.5 25595.5 45903.5
E 27218.5 22175.5 31252.5 28762.5 25934.5 26059.5 25268.5 21926.5 27583.5 22265.5 23351.5 45558.5
F 25991.5 22618.5 21092.5 23462.5 24527.5 23829.5 17623.5 26706.5 28449.5 17885.5 26630.5 16715.5
G 47645.5 23888.5 18223.5 20335.5 24301.5 22857.5 21505.5 22180.5 16127.5 24515.5 22959.5 16249.5
H 42352.5 21084.5 22646.5 19115.5 23197.5 21374.5 23391.5 22867.5 13365.5 15517.5 20451.5 14123.5
KO/KO+SB 1 2 3 4 5 6 7 8 9 10 11 12
A 0.91 1.03 1.08 1.12 1.12 1.00 1.03 1.05 1.04 1.09 1.31
B 1.03 0.97 1.11 1.14 1.10 1.09 1.03 1.04 1.00 1.11 1.03
C 1.18 1.08 1.09 1.10 1.02 0.66 1.08 0.81 1.02 1.08 1.08 1.02
D 1.05 1.13 1.04 1.06 1.10 1.03 0.99 1.08 0.97 1.12 1.10
E 1.05 1.03 1.11 1.17 1.14 1.15 0.82 1.05 1.13 1.05
F 1.10 1.07 1.02 1.06 0.92 1.08 1.02 0.98 1.04 1.11 1.07 1.18
G 1.02 0.99 0.93 1.09 1.02 1.05 1.07 1.13 1.14 1.08
H 1.04 1.01 0.84 1.06 1.11 0.98 1.01 1.08 0.94 0.97 1.06
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ratios vs. SB treatment were calculated for WT (C) and KO cells (F). Significant differences 
are highlighted in yelow. 
 
Array of antioxidant enzymes 
 
A 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Suppl. Figure 4. Gene expression array data. (A) 
Heatmap representation of the genes analyzed in the 
Human Oxidative Stress and Antioxidant Defense RT2 
Profiler™ PCR Array. (B) A parallel set of samples was 
used for immunoblot analyses with the indicated 
antibodies to confirm inhibition of the p38 MAPK 
pathway. 
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Suppl. Table 2. Proteins identified in band 1 
Band Key Gene Protein 
SB Q6IFZ6 Krt77 Keratin, type II cytoskeletal 1b 
SB P05786 KRT8 Keratin, type II cytoskeletal 8 
NT Q1LSP0 tgt Queuine tRNA-ribosyltransferase 
NT P08729 KRT7 Keratin, type II cytoskeletal 7 
SB P02533 KRT14 Keratin, type I cytoskeletal 14 
SB Q7SY65 krt18b Keratin, type I cytoskeletal 18-B 
SB Q6EIY9 KRT1 Keratin, type II cytoskeletal 1 
NT Q9Z2K1 Krt16 Keratin, type I cytoskeletal 16 
SB Q6IMF3 Krt1 Keratin, type II cytoskeletal 1 
SB P08776 krt8 Keratin, type II cytoskeletal 8 
NT B2FN00 tgt Queuine tRNA-ribosyltransferase 
SB Q5K2P2 - Keratin, type I cytoskeletal 15 
SB Q6IFV3 Krt15 Keratin, type I cytoskeletal 15 
SB Q8BGZ7 Krt75 Keratin, type II cytoskeletal 75 
SB P51856 - Keratin, type I cytoskeletal 19 
SB Q5FJN8 - tRNA pseudouridine synthase B 
SB Q6P6Q2 Krt5 Keratin, type II cytoskeletal 5 
SB Q7SYF8 - Keratin, type I cytoskeletal 18 
SB P04264 KRT1 Keratin, type II cytoskeletal 1 
SB Q8TBZ0-2 CCDC110 Isoform 2 of Coiled-coil domain-containing protein 
110 
SB P13549 eef1a-s Elongation factor 1-alpha, somatic form 
SB Q8VED5 Krt79 Keratin, type II cytoskeletal 79 
SB Q29S21 KRT7 Keratin, type II cytoskeletal 7 
NT Q2M2I5 KRT24 Keratin, type I cytoskeletal 24 
SB P45983-4 MAPK8 Isoform 4 of Mitogen-activated protein kinase 8 
NT Q8LPC4 - Elongation factor 1-alpha 
SB Q4FZU2 LOC68331
3 
Keratin, type II cytoskeletal 6A 
SB P08727 KRT19 Keratin, type I cytoskeletal 19 
NT P34825 - Elongation factor 1-alpha 
NT A5A6M6 KRT1 Keratin, type II cytoskeletal 1 
SB O57607 LOC10013
6778 
Keratin, type I cytoskeletal 18 
SB P04259 KRT6B Keratin, type II cytoskeletal 6B 
SB Q3SZV3 EEF1G Elongation factor 1-gamma 
SB P27592 - Elongation factor 1-alpha 
SB P24789 vim1 Vimentin-1/2 
SB P35908 KRT2 Keratin, type II cytoskeletal 2 epidermal 
SB P13647 KRT5 Keratin, type II cytoskeletal 5 
NT P16878 xenck55 Keratin, type II cytoskeletal 
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Suppl. Table 3. Proteins identified in band 2 
Band Key Gene Protein 
NT P48674 vim Vimentin 
NT P02533 KRT14 Keratin, type I cytoskeletal 14 
NT Q29426 - Keratin, type II cytoskeletal 3 
NT Q6IMF3 Krt1 Keratin, type II cytoskeletal 1 
NT Q6EIZ0 KRT10 Keratin, type I cytoskeletal 10 
NT Q9NRL2-2 BAZ1A Isoform 2 of Bromodomain adjacent to zinc finger 
domain protein 1A 
SB P08777 MGC68905 Keratin, type I cytoskeletal 47 kDa 
NT Q3TTY5 Krt2 Keratin, type II cytoskeletal 2 epidermal 
NT Q8BGZ7 Krt75 Keratin, type II cytoskeletal 75 
SB P51856 - Keratin, type I cytoskeletal 19 
NT P19013 KRT4 Keratin, type II cytoskeletal 4 
NT Q95JF4 - DnaJ homolog subfamily A member 1 
SB P08515 - Glutathione S-transferase class-mu 26 kDa isozyme 
NT Q7SYF8 - Keratin, type I cytoskeletal 18 
SB P08730 Krt13 Keratin, type I cytoskeletal 13 
NT P49411 TUFM Elongation factor Tu, mitochondrial 
NT A1KQY9 - Keratin, type I cytoskeletal 18-A 
NT O95678 KRT75 Keratin, type II cytoskeletal 75 
NT Q29S21 KRT7 Keratin, type II cytoskeletal 7 
NT Q5XQN5 KRT5 Keratin, type II cytoskeletal 5 
NT P38989 SMC2 Structural maintenance of chromosomes protein 2 
SB P06394 KRT10 Keratin, type I cytoskeletal 10 
SB P25030 Krt20 Keratin, type I cytoskeletal 20 
SB Q6PVZ1 KRT14 Keratin, type I cytoskeletal 14 
NT Q4FZU2 LOC683313 Keratin, type II cytoskeletal 6A 
SB Q63279 Krt19 Keratin, type I cytoskeletal 19 
SB P08727 KRT19 Keratin, type I cytoskeletal 19 
NT Q22909 ceh-30 Homeobox protein ceh-30 
SB Q6IFX2 Krt42 Keratin, type I cytoskeletal 42 
NT P48677 - Glial fibrillary acidic protein 
NT O93532 LOC395772 Keratin, type II cytoskeletal cochleal 
SB P04104 Krt1 Keratin, type II cytoskeletal 1 
NT Q5XKE5 KRT79 Keratin, type II cytoskeletal 79 
NT P08728 LOC514812 Keratin, type I cytoskeletal 19 
SB P35661 - Glutathione S-transferase class-mu 26 kDa isozyme 
NT P08728 LOC514812 Keratin, type I cytoskeletal 19 
SB O18740 KRT9 Keratin, type I cytoskeletal 9 
NT P13647 KRT5 Keratin, type II cytoskeletal 5 
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Suppl. Table 4. Proteins identified in band 3 
Band Key Gene Protein 
NT Q1LSP0 tgt Queuine tRNA-ribosyltransferase 
SB Q6EIZ0 KRT10 Keratin, type I cytoskeletal 10 
NT P13646-3 KRT13 Isoform 3 of Keratin, type I cytoskeletal 13 
NT P08778 LOC397756 Keratin, type I cytoskeletal 47 kDa 
NT Q61781 Krt14 Keratin, type I cytoskeletal 14 
NT P19013 KRT4 Keratin, type II cytoskeletal 4 
NT Q6IFW6 Krt10 Keratin, type I cytoskeletal 10 
SB P08515 - Glutathione S-transferase class-mu 26 kDa isozyme 
NT O77727 - Keratin, type I cytoskeletal 15 
NT P19001 Krt19 Keratin, type I cytoskeletal 19 
SB A8GJ49 Spro_4044 Probable Fe(2+)-trafficking protein 
SB Q5XQN5 KRT5 Keratin, type II cytoskeletal 5 
SB P48672 - Vimentin A2 
NT A7YWK3 KRT73 Keratin, type II cytoskeletal 73 
NT P11679 Krt8 Keratin, type II cytoskeletal 8 
SB P35661 - Glutathione S-transferase class-mu 26 kDa isozyme 
NT P02538 KRT6A Keratin, type II cytoskeletal 6A 
SB P84048 - Histone H4 
SB Q89743 - Uncharacterized protein DR7 
NT Q29426 - Keratin, type II cytoskeletal 3 
NT P50446 Krt6a Keratin, type II cytoskeletal 6A 
NT Q6IMF3 Krt1 Keratin, type II cytoskeletal 1 
NT B2FN00 tgt Queuine tRNA-ribosyltransferase 
NT Q6IFV3 Krt15 Keratin, type I cytoskeletal 15 
NT Q6P6Q2 Krt5 Keratin, type II cytoskeletal 5 
NT Q7SYF8 - Keratin, type I cytoskeletal 18 
NT O95678 KRT75 Keratin, type II cytoskeletal 75 
NT Q61414 Krt15 Keratin, type I cytoskeletal 15 
NT P48668 KRT6C Keratin, type II cytoskeletal 6C 
NT P08779 KRT16 Keratin, type I cytoskeletal 16 
NT O76013-2 KRT36 Isoform 2 of Keratin, type I cuticular Ha6 
NT Q22909 ceh-30 Homeobox protein ceh-30 
NT O93532 LOC395772 Keratin, type II cytoskeletal cochleal 
SB P24789 vim1 Vimentin-1/2 
SB P04104 Krt1 Keratin, type II cytoskeletal 1 
NT P19012 KRT15 Keratin, type I cytoskeletal 15 
NT A1L317 Krt24 Keratin, type I cytoskeletal 24 
NT P13647 KRT5 Keratin, type II cytoskeletal 5 
NT P16878 xenck55 Keratin, type II cytoskeletal 
NT Q9QWL7 Krt17 Keratin, type I cytoskeletal 17 
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Título 
Regulación de la supervivencia de las células cancerígenas por p38 MAPK. 
 
Sinopsis 
La regulación del estado redox es esencial para mantener la homeostasis celular. 
De hecho, la desregulación de la producción de especies reactivas de oxígeno 
(ROS) ha sido asociada con un incremento de la tumorogenicidad en células 
epiteliales. Sin embargo,  los efectos pro-tumorogénicos de la acumulación de 
ROS pueden resultar un arma de doble filo, ya que altos niveles de estas especies 
pueden disminuir el umbral apoptótico para la citotoxicidad. Por tanto, la 
regulación redox juega un papel importante en la supervivencia de la célula 
tumoral. 
 
La proteína kinasa p38α is una reguladora importante de muchos procesos 
celulares. Está bien establecido que la señalización de p38α regula negativamente 
la transformación de la célula epitelial, pero un aumento de su actividad kinasa ha 
sido correlacionado con un mal pronóstico clínico en algunos tipos de tumores. 
Esto, junto con el hecho de que se ha mostrado que p38α es necesaria para la 
proliferación de algunas líneas celulares de cáncer, nos indujo a pensar que esta 
proteína podría ser una buena diana para la terapia contra el cáncer. 
 
Por tanto, llevamos a cabo un screening para identificar compañeros letales 
sintéticos de p38α, pero estos resultados todavía tienen que terminar de ser 
validados. No obstante, proporcionamos evidencia basada en inhibidores 
químicos y en depleciones génicas, de que p38α coopera con cisplatino para 
matar a las células tumorales. Aquí mostramos que la inhibición de p38α resulta 
en el aumento de ROS, que a su vez activa la ruta de JNK mediante la inactivación 
de sus fosfatasas, y así sensibiliza a las células tumorales humanas a la apoptosis 
inducida por cisplatino. Además, usando un modelo animal de cáncer de mama, 
mostramos que la inhibición de p38α coopera con el tratamiento de cisplatino 
para reducir el tamaño de los tumores y su malignidad in vivo. En su conjunto, 
nuestros resultados revelan una nueva función de p38α que ayuda a las células 
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tumorales a sobrevivir a los tratamientos quimioterapéuticos, manteniendo la 
expresión de enzimas antioxidantes, y muestran que la combinación de 
inhibidores de p38α con cisplatino podría ser potencialmente explotada en la 
terapia contra el cáncer. 
 
Introducción 
1. El cáncer, una enfermedad antigua y mundial 
Se podría pensar que el cáncer es una enfermedad moderna, sin embargo ha 
existido durante siglos. Ha sido claramente identificado en estudios de momias 
egipcias (Granville, 1825) e incluso representado en obras de arte a lo largo de los  
siglos (Vaidya, 2007). No obstante, hoy en día es un fenómeno más común, 
principalmente por el crecimiento de la población mundial, el incremento de la 
esperanza de vida y los avances en la civilización.  
 
La tumorogénesis es un proceso de múltiples pasos de alteraciones genéticas que 
conducen la transformación progresiva de células normales en otras altamente 
malignas, la cuales poseen defectos en los circuitos regulatorios que gobiernan su 
proliferación y homeostasis. El cultivo de células tumorales in vitro y la disección 
de sus componentes moleculares ha generado gran parte del conocimiento que 
actualmente poseemos sobre los procesos moleculares subyacentes al desarrollo 
del cáncer. Hanahan y sus compañeros sugirieron que el amplio repertorio de 
genotipos celulares observados es la manifestación de seis alteraciones esenciales 
en la fisiología celular, que colectivamente dictan el crecimiento maligno: auto-
suficiencia de señales de crecimiento, insensibilidad a las señales inhibidoras del 
crecimiento, evasión de  la apoptosis, potencial replicativo ilimitado, angiogénesis 
mantenida e invasión tisular, y metástasis (Hanahan and Weinberg, 2000) (Fig. 1).  
 
El ratón de laboratorio (Mus musculus) ha revolucionado nuestra capacidad de 
estudiar las funciones génicas in vivo y entender los mecanismos moleculares de 
la patogénesis del cáncer. Hoy en día existen numerosas técnicas para su 
manipulación genética (Cheon and Orsulic, 2011) y esto ha permitido la 
generación de un gran número de modelos animales para recapitular las 
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enfermedades humanas (Frese and Tuveson, 2007). Aquí nos centraremos en un 
modelo animal de cáncer de mama, el MMTV-PyMT. 
 
El cáncer de mama es sin duda el más comúnmente diagnosticado en mujeres 
alrededor del mundo (pasando a ser el segundo si combinamos las estadísticas de 
ambos sexos), ya que representa casi un cuarto (23%) de todos los cánceres 
diagnosticados en mujeres. Además, también es la causa más común de muerte en 
mujeres a nivel mundial (Cancer Research UK, 2011). Los modelos animales de 
cáncer de mama modificados genéticamente exhiben muchas características del 
cáncer humano, y por tanto son valiosos para investigar la biología y patogénesis 
de esta enfermedad. Sin embargo, dada la complejidad y heterogeneidad del 
cáncer de mama, no hay un único modelo que recapitule todos los aspectos de 
esta enfermedad. 
 
El poliomavirus murino (PyV) puede causar una gran variedad de tumores en 
diferentes tipos de células (Dawe et al., 1987; Fluck and Haslam, 1996). La 
proteína transformante más importante que producen es la oncoproteina MT, cuya 
expresión trangénica puede causar tumores en un gran rango de tejidos (Cecena et 
al., 2006; Guy et al., 1992; Rassoulzadegan et al., 1990; Tehranian et al., 1996). 
Cuando PyMT se expresa bajo el control del promotor de la glándula mamaria, 
MMTV, se inducen carcinomas metastáticos (Guy et al., 1992). Las primeras 
lesiones hiperplásicas surgen a edades muy tempranas y están localizadas 
próximas al pezón. Tras el crecimiento prepubertal, los ductos se elongan todavía 
más bajo la influencia hormonal y nuevas lesiones aparecen en los brotes 
terminales distales, que se fusionan con los tumores próximos a los pezones en 
estadíos tardíos. Se indentificaron cuatro estadíos con similitudes a los tumores 
humanos (hiperplasia, adenoma o neoplasia mamaria intraepitelial (MIN), 
carcinoma in situ y carcinoma invasivo), que aparecen descritos en la figura 2. 
Análisis de agrupación jerárquica han emplazado a los tumores del modelo 
MMTV-PyMT en un grupo luminal subtipo B (Fluck and Schaffhausen, 2009) (Fig. 
3). 
2. Las cascadas de señalización MAPK 
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Las células necesitan estar constantemente alerta de los cambios en el medio 
extracelular para responder en consecuencia, de modo que han desarrollado una 
gran variedad de mecanismos para recibir señales, transmitir la información y 
coordinar las respuestas apropiadas. Estas normalmente están mediadas por la 
activación de factores de transcripción, los cuales inducen los procesos celulares 
necesarios. Sin embargo, la mayoría de agentes extracelulares no pueden cruzar la 
membrana plasmática para activar a los genes correspondientes. Por el contrario, 
estos genes usan “líneas de comunicación”, conocidas como “rutas de 
señalización”, para transmitir las señales a sus objetivos citoplasmáticos y 
nucleares. En muchos casos, las rutas de señalización operan a través de 
fosforilaciones secuenciales y son llamadas “cascadas de proteínas kinasas”. Este 
tipo de mecanismo de señalización es usado por las proteínas kinasas activadas 
por mitógenos  (MAPK), que son una familia evolutivamente conservada de 
proteinas serina treonina de la que se han descrito principalmente cuatro rutas 
canónicas en los últimos 20 años: las kinasas reguladas por señales extracelulares 
1 y 2 (ERK1/2) (Boulton et al., 1991), kinasas N-terminales de Jun 1-3 (JNK 1-3), 
p38 MAPK α, β, γ, ∂ (p38α-∂) (Freshney et al., 1994; Han et al., 1994; Rouse et al., 
1994) y las ERK5 (Lee et al., 1995; Zhou et al., 1995) (Fig. 4). 
 
Las cuatro p38 MAPK descritas están codificadas por cuatro genes diferentes y 
varían en sus patrones de expression tisular, siendo p38α la única expresada 
ubícuamente y en cantidades significativas en la mayoría de los tipos celulares, 
mientras que las otras suelen ser más tejido-específicas (Cuadrado and Nebreda, 
2010). A pesar de su alta homología de secuencia, las isoformas de p38 MAPK 
difieren en su sensibilidad a inhibidores químicos (Coulthard et al., 2009). El 
descubrimiento de las condiciones patológicas en que las p38 MAPK están 
involucradas (Fig. 5) apoya el potencial interés terapéutico de modular la actividad 
de estas kinasas. Drogas del tipo piridinil-imidazol, como SB203580, fueron los 
primeros inhibidores identificados y se caracterizan porque encajan en el sitio de 
unión del ATP (Fig. 6), de modo que compiten con éste por la unión.  
 
En los últimos años, se ha visto que los miembros de la familia de p38 MAPK 
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estaban involucrados en varios de los procesos de transformación tumoral, siendo 
asociados sobre todo con funciones supresoras de la tumorogénesis. En el caso de 
p38α, estas funciones supresoras parecen operar principalmente en el inicio del 
proceso de transformación (Dolado et al., 2007; Hui et al., 2007; Ventura et al., 
2007), ya que se ha correlacionado un incremento de la fosforilación de p38 
MAPK con baja supervivencia general en pacientes con cánceres de mama 
negativos para HER-2 (Esteva et al., 2004) o con carcinoma hepatocelular (Wang 
et al., 2012). Sin embargo, el papel pro-tumorogénico de p38α no sólo está 
basado en correlaciones, sino que también se ha visto que puede contribuir a la 
proliferación de líneas celulares de cáncer de mama (Chen et al., 2009), 
colorrectales (Chiacchiera et al., 2009), de próstata (Ricote et al., 2006) o piel 
(Schindler et al., 2009). 
 
Las tres proteínas JNK descritas también están codificadas por genes diferentes y 
pueden llegar a generar hasta diez isoformas diferentes (Dreskin et al., 2001; 
Gupta et al., 1996). Mientras que JNK1 y JNK2 se expresan en casi todos los tipos 
celulares, JNK3 está principalmente localizada en cerebro y, en menor medida, en 
corazón y testículos (Bode and Dong, 2007). 
 
La ruta de JNK se activa en respuesta a estrés, pero su señalización dependerá del 
contexto celular, ya que ha sido implicada tanto en procesos apoptóticos como de 
supervivencia (Ip and Davis, 1998). Uno de los estímulos que activa a JNK es el 
cisplatino (CDDP), un pequeño complejo inorgánico neutro que se activa tras 
entrar en la célula, donde reemplaza sus ligandos cis-cloro con moléculas de agua 
(el-Khateeb et al., 1999; Kelland, 2000). Esta forma acuosa es muy reactiva hacia 
los centros nucleofílicos de las proteinnas, RNA, DNA, fosfolípidos de membrana 
y microfilamentos, aunque en general sus propiedades antitumorales están 
asociadas a su capacidad de unirse al DNA y generar roturas de cadena simple en 
última instancia (Fuertes et al., 2003; Jamieson and Lippard, 1999). Hoy en día se 
usa frecuentemente en la clínica para tratar tumores sólidos. 
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Las proteínas implicadas en el reconocimiento de la unión del cisplatino al DNA 
son las que disparan la señalización de las MAPK, que son las últimas 
responsables de llevar a cabo los efectos citotóxicos de esta droga. En la mayoría 
de los sistemas celulares investigados, la activación de JNK en respuesta a 
cisplatino induce la muerte celular  (Koyama et al., 2006; Krilleke et al., 2003; Li 
et al., 2005; Mansouri et al., 2003; Sanchez-Perez et al., 2002; Sanchez-Perez et 
al., 1998; Sanchez-Perez and Perona, 1999). De hecho, la falta de activación 
sostenida de JNK en células resistentes a cisplatino determina su supervivencia tras 
tratamiento con este compuesto, cosa que no sucede en el caso de las células 
sensibles a cisplatino (Li et al., 2005). 
 
3. La familia de proteínas tirosina fosfatasas 
Puesto que las MAPK son mediadoras esenciales de muchos de los procesos 
celulares inducidos por estimulación, su inactivación es crítica para alcanzar tan 
sólo una activación transitoria y poder regular así la intensidad de señal, que 
determinará respuestas específicas. El cese de la actividad kinasa implica la 
activación de la familia de las proteínas tirosina fosfatasas (PTP), que están 
agrupadas en cuatro subfamilias según la secuencia aminoacídica de su dominio 
catalítico: las de tipo I, II y III (todas basadas en cisteína) y las basadas en aspártico 
 (Alonso et al., 2004) (Fig. 8). Las PTP de tipo I se pueden dividir a su vez en dos 
grupos según la similitud de sus dominios catalíticos: las PTP clásicas, que son 
tirosina específicas; y las fosfatasas de especificidad dual (DUSP). Las de tipo II 
sólo contienen un tipo de fosfatasas, las PTP de bajo peso molecular (LMWPTP), 
que están relacionadas con fosfatasas bacterianas de bajo peso molecular, 
evolutivamente conservadas (Alonso et al., 2004). El tipo III son tirosina y treonina 
específicas (Alonso et al., 2004; Russell and Nurse, 1986) y consisten en 
reguladores del ciclo celular: Cdc25A, Cdc25B y Cdc25C, que defosforilan a 
ciclinas dependientes de kinasas (Karlsson-Rosenthal and Millar, 2006). 
Finalmente, las PTP basadas en aspártico, incluyen las fosfatasas específicas de 
tirosina EyA (“eyes absent”) y las haloácido deshalogenasas (HAD) (Moorhead et 
al., 2007). Estas últimas son un grupo heterogéneo de fosfatasas que pueden ser 
específicas tanto de tirosina (Rebay et al., 2005) como de serina (Gohla et al., 
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2005; Yeo et al., 2003) y tienen sustratos muy diversos. Aquí nos centraremos 
únicamente en las PTP tipo I. 
 
Las PTP clásicas son de tipo I y pueden ser proteínas tipo receptor (RPTP, que 
están ancladas a membrana) o solubles (Fig. 9). Las RPTP tienen el potencial de 
regular la señalización mediante defosforilaciones controladas por ligando. 
Muchas de ellas presentan características de moléculas de adhesión celular en su 
segmento extracelular y han sido implicadas en procesos involucrados en 
contactos célula-célula y célula-matriz. Las PTP solubles, o citoplasmáticas, se 
caracterizan por la presencia de secuencias reguladoras que flanquean el dominio 
catalítico y controlan su actividad, tanto directamente, como mediante 
interacciones en el sitio activo que modulan su actividad o controlan la 
especificidad del sustrato. 
 
Las DUSP son un grupo muy grande y heterogéneo, que también pertenecen al 
tipo I, y se caracterizan por su habilidad para defosforilar tanto residuos de tirosina 
como de serina treonina dentro de un mismo sustrato. Uno de los grupos mejor 
caracterizado es el de las fosfatasas de kinasas activadas por mitógeno (MKP), 
formadas por 10 proteínas (Table 1). Cada una de las MKP muestran especificidad 
de sustrato por una o varias de las MAKP ERK, JNK o p38 (Fig. 10).  
 
Las PTP pueden ser objeto de modificaciones postraduccionales, como por 
ejemplo la oxidación. La presencia de una cisteína catalítica de bajo pKa (den 
Hertog et al., 2005; Salmeen and Barford, 2005; Tonks, 2005) en su sitio activo, 
hace que las PTP sean especialmente sensibles a la inactivación por oxidación de 
esta cisteína, que induce profundos cambios en la arquitectura del sitio catalítico. 
Los estímulos fisiológicos provocan la producción localizada de especies reactivas 
de oxígeno (ROS), que llevan a la oxidación e inactivación de aquellas PTP que 
normalmente están atenuando la respuesta de señalización. Esta oxidación es 
transitoria, de modo que las PTP son reducidas de nuevo para volver a sus estado 
activo gracias a la acción de agentes reductores como la tiorredoxina o el 
glutatión.  
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4. El estrés oxidativo 
Definimos estrés oxidativo como una situación de desbalance entre los factores 
pro-oxidantes y antioxidantes celulares, que están controlados por múltiples 
factores y pueden conducir al daño celular. Las especies reactivas de oxígeno 
(ROS), como el anión superóxido (O2
-), el peróxido de hidrógeno (H2O2) y el 
radical hidroxil (HO·), son especies de oxígeno, radicales y no radicales, que están 
formadas por la reducción parcial del oxígeno y juegan un papel clave en el estrés 
oxidativo, el cual provoca daños en ácidos nucleicos, lípidos y proteínas. 
 
Los altos niveles de ROS en las células cancerígenas pueden ser resultado de su 
incrementada actividad metabólica, disfunción mitocondrial, actividad 
peroxisomal, actividad oncogénica, actividad incrementada de oxidasas, y otras, 
junto con su interacción con células inmunes infiltrantes (Storz, 2005; Szatrowski 
and Nathan, 1991). En la mitocondria, las ROS son producidas como un producto 
inevitable de la fosforilación oxidativa (Fig. 11).  
 
En situaciones fisiológicas normales, los niveles intracelulares de ROS están 
controlados para impedir el daño celular. Esto es posible gracias tanto a moléculas 
no enzimáticas (glutatión, flavonoides, vitaminas A, B y C…) como a enzimas 
antioxidantes (catalasa, glutatión peroxidasas -GPX-, superóxido dismutasas -SOD-
, tiorredoxinas…), que específicamente capturan diferentes tipos de ROS (Fig. 11). 
Sin embargo, puesto que las células cancerígenas producen altos niveles de ROS y 
además están expuestas a muchos oxidantes exógenos, son capaces de adaptarse a 
altos niveles de estrés oxidativo (Kim et al., 2006; Schneider and Kulesz-Martin, 
2004) y promover rutas de supervivencia (Irmak et al., 2003) o expresar altos 
niveles de antioxidantes (Young et al., 2004). Esta capacidad antioxidante 
incrementada probablemente les sea útil como mecanismo evasor de la apoptosis 
(Trachootham et al., 2006) (Fig. 12). 
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Objetivos 
Se ha demostrado que p38α tiene un papel supresor de tumores basado en su 
habilidad para regular negativamente la proliferación celular y por inducir muerte 
celular. Sin embargo, la mayoría de estos estudios se han limitado a la 
investigación de las funciones de p38α durante la iniciación tumoral, pero todavía 
no entendemos completamente las funciones de p38α en la progresión tumoral. 
 
Por tanto, el objetivo de este trabajo es determinar si p38α podría ser una 
potencial diana terapéutica para la quimioterapia siguiendo estas dos 
aproximaciones: 
- realizar un screening para identificar compañeros sintéticos letales de 
p38α 
- determinar si la inhibición de p38α podría sinergizar con los tratamientos 
quimioterapéuticos para inducir la muerte de las células cancerígenas.  
 
 
Resultados 
Para determinar si p38α podría ser una diana terapéutica de interés, seguimos dos 
enfoques diferentes: buscar compañeros letales sintéticos de p38 MAPK y estudiar 
si su inhibición podría sinergizar con agentes quimioterapéuticos para inducir la 
muerte de la célula cancerígena. 
 
1. p38 MAPK como un compañero letal sintético 
El concepto de letalidad sintética surgió como una alternativa prometedora a los 
inespecíficos, y por tanto agresivos, tratamientos quimioterapéuticos en algunos 
tipos de cáncer. De hecho, ya existen resultados destacables al respecto usando 
este abordaje, como es el caso del tratamiento con inhibidores de la poli(ADP-
ribosa) polimerasa (PARP) para el tratamiento de tumores de mama portadores de 
mutaciones en BRCA (Fong et al., 2009). Dos genes se consideran como sintéticos 
letales si la mutación de ambos es letal, pero no así su mutación independiente 
(Kaelin, 2005).  
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Con el objetivo de encontrar compañeros letales sintéticos de p38 MAPK, 
combinamos su inhibición  con la de otras rutas importantes para la supervivencia 
de la célula cancerígena, como ERK y mTOR. Medición de la apoptosis celular 
nos indicó que no había ningún sinergismo que eficientemente matara a las 
células cancerígenas, ni en condiciones basales (Fig. 16A), ni tras el tratamiento 
con agentes quimioterapéuticos (Fig. 16B). Los mismos resultados fueron 
obtenidos al medir el porcentaje de viabilidad celular en diferentes líneas de 
cáncer, también en condiciones basales (Fig. 17A) y estimuladas (Fig. 17B). 
 
Puesto que ninguna de las rutas testadas resultaron ser sintéticos letales de p38 
MAPK decidimos realizar un screening para comprobar 84 inhibidores (Suppl. Fig. 
1) que afectan a 36 rutas de señalización diferentes (Suppl. Table 1). Se 
compararon células HCT116 y HCT116 p53-/- sin tratar con las tratadas con 
SB203580, un inhibidor químico de p38 MAPK, en todos los casos estimuladas 
con cisplatino (una droga ampliamente usada en la clínica para el tratamiento de 
tumores sólidos), ya que se vio que respondían a esta droga (Fig. 18). Tras 
comparar el incremento de viabilidad relativo a las células tratadas con SB203580 
(los datos originales se pueden contrar en la Suppl. Figure 2), identificamos 3 rutas 
que presentaban cambios significativos: IKK2, PKCs y eEF2 (Fig. 19). Aunque tan 
sólo la última se podría considerar un compañero sintético letal  de p38 MAPK, ya 
que las dos primeras incrementaban la viabilidad celular combinar su inhibición 
con la de p38 MAPK en vez de reducirla. Parece que la letalidad sintética de eEF2 
kinasa funciona sólo en el caso de células que tienen un p53 salvaje, aunque 
todavía se necesita caracterizar adecuadamente esta candidata. 
 
2. Sensibilización a quimioterapia por inhibición de p38 MAPK 
En la búsqueda de compañeros letales sintéticos de p38 MAPK advertimos que 
sólo con inhibir esta ruta ya disminuíamos la viabilidad de la célula tumoral tras el 
tratamiento con agentes quimioterapéuticos (Figs. 16-18). Para determinar el papel 
de la señalización de esta proteína en la supervivencia celular, expusimos varias 
células de cáncer de mama (MCF7) y colon (HT-29 y SW620) al tratamiento con 
cisplatino y el inhibidor SB203580. Tras medir la apoptosis de estas células 
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mediante diferentes técnicas, vimos que el tratamiento combinado producía un 
efecto aditivo a la hora de inducir la muerte de las células tumorales (Fig. 20). Este 
mecanismo era independiente del papel que p38 MAPK desempeña en la 
proliferación de algunas células cancerígenas (Fig. 21), y no está relacionado con 
el estado de p53 (Table 2). Además, hemos visto que la incubación con SB203580 
no induce daño en el DNA (Fig. 22).  
 
Varios estudios indican que la señalización de p38 MAPK puede regular 
negativamente la ruta de JNK en diferentes contextos, principalmente en células 
no transformadas (Perdiguero et al., 2007b; Wagner and Nebreda, 2009). Puesto 
que JNK juega un papel importante en la inducción de apoptosis (Davis, 2000), 
investigamos si esta ruta estaba también implicada en el aumento de apoptosis 
observado en las células cancerígenas tratadas con cisplatino. Efectivamente 
comprobamos la correlación inversa entre las rutas de JNK y p38 MAPK Fig. 23A) 
y su sensibilización a apoptosis tanto con el uso de inhibidores (Fig. 23B) como de 
herramientas genéticas (siRNA y shRNA) (Fig. 24). 
 
Se sabe que la señalización de JNK puede ser activada por ROS (Shen and Liu, 
2006)  y al revés, que altos niveles de ROS correlacionan con activación de JNK 
en células cancerígenas humanas (Dolado et al., 2007). Además, parece que p38 
MAPK también puede impedir la acumulación de ROS en células no 
transformadas y la inhibición de esta ruta ha sido correlacionada con un patrón de 
expresión génica relacionado con estrés oxidativo (Mateescu et al., 2011). Por 
tanto, imaginamos que la inhibición de p38 MAPK podría resultar en un aumento 
de los niveles de ROS, que a su vez activarían la ruta de JNK. Y esto es 
exactamente lo que encontramos, como se puede observar en las figuras figure 25 
y figure 26 , respectivamente. 
 
Nos preguntamos si la inhibición de p38 MAPK también podría sensibilizar 
células con altos niveles basales de ROS a apoptosis, de modo que comparamos 
las células de cáncer de mama MDA-MB-231 y MCF7, ya que las primeras tienen 
mayores niveles basales de ROS que las segundas (Fig. 27A). Resultó muy 
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interesante descubrir que el mismo mecanismo operaba en estas células, es decir, 
la inhibición de p38 MAPK induce la acumulación de ROS, lo que activa a JNK y 
sensibiliza a apoptosis tras el tratamiento con cisplatino. 
 
Para determinar el mecanismo por el cual p38 MAPK regula la producción de 
ROS, realizamos un array de expresión de 84 genes implicados en estrés oxidativo 
(Suppl. Fig. 3), y descubrimos que había 8 genes de enzimas antioxidantes cuya 
expresión se reducía al inhibir p38 MAPK. No obstante, sólo 3 de ellos se 
mantenían significativamente reducidos al inhibir p38 MAPK en dos líneas 
celulares de cáncer de mama y colon (Table 3). Uno de estos genes, PTGS2, que 
codifica para la proteína antiinflamatoria COX-2, a pesar de estar regulado por 
p38 MAPK, demostró no estar implicado en la regulación de ROS (Fig. 28A). Pero 
sí observamos que los dos restantes, GPX5 y TXNDC2, que codifican para una 
glutatión peroxidasa y una tioredoxina, respectivamente, regulan los niveles 
basales de activación de JNK (Fig. 28B), simulando los resultados obtenidos 
cuando aumentan los niveles de ROS al inhibir p38 MAPK. Asimismo, también 
comprobamos que la producción de ROS tras la inhibición de p38 MAPK también 
podría ser mitocondrial, pero no regulada por Nox (Fig. 28C). Finalmente, ha sido 
interesante descubrir que los mecanismos de regulación por p38 MAPK de las 
enzimas antioxidantes catalasa y SOD que ha sido observada en células no 
tumorales (Gutierrez-Uzquiza et al., 2012), no se mantiene en nuestras células 
cancerígenas (Fig. 28D), sugiriendo que la regulación de ROS por p38 MAPK es 
diferente en células transformadas y en las que no lo son. 
 
Otros trabajos han mostrado que ROS puede inhibir la actividad de fosfatasas, 
debido a que su cisteína catalítica puede ser inactivada por oxidación (Kamata et 
al., 2005; Teng et al., 2007). Así, pensamos que la activación de la ruta de JNK 
tras la inhibición de p38 MAPK podría ser debida a la inhibición de la actividad 
fosfatasa tras el aumento de ROS. De este modo demostramos que tanto tirosina 
fosfatasas como serina treonina fosfatasas pueden estar implicadas en la 
regulación de JNK tras la inhibición de p38 MAPK dependiendo del tipo celular 
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(Fig. 30), y que muy probablemente los activadores de JNK no estuviesen 
implicados en este proceso de activación (Fig. 31).  
 
Para determinar si nuestras observaciones podían tener alguna relevancia in vivo, 
usamos un modelo de ratón de cáncer de mama, el MMTV-PyMT, mediante el 
cual los animales desarrollan tumores de mama de forma espontánea en torno a 
los 2.5 meses de edad. Tras aplicar tres tratamientos diferentes (el inhibidor de p38 
MAPK PH-797804, cisplatino, o la combinación de los dos) y compararlos con la 
evolución de los tumores de los animales control (sólo tratados con el vehículo de 
los tratamientos), observamos que el doble tratamiento provocaba una reducción 
del tamaño de los tumores de más del 90% a los 18 días de seguimiento, mientras 
que el cisplatino sólo los reducía un 50% (Fig. 32A). Análisis 
inmunohistoquímicos de las muestras a 7 días revelaron que la ruta de JNK se 
activaba tras la inhibición de p38 MAPK y que esto correlacionaba con un 
aumento de apoptosis, menor malignidad del tumor y reducción de la 
proliferación (Fig. 32B-D). También ha sido interesante descubrir que había un 
aumento de oxidación celular al tratar con PH-797804 (Fig. 32E). Los tumores 
también fueron analizados por inmunohistoquímica al final del experimento, lo 
que confirmó que éstos mantenían reducido su nivel de proliferación en el doble 
tratamiento y, lo que es más importante, la malignidad de los tumores seguí siendo 
menor (Fig. 33). Tras esta observación, pensamos que en el caso eventual de una 
recidiva, estos tumores más pequeños y menos proliferativos tardarían más en 
volver a crecer, comparados con los tratamientos independientes, y fue 
exactamente lo que observamos al repetir el experimento en las mismas 
condiciones pero cesando los tratamientos a día 15 (Fig. 34).  
 
Hemos visto que otros tipos de células cancerígenas humanas también 
presentaban activación de la ruta de JNK tras la inhibición de p38 MAPK (Fig. 35), 
y que esto sensibilizaba a apoptosis (Fig. 36), indicando que el mecanismo aquí 
descrito podría aplicar a un amplio abanico de células tumorales. Además, ha sido 
interesante observar que la activación de JNK tras la incubación con SB203580 
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era eminentemente citoplasmática, contrastando con la intensa activación nuclear 
que produce la radiación UV (Fig. 37).  
   
Discusión 
Se sabe que las ROS juegan un papel muy importante en la homeostasis de la 
célula tumoral, pero muchos estudios han descrito cómo altos niveles 
intracelulares de éstos están asociados con apoptosis. JNK es un importante 
mediador de la inducción de apoptosis en respuesta a diferentes agentes 
quimioterapéuticos, en particular a cisplatino. Nosotros hemos encontrado que la 
inhibición de la señalización de p38α en las células cancerígenas es suficiente 
para aumentar los niveles de ROS, que a su vez estimulan la apoptosis mediada 
por JNK en respuesta a cisplatino. Trabajos previos han mostrado que las rutas de 
JNK y p38 MAPK pueden interactuar a muy diversos niveles, principalmente en 
células no transformadas (Wagner and Nebreda, 2009), pero esta es la primera vez 
que se muestra que esta conexión puede estar mediada por ROS en células 
tumorales. También proporcionamos evidencias de la relevancia biológica de este 
mecanismo en la respuesta de las células cancerígenas a los tratamientos 
quimioterapéuticos, ampliando otras publicaciones donde mencionaban la 
implicación de ROS en la apoptosis mediada por JNK (Hou et al., 2008; Kamata et 
al., 2005). 
 
ASK1 se ha propuesto como un regulador clave de la apoptosis en respuesta a 
estrés oxidativo a través de la activación de MKK4 y MKK7 (Takeda et al., 2008). 
Sin embargo, estos activadores de JNK no parecen estar implicados en el proceso 
de activación de JNK que describimos aquí. Nuestros resultados indican que la 
inhibición de fosfatasas de JNK por la acumulación de ROS intracelulares es la 
responsable de la activación de esta proteína tras la inhibición de p38 MAPK. 
Tampoco hemos encontrado ninguna evidencia de que esta inhibición afecte a la 
expresión de la fosfatasa nuclear inducible MKP1 (Keyse, 2008), la cual, 
basándose en experimentos de sobreexpresión, ha sido propuesta como 
reguladora de la activación de JNK inducida por cisplatino (Sanchez-Perez et al., 
2000). Sin embargo, analizando las fosfatasas citoplasmáticas que regulan JNK 
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(Dickinson and Keyse, 2006), hemos visto que DUSP8 controla los niveles basales 
de fosforilación de JNK en las células MCF7 de cáncer de mama. Además, se ha 
descrito que DUSP8 puede interaccionar con células no estimuladas (Sanchez-
Perez et al., 2000). Curiosamente, también proporcionamos evidencia de que esta 
fosfatasa no parece jugar un papel relevante a la hora de regular la fosforilación 
basal de JNK en otras líneas de cáncer humanas. Por tanto, nuestros resultados 
indican que las fosfatasas implicadas en la regulación de la actividad basal de JNK 
varían dependiendo del tipo de línea celular. 
 
También hemos abordado la cuestión de cómo la inhibición de p38α aumenta los 
niveles de ROS en las células cancerígenas. Experimentos usando rotenona 
sugieren que el transporte de electrones a través de la cadena respiratoria 
mitocondrial podría contribuir a la generación de ROS tras la inhibición de p38α. 
Además hemos identificado dos genes antioxidantes, GPX5 y TXNDC2, que están 
positivamente regulados por p38α en células cancerígenas y que controlan los 
niveles de actividad basal de JNK. Por tanto, p38α podría regular negativamente la 
acumulación de ROS a diferentes niveles. Interesantemente, ha sido mostrado que 
la señalización de p38α regula negativamente la acumulación de ROS en MEFs a 
través del incremento de expresión de catalasa y superóxido dismutasa (Gutierrez-
Uzquiza et al., 2012), pero nosotros no hemos encontrado ninguna evidencia de 
que estas dos enzimas estén reguladas por p38α en las células cancerígenas que 
hemos analizado. Esto indica que la señalización de p38α puede regular la 
acumulación de ROS por diferentes mecanismos en células transformadas. De 
hecho, la diferente sensibilidad de las células transformadas y las que no lo son, 
ha sido propuesto como un hecho terapéuticamente relevante de forma potencial 
(Mateescu et al., 2011; Raj et al., 2011; Shaw et al., 2011).  
 
En este trabajo demostramos que la actividad aumentada de JNK sensibiliza a las 
células cancerígenas a apoptosis inducida por tratamientos quimioterapéuticos y, 
además, esta respuesta parece estar conservada en diferentes tipos de células 
tumorales, sugiriendo que podría ser potencialmente explotado para terapia 
antitumoral en combinación con agentes inductores del estrés oxidativo (Engel 
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and Evens, 2006). Así, la inhibición de p38α sensibilizaría a las células tumorales 
al tratamiento con estos agentes. 
 
Usando un modelo animal de cáncer de mama y un inhibidor de p38α que está 
en ensayos clínicos para procesos antiinflamatorios (Goldstein et al., 2010; Hope 
et al., 2009), hemos confirmado in vivo que la inhibición de p38α coopera con el 
cisplatino para matar a las células tumorales. Además, no sólo los tumores de 
mama eran más pequeños, sino que también se veían histológicamente menos 
malignos. La proliferación celular también había sido reducida, indicando que la 
inhibición de p38α podría ralentizar probablemente el crecimiento de nuevos 
tumores en el caso de una recidiva, como efectivamente hemos corroborado. 
 
Se ha publicado que la inhibición de p38 MAPK podría ayudar a algunos agentes 
quimioterapéuticos a matar a las células cancerígenas. Este es el caso de células 
de mieloma tratadas con bortezomib (Navas et al., 2006), células de linfoma 
tratadas con etoposida (Kurosu et al., 2005), o gliomas tratados con temozolomida 
(Demuth et al., 2007). En estos casos, el incremento del efecto citotóxico 
observado tras la inhibición de p38 MAPK estaba asociado a una parada defectiva 
del ciclo celular en G2. Se ha propuesto que la señalización de p38α podría tener 
un papel importante para regular la expresión de proteínas implicadas en la 
supervivencia de células paradas en G2 (Phong et al., 2010). En cambio, nosotros 
mostramos que la inhibición de p38α resulta en la acumulación de ROS y 
activación de JNK, sensibilizando a las células tumorales a apoptosis inducida por 
cisplatino, tanto en líneas celulares de cáncer humanas como en un modelo 
animal de cáncer de mama. Parece poco probable que la parada de ciclo celular 
sea requerida para la acumulación de ROS en respuesta a la inhibición de p38α, 
aunque no podemos descartar que la parada en G2 contribuya a la reducción en 
proliferación de las células tumorales tras incubación con el inhibidor de p38α. 
Nuestros resultados también indican que el efecto cooperativo de la inhibición de 
p38α junto con el tratamiento de cisplatino probablemente sea independiente de 
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p53, ya que hemos observado este efecto pro-apoptótico en células cancerígenas 
con distintos estados de p53.  
 
En su conjunto, estos resultados revelan un nuevo mecanismo mediante el cual 
p38α contribuye a la supervivencia de la célula tumoral manteniendo bajos los 
niveles de ROS, y sugieren que la combinación de inhibidores de p38α con 
agentes quimioterapéuticos podrían ser considerados para la terapia antitumoral. 
 
Conclusiones 
1. La kinasa eEF2 podría ser una compañero letal sintético de p38 MAPK en 
células cancerígenas con p53 salvaje en respuesta al tratamiento con cisplatino. 
 
2. p38 MAPK no es necesaria para la proliferación basal de todas las células 
cancerígenas. 
 
3. Disfunción de p38α activa la ruta de JNK en células cancerígenas en 
condiciones basales y las sensibiliza a apoptosis, independientemente del estado 
de p53. 
 
4. La inhibición de p38 MAPK regula negativamente la producción de enzimas 
antioxidantes, incrementando así los niveles de ROS en la célula cancerígena, lo 
que conduce a la inactivación de las fosfatasas de JNK. 
 
5. La inhibición de p38 MAPK coopera con el cisplatino para reducir el tamaño y 
malignidad de los tumores en un modelo de ratón de cáncer de mama. 
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